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Chapter 1
Summary
A major concern in drug development is the characterization of new molecular entities (NMEs)
with respect to their safety and efficacy. Both factors are determined by the drugs exposure within
the body or its compartments. Thus, to be efficacious a drug needs to reach its target site where a
decrease in exposure can result in a loss of efficacy. On the contrary, an increased accumulation of
drug in tissues potentially causes adverse drug reactions and toxicity. Alterations in drug exposure,
such as observed from drug-drug interactions (DDI) due to co-medication, can therefore signifi-
cantly impact a drugs safety and efficacy.
A fundamental pharmacokinetic (PK) parameter affecting a drugs exposure is the clearance, which
describes the elimination rate of a drug from the body or its compartments. The major clearance
organs are the liver and the kidney, where drugs are eliminated by metabolic degradation and/or
secretion. In order to enter and leave cellular compartments of eliminating organs, drugs need to
cross cellular membranes. However, due to their physiochemical properties, many compounds
are unable to cross membranes by passive diffusion. These compounds need to interact with drug
transporters which mediate the cellular uptake and efflux of their substrates. Thus, transporters play
a pivotal role in drug absorption, distribution, metabolism, and excretion (ADME). Consequently,
alterations in transporter activity can significantly impact drug exposure resulting in potentially
altered safety and efficacy profiles.
In early drug development, information on the human in vivo PK profile of NMEs are lack-
ing. Besides in vivo PK studies in preclinical animal species, first investigations of pharmacokinetic
parameters are commonly assessed with the help of cell-based in vitro systems. In this work, the
prediction of human drug clearances and the assessment of the clinical drug-drug interaction (DDI)
potential from in vitro drug permeation studies was investigated. Within this context, the following
aims were defined: (i) The establishment of an in vitro-in vivo extrapolation (IVIVE) method to
predict the renal clearance of drugs; (ii) The investigation of the transporter protein expression-
activity relationship to predict the contribution of transporters involved hepatic drug uptake; (iii)
The prediction of the DDI potential of statins based on an extended mechanistic hepatic clearance
IVIVE model; (iv) The assessment of the inhibitory potential of telaprevir on renal and hepatic
drug transporters.
1
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In the first study, we investigated the prediction of the human renal drug clearance based on
in vitro drug transport studies. The renal clearance process is composed of glomerular filtration,
tubular secretion, and tubular reabsorption. Currently, in vitro-based methods to assess the net renal
clearance based on its underlying processes are lacking. This study therefore aimed to develop
a novel IVIVE method that allows the prediction of the human renal clearance as well as the
investigation of the physiological mechanisms driving renal excretion.
For this purpose, 20 marketed drugs covering a wide range of physiochemical properties and all four
classes of the Biopharmaceutics Drug Disposition Classification System (BDDCS) were chosen
as study compounds. LLC-PK1 cells were selected as in vitro system to measure the bidirectional
transmembrane permeation of the study compounds. Subsequently, the generated data were scaled
to human organ level using the renal proximal tubule surface as scaling factor. Finally, the upscaled
values were applied to a novel mechanistic model and the net human renal clearances were predicted
based on renal filtration, secretion, and reabsorption.
For our study compounds, the LLC-PK1 cells were a feasible in vitro tool to investigate the renal
secretion of basic and neutral drugs. However, secretion clearance for anionic drugs was under-
estimated, likely due to a lack of a functional expression of a transport system for organic anions.
Nevertheless, including all study compounds our model demonstrated a good predictability of
the in vivo reported renal clearances. Thus, for 19 out of 20 drugs the net renal clearances were
predicted within the three-fold deviation of the clinically observed values. Moreover, we showed
that the contribution of the different processes driving the net renal clearances were dependent on
the physiochemical drug properties, thereby correlating with their BDDCS assignments. Therefore,
our novel IVIVE method allowed the mechanistic assessment of the underlying processes driving
renal excretion and the prediction of the human net renal clearance for a diverse set of compounds.
Human cryopreserved suspended hepatocytes express a multitude of drug uptake transporters.
Therefore, they represent a widely used in vitro system to investigate the in vivo-like hepatic drug
disposition. However, many drugs including statins exhibit overlapping transporter specificities.
Their hepatic drug uptake reflects the sum of all active transporter-mediated processes and passive
diffusion. Thus, efforts have been made to assess the quantitative involvement of specific trans-
porters in the net hepatic drug uptake. Recently, quantitative targeted absolute proteomics (QTAP)
methods have been established to determine the abundances of drug transporter proteins in tissue
and cell samples. First studies applied QTAP analysis to determine the contribution of specific
transporters to the net hepatic drug uptake by using absolute transporter protein abundances as
surrogates for their activities. However, this method implies that the transporter protein expression
directly correlates with the transporter activity.
It was the aim of the second study to further investigate the transporter protein expression-activity
relationship to determine the contribution of the organic anion transporting polypeptide (OATP)
1B1 and OATP1B3 to the net hepatic uptake of statins. By that, it was aimed to assess if relative
transporter expression factors (REF) could be used to extrapolate the OATP1B1 and OATP1B3
activities determined in single-transporter expressing cell lines into hepatocytes activities.
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Absolute OATP1B1 and OATP1B3 expression levels in pooled human cryopreserved hepatocytes
and single-transporter-expressing HEK293 cells were determined by QTAP analysis. Moreover,
the transporter activities were assessed from drug uptake studies in hepatocytes and HEK293
OATP1B1/1B3 cells. Subsequently, REFs were used to extrapolate the activity data generated in
recombinant cell lines to hepatocyte values. Finally, to validate the approach the predictions based
on REF-scaling were compared to predictions based on a previously established scaling method
using relative transporter activity factors (RAFs).
The obtained transporter protein levels in the cryopreserved hepatocytes were in agreement with
literature data. Furthermore, the predicted transporter activities based on either REF or RAF
scaling were highly similar. This finding indicates a direct relationship between transporter protein
expression and activity. Moreover, we were able to predict the OATP1B1 and OATP1B3 activities
in hepatocytes from uptake studies in cell lines over-expressing the specific transporter. Thus,
for six out of ten compounds, the predicted transporter activities in hepatocytes were within a
two-fold deviation from the determined value, regardless of the scaling method applied. For two
transporter-specific compounds as well as for atorvastatin, pravastatin, rosuvastatin, and simvastatin
the active hepatic uptake was found to be exclusively mediated by OATP1B1 and/or OATP1B3.
In contrast, our results indicated the likely involvement of other hepatic uptake transporters [e.g.
OATP2B1 or the sodium-taurocholate cotransporting polypeptide (NTCP)] to the net active uptake
of cerivastatin, fluvastatin, pitavastatin, and lovastatin.
As introduced above, drug exposure determines a compounds safety and efficacy. Thereby, drug
clearance impacts the exposure of a compound to the body or its compartments. Co-medication
can alter the clearance profile of drugs resulting in DDIs that potentially affect the drugs safety
or efficacy. Recently, the Extended Clearance Concept Classification System (ECCCS) has been
introduced which enables the anticipation of DDI potential of drugs based on their in vitro assessed
rate-limiting hepatic clearance pathways.The third study of this work aimed to predict the human
hepatic clearance of statins by IVIVE to subsequently predict their DDI potential based on the
mechanistic extended clearance concept.
In a first step, IVIVE was applied to predict the human hepatic drug clearances. For this purpose
the hepatobiliary disposition of eight statins was determined using suspended human cryopreserved,
and sandwich-cultured hepatocytes. Moreover, human liver microsomal metabolic data of each
statin were obtained from literature. Subsequently, the in vitro clearances were scaled to human
organ level with the help of reported scaling parameters and the net hepatic clearance of each statin
was predicted. In a second step, the mechanistic extended clearance concept was applied to assess
the DDI potential of each statin. Therewith, the impact of selected perpetrator drugs on hepatic
uptake, metabolism, and biliary secretion of the statins was simulated and the resulting changes in
exposure were compared with clinical observations from drug-drug interaction studies.
Our approach resulted in a high predictability of the human hepatic clearance with atorvastatin,
fluvastatin, lovastatin acid, pitavastatin, pravastatin, and simvastatin acid projected within the
two-fold deviation to the reported values. Cerivastatin was predicted within a three-fold devia-
tion while rosuvastatin was six-fold under-predicted. Moreover, the predicted DDI potentials of
each statin were in excellent agreement with the reported values. We showed that for lovastatin
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acid and simvastatin acid assigned to ECCCS class 1, as well as for fluvastatin, cerivastatin, and
pitavastatin assigned to ECCCS class 2, inhibition of metabolism was projected as major DDI
potential. For pravastatin and rosuvastatin (ECCCS class 4) and for atorvastatin (ECCCS class 2)
the DDI potential was attributed to all clearance processes driving the hepatic elimination of these
statins. Thereby, we showed that a concomitant inhibition of active hepatic uptake, metabolism,
and biliary secretion substantially increased the anticipated DDI effects compared to only inhibition
of single clearance pathways. In conclusion, we demonstrated that the DDI potential of statins can
be assessed in vitro, based on the extended clearance concept. Furthermore, we showed that the
ECCCS class assignments of statins well predicted their major DDI potential.
As illustrated above NMEs can be the victim of drug-drug interactions. In addition to the as-
sessment of the DDI potential for victim drugs it is also crucial to characterize NMEs with respect
to their perpetrator potential. In the last study of this work we therefore investigated the potential of
the new antiviral drug telaprevir to inhibit renal and hepatic transporters of the solute carrier family.
The inhibitory effect of telaprevir on OATP1B1, OATP1B3, the organic anion transporters (OAT)1,
OAT3, the organic cation transporters (OCT) 1, OCT2, and the multidrug and toxin extrusion
protein (MATE) 1 was investigated in single-transporter expressing HEK293 cells. For this purpose,
the uptake of known transporter reference substrates was assessed in the presence and absence of
increasing telaprevir concentrations. Subsequently, the inhibitory effect of telaprevir on the specific
transporters was measured by determination of IC50 values.
We showed that telaprevir exhibited significant inhibition of the renal transporters, OCT2 and
MATE1 with IC50 values of 6.4 µM and 23.0 µM, respectively. In contrast no effect of telaprevir
on the renal transporters OAT1 and OAT3 was observed. Furthermore, telaprevir inhibited all
investigated hepatic transporters with IC50 values of 2.2 µM for OATP1B1, 6.8 µM for OATP1B3,
and 20.7 µM for OCT1. Telaprevir has a reported maximal plasma concentration of 5.2 µM.
Therefore, telaprevir is anticipated to be a potent in vivo inhibitor of OATP1B1, OATP1B3 and
OCT2. Consequently, clinically relevant DDI might result upon co-administration of telaprevir
with a substrate of these transporter.
Chapter 2
Introduction
2.1 Drug Transporters
Drug transporters are membrane-bound proteins. They are expressed in tissues throughout the body
and localized at the blood-tissue or tissue-lumen boundary epithelial in various organs (Klaassen and
Aleksunes, 2010). There, they mediate the cellular influx or efflux of endogenous compounds such
as hormones, nucleotides, vitamins or metabolites as well as of xenobiotics including various drugs.
Due to their physiochemical properties many of these compounds cannot cross cellular membranes
passively and hence need to interact with drug transporters to penetrate into tissues. Consequently,
drug transporters play a pivotal role in absorptive, distributive, and secretive processes within the
body.
With respect to their molecular characteristics, drug transporters are grouped into two super-
families: solute carriers (SLCs) and adenosinetriphosphate binding cassettes (ABCs) (Klaassen
and Aleksunes, 2010). Figure 2.1 illustrates drug transporters from the SLC and ABC families
expressed in liver, kidney, intestine, and brain that are known to play a key role in the disposition of
drugs. In the following sections, major SLC and ABC transporters are introduced.
2.1.1 SLC transporters
The solute carrier family is grouped into 52 subfamilies containing 386 proteins in human (Sch-
lessinger A and KM, 2013). Most members of the SLC family function as cellular uptake trans-
porters that facilitate the membrane permeation of a variety of compounds. Therefore, transport by
SLC transporters can be a requirement for the tissue penetration of drugs. In the following, SLC
transporters that are recognized to play a significant role in drug disposition are introduced.
SLC22 transporters
The SLC22 subfamily includes members of organic anion transporters (OATs) and organic cation
transporters (OCTs) that mediate the cellular uptake of anionic, cationic, and zwitterionic com-
pounds (Russel, 2010).
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Figure 2.1: Localization of drug transporters in enterocytes, hepatocytes, kidney proximal tubule cells, and
brain capillary endothelial cell. Transporters of the adenosinetriphosphat binding cassette (ABC) family are
shown in dark gray and members of the solute carrier (SLC) are light gray. Arrows indicate the direction of
drug transport. For hepatocytes, the canicular membrane that separates the bile pockets is indicated in black.
According to the international transporter consortium (ITC), transporters that should be primarily considered
in drug development are indicated in bold letters (Hillgren et al., 2013). The following abbreviations are used:
BCRP, breast cancer resistance protein; BSEP, bile salt export pump; MATE, multidrug and toxin extrusion
protein; MRP, multidrug resistantance-accociated protein; NTCP, sodium-taurocholate co-transporting
polypeptide; OAT, organic anion transporter; OATP, organic anion transporting polypeptide; OCT, organic
cation transporter: OCTN, organic cation transporter novel; PEPT, peptide transporter.
Substrates of OATs are generally hydrophilic with a molecular weight below 500 Da (Russel, 2010).
OATs interact with various endogenous compounds e.g. bile salts and steroid hormones, as well
as drugs including diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. methotrexate),
antivirals (e.g. adefovir, tenofovir), and statins (e.g. pravastatin, rosuvastatin) (Riedmaier et al.,
2012).
As illustrated in Figure 2.1 OAT1 (SLC22A6) , OAT2 (SLC22A7) , and OAT3 (SLC22A8) are
co-expressed at the basolateral membranes of kidney proximal tubule cells (PTCs) (Hosoyamada
et al., 1999; Sun et al., 2001). In contrast to OAT1 and OAT3, which are predominately expressed
in the kidney, OAT2 is mainly localized in hepatocytes (Sun et al., 2001; Sekine et al., 1998). In
the kidney, OAT4 (SLC22A11) is expressed at the apical membrane of PTC (Ekaratanawong et al.,
2004). There it is involved in secretive and reabsorptive processes of organic anions and is shown
to mediate the exchange of urate (Hagos et al., 2007).
Major organic cation transporters are OCT1 (SLC22A1), OCT2 (SLC22A2), and OCT3 (SLC22A3)
which mediate the cellular uptake of cationic compounds (MW < 400 Da) including hormones,
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metabolites, and neurotransmitters, as well as of drugs such as antihistamines (e.g. cimetidine),
anti-arrhytmics (e.g. quinidine), or anti-diabetics (e.g. metformin) (Roth et al., 2012; Nies et al.,
2011).
Expressed at basolateral membranes, OCT1 and OCT2 are generally considered to be liver and
kidney specific transporters, respectively, while OCT3 expression has been shown in various tissues
throughout the body (Nies et al., 2011). The organic cation and carnitine transporter novel (OCTN)1
(SLC22A4) and OCTN2 (SLC22A5) are expressed in various tissues and localized at the apical
membranes of PTC and enterocytes (Russel, 2010). OCTNs expressed at PTC are involved in the
reuptake of cations and carnitine from the tubular fluid (Roth et al., 2012).
SLCO transporters
The SLCO family consists of organic anion transporting polypeptides (OATP). These transporters
mainly mediate the cellular uptake of more bulky (MW > 450 Da), hydrophobic organic anions
including bile acids, thyroid hormones, or hormone conjugates (Russel, 2010). Besides endogenous
substrates, OATPs transport various drugs including statins (e.g. atorvastatin, pravastatin) , sartans
(e.g. telmisartan, valsartan), or antihistamines (e.g. fexofenadine) (ITC, 2010).
As summarized by Hagenbuch et al. among OATPs, OATP1B1 (SLCO1B1) and OATP1B3
(SLCO1B3) are exclusively expressed in the liver while other members of the family such as
OATP1A2 (SLCO1A2) and OATP2B1 (SLCO2B1), show broad tissue localizations (Hagenbuch
and Gui, 2008). OATP4C1 (SLCO4C1) is a kidney-specific transporter expressed at the apical
membrane of PTC (Hagenbuch and Gui, 2008).
SLC47 transporters
Solute carriers mainly consist of cellular uptake transporters. An exception is described by the group
of SLC47 transporters, including the multidrug and toxin extrusion protein (MATE)1 (SLC47A1),
MATE2 (SLC47A2) and the splice variant MATE2-K (Hillgren et al., 2013). MATEs exhibit
overlapping substrate specificity with OCTs and mediate the cellular efflux of cationic compounds
(Tanihara et al., 2007). Apically expressed, MATE1 is localized in hepatocytes and PTC while
MATE2-K is almost exclusively expressed in the kidney (Otsuka et al., 2005; Tanihara et al.,
2007).
SLC10 transporters
The sodium-taurocholate co-transporting polypeptide (NTCP) (SL10A1) is a member of the SLC10
subfamily that contains sodium-dependent bile acid transporters. Among them, NTCP is a liver
specific uptake transporter expressed at the basolateral membrane of hepatocytes (Petzinger, 2006).
Besides the transport of conjugated bile acids, NTCP is involved in the hepatic uptake of statins (Bi
et al., 2013).
SLC15 transporters
The SLC15 subfamily contains proton-coupled oligopeptide transporters that mainly mediate
the transport of di- and tripeptides as well as peptide-like drugs including β-lactam antibiotics
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(Brandsch, 2009). At the apical membrane of PTCs, the peptide transporters (PEPT)1 (SLC15A1)
and PEPT2 (SLC15A2) mediate the active cellular reabsorption of di- and tripeptides from the
tubular fluid (Brandsch, 2009; Smith et al., 2013). Moreover, PEPT1 is apically expressed in
enterocytes where it is involved in the absorption of its substrates from the intestine into the blood
circulation.
2.1.2 ABC transporters
The ABC superfamily contains seven subfamilies, denoted A to G, which currently include 52
human transporters (Sair, 2014). Human ABC transporters that play a key role in drug disposition
are exclusively efflux transporters. Physiologically, these transporters exhibit protective functions.
Expressed at the interface to sensitive tissues e.g. at the blood-brain or blood-placenta barrier,
they prevent potential toxic compounds to accumulate into cells (König et al., 2013). However,
in pharmacotherapy this protective function also has its downside. In fact, the impact of drug
efflux transporters on drug disposition became first recognized by their role in multidrug resistance
(MDR) and treatment failure due to the transporter-mediated efflux of anticancer-agents from the
target tissue (Fletcher et al., 2010). In the following, major members of the ABC family that are
involved in drug distribution are introduced.
ABCB transporters
The ABCB subfamily includes the most well studied efflux transporter, the P-glycoprotein (P-gp)
(ABCB1). Also denoted MDR1, P-gp was first identified in tumor cells where it was studied in the
context of MDR (Juliono and Ling, 1976). As illustrated in Figure 2.1, P-gp is localized in various
tissues and apically expressed in liver, kidney, and intestine and basolaterally expressed in the brain
(Klaassen and Aleksunes, 2010). It exhibits a broad substrate variety but generally mediates the
cellular efflux of bulky (> 500 Da), cationic compounds including protease inhibitors (e.g. indinavir,
ritonavir), anti-arrhytmics (e.g.digoxin) or anticancer drugs (e.g. vinblastine, imatinib) (Russel,
2010; ITC, 2010).
Besides P-gp, the bile salt export pump (BSEP) (ABCB11 ) is another member of the ABCB
subfamily that has been shown to be of importance in drug disposition. BSEP is predominately
expressed at the apical membrane of hepatocytes where it mediates the cellular efflux of conjugated
and unconjugated bile salts into the bile (Gerloff et al., 1998). Furthermore, BSEP is reported to be
involved in the hepatic secretion of the statin pravastatin (Hirano et al., 2005).
ABCC transporters
The ABCC subfamily contains multidrug resistance-associated proteins (MRPs). Among MRPs,
MRP2 (ABCC2), MRP3 (ABCC3), and MRP4 (ABCC4) are involved in the cellular efflux of organic
anionic compounds. MRPs mediate the disposition of endogenous compounds such as bilirubin-
diglucuronide, bile acids, or urate as well as various drugs including antivirals (e.g. adefovir,
tenofovir), NSAIDs (e.g. methotrexate), or anticancer agents (e.g. vinblastine) (Russel, 2010; ITC,
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2010).
MRPs are localized in multiple tissues, including brain, liver, kidney, intestine or placenta (Klaassen
and Aleksunes, 2010). In hepatocytes MRP4 is expressed at the basolateral membrane, mediating
the transport of substrates from hepatocytes into the blood circulation.
ABCG transporters
The breast cancer resistance protein (BCRP) (ABCG2) is the predominant member of the ABCG
subfamily that is involved in active cellular efflux of drugs. BCRP was first discovered in a resistant
breast cancer cell line (Doyle and Yang, 1998). It shows a diverse expression pattern and is apically
expressed in hepatocytes, PTCs, and enterocytes and basolaterally localized in brain endothelial
cells (Klaassen and Aleksunes, 2010). Substrates of BCRP are hydrophobic compounds including
conjugated steroid hormones, folates or uric acid, as well as anticancer agents (e.g. imatinib,
erlotinib), statins (e.g. pravastatin, rosuvastatin) or the antineoplastic agent mitoxantrone (Russel,
2010).
2.2 Mechanism of Drug Permeation over Cellular Membranes
As described in the previous section, drugs have to cross cellular barriers to distribute within the
body. This can occur by paracellular or transcellular movements while the latter one is more
common for drugs (Rowland and Tozer, 2011c). Most drugs are small molecules (100 - 1000 Da)
that cross cellular membranes (transcellular) by passive diffusion and/or active drug transporter-
mediated transport (Rang et al., 2012). In the following, these mechanism are introduced and the
impact of physiochemical drug properties on passive permeation is described.
2.2.1 Passive permeation and active transport
Diffusion is a passive process which is mathematically described by Fick’s first law of diffusion
(Silbernagel and Despopoulos, 2009):
Jdif = D · A · ∆S∆X (2.1)
where Jdif states the diffusive transport rate (mol/s), D is the diffusion coefficient (m2/s), A is the
surface area (m2), ∆S is the difference in substrate concentration (mol/m3), and ∆X states the
membrane thickness (m). For passive permeation over cellular membranes (Jpas) Eq.2.1 is adapted
to account for the lipid solubility of the substrate:
Jpas = k · D∆x︸ ︷︷ ︸
P
·A · ∆S = P · A · ∆S (2.2)
where permeability [P; (m/s)] is a function of the the oil-and-water partition coefficient, k (-), D,
and ∆X (Silbernagel and Despopoulos, 2009). In pharmacokinetics, permeation over the cellular
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Figure 2.2: Mechanism of drug permeation over cellular membranes. Biological membranes are lipid-bilayers
containing a hydrophilic head and lipophilic tail. Transcellular movements of drugs over the lipid-bilayer
occurs by passive diffusion (PSpas) and/or transporter-mediated permeation (PSact) by ABC (A) or SLC (S1-3)
transporters. ABC transporters use the hydrolyis of ATP as source of energy to transport drugs against their
electrochemical gradient. SLC transporters work as channels (S1) or co-transporters which either mediate
the antiport (S2) or symport (S3) of drugs and co-substances. Red and gray arrows indicate the direction of
drug permeation and co-substances, respectively.
membrane is generally normalized to the initial substrate concentration (S0) and the resulting
permeability is referred as surface permeability [PS, (m3·s-1)]. Consequently, with respect to
equation 2.2 passive surface permeation (PSpas) is described as followed (Tavelin et al., 2002):
PSpas =
Jpas
S0
(2.3)
Drug transporter mediated permeation is distinguished in primary and secondary active transport
or facilitated diffusion. Members of the ABC family are primary active transporters, that use
energy obtained from hydrolysis of ATP to move substrates against their electrochemical potential
(Klaassen and Aleksunes, 2010). In contrast, most SLC transporters act as channels and uniporters
by facilitating diffusion across membranes (Klaassen and Aleksunes, 2010). Other SLC members
are co-transporters that act as secondary active transporters which use established electrochemical
gradients as driving force to move substrates in the same direction (symport) or opposite direction
(antiport). Figure 2.2 summarizes the mechanism of membrane permeation.
The drug permeation mediated by drug transporters is an active process characterized by satura-
bility. Mathematically its transport rate (Jact) can be expressed by the Michaelis-Menten equation
(Silbernagel and Despopoulos, 2009):
Jact =
Jact,max · S0
Km+ S0
(2.4)
where Jact,max (mol/s) is the maximum transporter mediated transport rate, and Km is the michaelis-
menten constant (mol/m3).
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Analogue to PSpas, the transporter-mediated surface permeability (PSact) is derived by dividing
equation 2.4 by S0:
PSact =
Jact,max
Km+ S0
(2.5)
Finally, the total surface permeation PStot of a drug over cellular membranes is a function of PSact
and PSpas:
PStot = PSact + PSpas (2.6)
2.2.2 The impact of physiochemical drug properties on passive diffusion
As shown in Figure 2.2, biological membranes are bilayers of amphiphatic phospholipids that
contain a hydrophilic head oriented the outside of the bilayer and inwardly oriented lipophilic tails
(Brunton et al., 2011). Lipophilic compounds can dissolve in the lipid-bilayers and the degree of
lipophilicity correlates with the membrane permeability of a compound. Thereby, the partition
coefficient between an aqueous and octanol solution (logDpH), determined at a specific pH, is a
measure of the degree of lipophilicity (Khojasteh et al., 2011a). Thus, the higher logDpH, the more
lipophilic and the less hydrophilic is a drug.
Generally, diffusion through the lipid-bilayer is favored for small, lipophilic, and unionized com-
pounds and decreases with the size of the molecule (Rowland and Tozer, 2011c). The pH partition
hypothesis states, that only unionized, lipophilic drug penetrates the membrane by passive diffusion
(Rowland and Tozer, 2011c). However, most drugs are weak acids or bases whose degree of
ionization is pH dependent (Rowland and Tozer, 2011c). Thereby, the pKa of a drug reflects the
degree of ionization which is defined as followed (Khojasteh et al., 2011a):
pKa = −pH + log
(
[A−]
[HA]
)
(2.7)
pKa = −pH+ log
(
[B]
[BH+]
)
(2.8)
where variables in brackets refer to concentrations, A states acids, B states bases, and H refers to
protons. Consequently, HA and B are the neutral form of acids and bases while A- and BH+ are
the ionized forms, respectively. Thus, equation 2.7 and 2.8 refer to the pKa for acidic and basic
compounds, respectively.
Figure 2.3 illustrates the influence of the pH on the degree of ionization for acids and bases. Given
the impact of the pH on a drugs ionization state, the rate of passive diffusion is influenced by
physiological pH differences within the body. An example is described by the passive permeation
of weak bases through kidney PTC. Proximal tubule cells separate the blood (pH 7.4) from the
tubular fluid (pH 6.8) (Silbernagel and Despopoulos, 2009). Since the degree of ionization of weak
bases is less on the blood site, their passive permeation is favored from blood to the tubular fluid
than the other way around.
Another example of the influence of charge on drug distribution is given by trapping of drugs in
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Figure 2.3: The influence of pH on drug ion-
ization. A- and BH+ refer to the ionized state
of acidic and basic compounds, respectively,
according to equations 2.7 and 2.8. The pka
defines the pH at 50% ionization which is
indicated with a red line.
intracellular organelles. Thus, lipophilic basic drugs that are neutral at physiological pH (7.4) are
shown to accumulate in lysosomes (pH 4-5), a process also known as lysosomal trapping (Kazmi
et al., 2013; Funk and Krise, 2012). Those drugs permeate into lysosomes by passive diffusion
and get protonated inside the organelle. With respect to the pH partition theory, only unionized
compounds can penetrate cellular membranes passively, and consequently lipophilic basic drugs
literally get trapped into lysosomes due to their charged state.
2.3 Human In Vivo Drug Elimination
After drugs reach the system circulation they are distributed and subsequently eliminated from
the body. In pharmacokinetics, drug elimination is described by the term clearance that refers to
the rate of elimination of a drug from the body or its compartments [CL; (L·h-1)] (Rowland and
Tozer, 2011a). In vivo , the systemic drug clearance can be assessed as the ratio of the drug dose
(mg) applied intravenously and the area under the drug concentration-time curve (AUC, mg·h·L-1)
(Rowland and Tozer, 2011b). The AUC is a measure of a drugs exposure, and thus directly impacted
by drug clearances.
The major clearance organs are the the liver and the kidney. There, an interplay between metabolic
enzymes and drug transporters mediate the elimination of drugs either by metabolism and/or by
direct secretion. In the following sections these elimination pathways are described. Moreover, a
drug classification system that allows the prediction of elimination pathways based on in vivo drug
metabolism data is briefly introduced.
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Figure 2.4: Microanatomy
of the liver. Blood en-
ters the liver mainly through
branches of the hepatic
artery and portal veins and
flows through sinusoids into
the central vein. Hepato-
cytes are the predominant
cells within the liver and me-
diate the secretion of com-
pounds from the blood into
the bile canaliculi. The fig-
ure was taken from Chu et al.
(Chu et al., 2013).
2.3.1 Hepatic clearance
The hepatic clearance of drugs from the blood invovles hepatic metabolism and hepatobiliary
secretion. After a brief introduction of the functional anatomy of the liver, these hepatic drug
elimination mechanism are introduced.
Liver anatomy
Figure 2.4 illustrates the microanatomy of the liver. Blood enters the liver through branches of the
portal vein and the hepatic artery, the main vascular blood supply systems (Malarkey et al., 2005).
Then, the blood flows into capillaries, called sinusoids, before it collects into the central veins. The
functional unit of the liver is the hepatic acinus containing branches of the hepatic artery, the portal
vein, the bile duct and the surrounding mass of liver cells (Kuntz and Kuntz, 2006). Hepatocytes
are the most abundant hepatic cells (60%) and are the place of hepatic drug elimination (Malarkey
et al., 2005; Rowland and Tozer, 2011a). They face sinusoids with their basolateral (sinusoidal)
and bile canaliculi with their apical (canicular) membranes.
Drug elimination
Before drugs can be eliminated from the blood they need to enter the hepatocytes. As illustrated
in Figure 2.1 hepatocytes express various drug transporters including OATPs, OAT2, OCT1, and
NTCP at their sinusoidal membrane that mediate the active hepatic uptake of drugs from the blood
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(Christoph, 2008). Elimination by biliary secretion is mediated by drug transporters expressed at
the canicular membrane including BCRP, MRP2, MATE1, P-gp, and BSEP (Christoph, 2008).
Hepatocytes are enriched with metabolic enzymes and metabolism is considered as the major
hepatic clearance pathway of drugs. Metabolism is categorized into phase I and phase II reactions
(Liddle and Stedman, 2007). Phase I reactions involve oxidation, reduction, and hydrolysis thereby
introducing reactive groups to the drug molecule (named functionalization). The majority of
metabolic phase I drug reactions is attributed to the the cytochrome P450 family (Williams et al.,
2004; Rowland and Tozer, 2011a). Within this family, CYP3A4 is the most abundant member
of CYP450 in the liver. Phase II reactions are described by conjugation processes including glu-
curonidation, acetylation, or sulfation that mainly result in an increased hydrophilicity of the drug
metabolite that facilitates its subsequent secretion (Liddle and Stedman, 2007). For most drugs
the predominant enzymes mediating phase II reactions are uridine diphosphate glucuronosyltrans-
ferases (UGTs) (Williams et al., 2004).
2.3.2 Renal clearance
Glomerular filtration, renal metabolism, tubular secretion, and tubular reabsorption concomitantly
contribute to the net renal blood clearance (Masereeuw and Russel, 2001). These processes take
place in the nephron, the functional unit of the kidney. In the following, the anatomy of the nephron
is briefly summarized and the renal clearance steps are illustrated.
Nephron anatomy
Figure 2.5 illustrates the nephron. It consists of the glomerulus and the renal tubules in which the
urinary filtrate is formed. The tubules are segmented into the proximal convoluted tubule, the loop
of henle, and the distal tubule which joints the collecting duct (Lote, 2012). Blood enters the kidney
through the renal artery which branches into final afferant arterioles that supply the glomerular
capillaries with blood. The glomerular capillaries form a knot called the Bowman’s capsule. The
blood leaves the glomerulus through efferent arterioles that from a net of peritubular capillaries
enclosing the tubular segments and subsequently leaves the kidney through the renal vein (Lote,
2012).
CHAPTER 2. INTRODUCTION | 15
Figure 2.5: The nephron as functional unit of the kidney. The nephron is localized in the cortex and medulla
of the kidney. It contains the Bowman’s capsule and tubules which are surrounded by a net of capillaries.
The tubules are segmented into proximal tubule, the loop of Henle, and the distal tubule. The figure was
taken from http://cnx.org.
Drug elimination
Drugs enter the kidney with the blood flow thereby reaching the nephron at the glomerulus. Within
the glomerulus, drugs can be subjected to filtration into the proximal tubule. Glomerular filtration is
a passive, size-selective process and only unbound drug with a molecular weight below 2000 g/mol
are filtered (Fagerholm, 2007). The rate at which the blood is filtered is called glomerular filtration
rate (GFR) that has an average value of 1.71 mL/(min·kg) in human (Rowland and Tozer, 2011a).
Drugs that don not undergo glomerular filtration leave the Bowman’s capsule through efferent
arterioles.
Tubular epithelial cells exhibit a boundary function between the blood to their basolateral and
the tubular fluid to their apical side, thereby mediating the transport of compounds from one
compartment into the other. Proximal tubule cells express a variety of drug transporters and are the
main side of active transport within the tubule (Masereeuw and Russel, 2001). Thus, drugs moving
within the blood flow along efferent arterioles can be actively taken up into PTCs by basolateraly
expressed transporters including OATs and OCTs and subsequently secreted into the tubular fluid
by apically transporters including MRPs, P-pg, MATEs, and BCRP (see Fig. 2.1).
Drugs in the tubular fluid can be subject to tubular reabsorption into efferent arterioles. For
most compounds, reabsorption mainly occurs by passive diffusion which is influenced by the
physiochemical properties of the drug (see section 2.2.2). However, drug uptake transporters
expressed at the apical membrane of PTCs including OCTNs, OAT4, or PEPTs are involved it the
active reuptake of drugs from the tubular fluid.
Drug clearance by metabolism mainly occurs in the liver, and metabolism in the kidney often is
expected to be a minor elimination pathway (Rowland and Tozer, 2011a). However, the proximal
tubule cells contain phase I and II metabolizing enzymes including members of the CYP450 family
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and UGTs (Lohr et al., 1998).
2.3.3 The Biopharmaceutical Drug Disposition Classification System
(BDDCS)
In 1995 Amidon and co-workers established a Biopharmaceutics Classification System (BCS) to
predict the rate and extend of oral drug absorption (Amidon et al., 1995). The BCS categorizes
drugs into four classes according to their aqueous solubility and intestinal permeability. According
to the Food and Drug Administration (FDA) the classification criteria are as follows: Drugs are
classified as highly soluble when the highest marketed dose strength is soluble in 250 mL of
aqueous media over a pH range of 1-7.5 and highly permeable when the extent of oral absorbed
drug is at least 90% of the administered dose in human (FDA, 2005). In 2005, Wu and Benet
applied the BCS to over 100 drugs (Wu and Benet, 2005). They recognized that the BCS class
assignment of drugs correlates with their main route of elimination. Thus, drugs assigned to class
1 (highly soluble; highly permeable) and class 2 (low soluble; highly permeable) are primarily
eliminated by metabolism while drugs assigned to class 3 (highly soluble; low permeable) and 4
(low soluble; low permeable) are primarily eliminated by renal and/or biliary secretion.
Following their analysis, Wu and Benet observed that a classification into high vs. low permeability
reflected the accessibility of drugs to metabolizing enzymes, thereby correlating with the main route
of drug elimination. Thus they proposed the Biopharmaceutical Drug Disposition Classification
System (BDDCS) which exchanged the permeability criterion from the BCS with the extent of
metabolism. Another rational behind the use of metabolism data rather than permeability data is
the easier access to human in vivo metabolism data (Wu and Benet, 2005).
Within the BDDCS drugs are classified as extensively metabolized when 70% or more of orally
administered drug undergoes metabolism. The purpose of the BDDCS is the prediction of drug
disposition, elimination pathways and drug-drug interaction, thereby assessing the involvement
of drug transporters (Wu and Benet, 2005; Benet, 2013). Table 2.1 lists BDDCS class-specific
characteristics. Drugs categorized in classes 1 and 2 are extensively metabolized and consequently
their major elimination organ is the liver while for classes 3 and 4 renal and/or biliary secretion of
unchanged drug is predicted as the main route of elimination.
Table 2.1: Characteristics of the BDDCS.
BDDCS solubility metabolism predicted transporter effects
Class 1 high extensive minimal effects in gut and liver
Class 2 low extensive efflux transporter effects predominate in gut;
both uptake and efflux transporters can affect liver
Class 3 high poor absorptive transporter effects predominate
Class 4 low poor absorptive and efflux transporter effects could be important
BDDCS refers to the Biopharmaceutics Drug Disposition Classification System. The table was adapted according to Wu
and Benet (2005).
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2.4 Cell-Based In Vitro Methods to Study Drug Membrane
Permeation in Liver and Kidney
The following sections introduce cell-based in vitro systems that are commonly used to investigate
the hepatic and renal drug membrane permeation. Furthermore, the methodology of frequently
used assays is summarized and the derivation of permeability values from these experiments is
explained.
2.4.1 Cell systems
Cell-based in vitro systems can be categorized in either primary systems or cell lines. Primary
systems are derived directly from intact tissues and exhibit a limited life-span (Masters, 2000).
In contrast, cell lines are subcultured systems from primary tissues and can be subjected to
immortalization. Therefore, immortalized cell lines or cell lines derived from cancerous tissue,
have the ability of unlimited reproduction making them a valuable in vitro tool (Masters, 2000).
Primary hepatocytes
As introduced in section 2.1, hepatocytes express a multitude of drug transporters at their basolateral
and canicular membranes. On a functional level, well-established hepatocyte models are commonly
used in vitro systems to study the hepatic drug uptake and hepatobiliary secretion (Yabe et al., 2011;
De Bruyn et al., 2011; Shitara et al., 2003). To overcome the shortage of freshly-isolated cells, cryo-
preservation methods have been established and cryopreserved hepatocytes are now commercially
available. Thereby, functional expression of drug uptake transporters in cryopreserved hepatocytes
was shown in various experiments (Shitara et al., 2003; Lu et al., 2006). A well-established assay
to investigate the hepatic drug uptake is performed with either freshly-isolated or cryopreserved
suspended hepatocytes. The suspended cells are incubated with the compound of interest and
subsequently the uptake is terminated by the so-called oil-spin-method, by separating the cells from
the incubation solution. The methodology of this assay is summarized in Figure 2.6.
During the isolation procedure, hepatocytes loose their cell polarization and hepatic architec-
ture, including the formation of bile pockets (Groothuis et al., 1981; Maurice et al., 1988). Besides,
it has been shown that after isolation apically expressed efflux transporters are rapidly internalized
(Bow et al., 2008; Hoffmaster et al., 2004). This can be overcome when using the so-called hepato-
cyte sandwich-culture technique where freshly-isolated cells are cultured between two layers of
gelled collagen. First shown by Dunn et al., sandwich-cultured hepatocytes retain their in vivo-like
physiology including polarized growth properties and formation of bile pockets, pre-requirements
for hepatobiliary secretion studies (Dunn et al., 1989, 1991). Thus, sandwich-cultured hepatocytes
provide a functional in vitro system to study active biliary drug excretion (Swift et al., 2010). Figure
2.6 illustrates the methodology of the sandwich-cultured based hepatocyte assay.
Hepatic drug uptake can also be assessed in sandwich-cultured hepatocytes. However, uptake
transporter expression on mRNA level is shown to be lower in sandwich-cultured hepatocytes
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the oil layer
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oil layer
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Methodology
Following incubation of suspended 
hepatocytes with the compound of 
interest, the cell suspension is placed 
on top of an oil layer in a microcentri- 
fugation tube (a). By centifugation
the cells move through the oil layer
into the alkaline solution while the
incubation solution stays on top of 
the oil layer. Following an overnight 
freezing peroid, the tube is cut 
through the oil layer, allowing a 
separate analysis of the amount of 
compound in the cell pellet and in
the incubation solution (b).a b
a
b
c
Methodology
Incubation of the test compound in a 
calcium containing buffer preserves 
tight junctions. Consequently, 
secreted compound accumulates
in the bile pockets (a). 
Incubations performed in calcium-free 
buffer disrupts the tight junctions (b). 
Subsequent washing steps remove
compound which is accumulated in 
the bile pockets. Thus, accumulation 
of compound within the cells can be 
measured.
The accumulated amount of com-
pound in the bile pockets (c) is deter-
mined by substracting the values 
obtained from incubations in the 
presence and abscence  of calcium.
Methodology
Incubation of a test compound solution
with plated transporter-transfected cells 
and  untransfected control cells in the 
presence and abscence of specific 
transporter inhibitors. Subsequently, 
the solution is aspirated and the com-
pound accumulation within the cell 
samples is analysed. 
Uptake-transporter interaction (a) with 
a compound is indicated if compound
accumulation in transfected cells is
significantly higher (i) compared to un-
transfected control cells and (ii) in the
abscence of control inhibitors. For ef- 
lflux-transporter studies (b) the oppsi-
te indicates a transporter-compound 
interaction.
A Hepatocyte oil-spin assay
B Sandwich-cultured hepatocyte assay
a
b
Advantages
Sandwich-cultured hepatocytes maintain the 
hepatocyte architecture and cell polarity. Cani-
cular efflux transporters are functionally 
expressed and hepatobiliary drug secretion
can be measured.
Disadvantages
The identification of transporter-specific com-
pound interaction is limited. The assay is 
costly and throughput is low.
Advantages
Feasible for studies with freshly-isolated or cryo-
preserved hepatocytes, thus allowing flexibility. 
Hepatocytes functionally express physiological 
uptake transporters and the net hepatic uptake 
can be assessed.
Disadvantages
Identification of transporter-specific compound 
interaction is limited. The assay throughput is low.
C Uptake and efflux transporter assay
Advantages
Allows characterization of transporter-specific 
substrates and inhibitors. Throughput is high
and the assay is cost-effective.
Disadvantages
These artificial cell systems do not represent 
physiological conditions in terms of transporter
activity and protein expression levels. 
D Transwell assay
Methodology
Cells are seeded on a porous filter-
membrane in transwell inserts. The
system contains two chambers and
bidirectional transmembrane trans-
port can be assessed following in-
cubation with a compound solution.
Advantages
Allows characterization of transporter-specific 
substrates and inhibitors. Cellular compound
uptake and transmembrane permeability can
be assessed.
Disadvantages
Cell systems require polarized thight growth
properties. The assay throughput is low. 
Figure 2.6: Overview of cell-based in vitro assays. Content is partially taken from Jin and Di (2008); Xia
et al. (2007).
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compared to suspended hepatocytes and variations in cultivation conditions can significantly al-
ter the transporter expression (Luttringer et al., 2002). Moreover, the sandwich-culture assay is
cost-intensive, cell cultivation is work-intensive, and throughput is low. Therefore, suspended
hepatocytes are commonly chosen as in vitro tool to assess the hepatic uptake of drugs.
Primary kidney cells
In contrast to hepatocytes, renal primary in vitro systems to study drug transport are less well-
established. As illustrated in section 2.1 human proximal tubule cells express a variety of drug
transporters that mediate renal drug secretion. Efforts have been made to establish PTC models
from various species (Lash et al., 2006; Terada and Inui, 2007; Brown et al., 2008; Gowder and
McMartin, 2010; Schlatter et al., 2006). Thereby, expression of major renal drug transporters in
freshly-isolated cells was demonstrated on mRNA, protein, and functional level. However, the
isolation procedure is very work-intensive and today no primary kidney model has been established
that provides an in vitro system applicable for reproducible transepithelial renal drug transport
studies.
Cell lines
Two heptocarcinoma cell lines evaluated for drug transporter expression and functional activity are
HepG2 and HepGR cells. In contrast to HepG2 cells which do not exhibit mRNA expression of
OATP1B1, NTCP, and OCT1, HepGR cells showed expression levels of major hepatic uptake and
efflux transporters on mRNA and functional level (Lee et al., 2006). However, in both cell lines
transporter expression was significantly down-regulated when compared to expression levels in
primary hepatocytes (Lee et al., 2006).
The porcine proximal tubule cell line LLC-PK1 and the American opossum kidney cell line OK
have been used to investigate in vitro renal drug permeation. Studies with LLC-PK1 cells indicated
that the cells contain a functional organic cation system, while OK cells are reported to exhibit a
functional organic anion system (Saito et al., 1992; Urakami et al., 2005; Takano et al., 1994; Habu
et al., 2000). Besides, studies showed that LLC-PK1 cells exhibit tight growth properties required
for transmembrane permeation studies, while this characteristic is lacking in OK cells (Liang et al.,
1999).
Although drug transporter expressions on mRNA level are shown for cell lines of hepatic and renal
origin, transporter expression mostly is significantly down-regulated compared to expression in
primary systems (Hilgendorf et al., 2007; Lee et al., 2006; Ahlin et al., 2009). Furthermore, cell
lines often do not exhibit both, a functional organic anion and cation transport system. That is why
primary cells are generally the in vitro system of choice to investigate the net permeation of drugs.
However, since primary cell systems express a multitude of drug transporters they are not suitable
in order to characterize transporter-specific drug interactions.
In contrast, transporter-overexpressing cell lines generated by stable or transient transfection are a
frequently used in vitro tool to assess transporters-specific drug transport. The human embryonic
kidney (HEK) cell line HEK293, LLC-PK1 and the Madin-Darby canine kidney cell line MDCK
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are widely used host cell lines to generate single, or multiple-transporter over-expressing systems
used for uptake, efflux or transmembrane permeability studies (Barton et al., 2013; Xia et al., 2007).
The methodology of these assays is illustrated in Figure 2.6.
2.4.2 Assessment of membrane permeation from cell-based in vitro
studies
Incubation studies with radio-labeled compounds are a frequently used method to quantify substance
accumulation within cells, or in the incubation media. Samples containing radioactivity can be
analyzed by liquid scintillation counting (LSC), a process referred to the conversion of the energy of
a radioactive decay event into photons of light. Thereby, the absolute sample activity is determined
in disintegrations per minute (dpm).
With the help of the in vitro systems introduced above, apparent surface permeabilities (PSapp) and
apparent transmembrane permeabilites (Papp) can be derived. As described in section 2.2.1, PSapp
and Papp reflect net values that can involve active, transporter-mediated, and passive permeation
processes. The derivation of PSapp and Papp values from in vitro assays and the assessment of the
contribution of active processes is described in the following.
Uptake and Efflux assays
Following cellular uptake or efflux experiments using radio-labeled compounds, the apparent
surface permeability (PSapp; µL·min-1·mg-1) is calculated as the amount of radioactivity associated
with the cells (Rsamp; dpm) divided by the concentration in the incubation medium (S0; dpm·µL-1)
and normalized to the incubation time (t;min) and the amount of protein (m; mg) within the
sample:
PSapp =
Rsamp
S0 · t ·mprot (2.9)
When incubation studies are performed with transporter-transfected cell system, the contribution
of active transport can be assessed by control experiments performed in mock-transfected cells.
Thereby, active transport is determined from the PSapp difference between studies performed in
transporter-expressing cells and mock-transfected cells (Webborn et al., 2007). However, for studies
in primary systems, including suspended and sandwich-cultured hepatocytes, no such control
systems are available.
A method to assess active uptake in these systems is to perform parallel incubations at 37◦C
and 4◦C, assuming that active transport is not functional at 4◦C. A drawback of this method is
that membrane fluidity and consequently passive permeation can be affected by this temperature
change, thus limiting this method for qualitative rather than quantitative investigations (Frezard and
Garner-Suillerot, 1998).
Another commonly used approach are control incubations performed in the presence of transporter
inhibitors. Thereby, a difference of permeability values obtained in the presence and absence
of the inhibitors indicate the involvement of active transport. Limitations are the availability of
CHAPTER 2. INTRODUCTION | 21
specific transporter inhibitors and the underlying assumption that the inhibitor totally inhibits the
respective transporter activity. Moreover, since active transport is a saturable process, incubation
studies performed with an increasing substrate concentration can be used to assess the involvement
of transporter-mediated processes. By that, a decrease in surface permeabilities by an increasing
substrate concentration indicates transporter saturation.
Transmembrane transport assays
Transport assays are a useful tool to directly investigate the permeability of a drug across cellular
monolayers. To perform transwell experiments, a polarized growth property and monolayer integrity
of the cells system are required. Following experiments using transwell inserts (see Figure 2.6), the
apparent permeability (Papp; cm·min-1) is determined as follows:
Papp =
VR · SR
A · t · SD,0 (2.10)
where VR is the incubation volume in the receiver chamber (µL); SR is the substrate concentration
in the receiver chamber at the end of the incubation (dpm·µL-1); t is the incubation time (min), A is
the transwell surface area (cm2); and SD,0 is the initial substrate concentration in the donor chamber
(dpm·µL-1).
Since cell polarization is a requirement, the permeability of a drug can be assessed from basolateral
to apical direction (BA) and vice versa (AB). The performance of bidirectional transwell studies
allows the determination of efflux ratios (ERs) that are defined as the ratio of Papp,BA to Papp,AB.
ERs that significantly differ from 1.0 indicate the involvement of active transport. Similar to uptake
and efflux studies, the contribution of active transport can also be assessed following compound
concentration-dependent experiments (transporter saturation) or permeation studies in the presence
of transporter inhibitors. Control experiments performed at 4◦C cannot be used to assess active
transport in transwell studies, since the membrane fluidity is affected by the change in temperature
impacting passive transcellular and paracellular drug permeation.
2.5 In Vitro in Vivo Extrapolation Methods to Predict the
Human Drug Clearance
Generally, in vitro- in vivo extrapolation (IVIVE) methods to determine human drug clearances
contain three major steps (Lave et al., 2009): (i) the in vitro determination of the underlying
processes driving the intrinsic organ clearance (CLint) ; (ii) the scaling of these in vitro parameters
to human in vivo values to determine CLint; (iii) the incorporation of CLint into whole organ models.
Thereby, CLint describes the ability of an organ to eliminate drugs by metabolic (CLmet) or secretive
(CLsec) processes, regardless of other impacting factors such as blood flow or drug binding to blood
or plasma proteins (Khojasteh et al., 2011b). These so-called "external" factors are taken into
account when applying whole organ models (Khojasteh et al., 2011b). In the following, IVIVE
methods to assess hepatic and renal drug clearances are introduced.
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2.5.1 Hepatic IVIVE methods
The first hepatic IVIVE was performed by Rane et al. (1977) who predicted the in vivo hepatic
clearance in rat from studies with liver microsomes. Generally, for the following 30 years human
hepatic IVIVE methods were mainly focused on metabolism studies in hepatocytes or liver mi-
crosomes by approximating the hepatic intrinsic clearance (CLh,int) with metabolic clearance only
(CLh,int ≈ CLmet). Although an overall good predictability was achieved a tendency to rather under-
predict the in vivo observed clearance became recognized and partially attributed to neglecting the
involvement of hepatic drug transport processes in this approach (Chaturvedi et al., 2001; Obach,
1999; Chiba et al., 2009).
With the establishment of hepatocyte in vitro assays to determine active hepatic uptake and biliary
secretion, studies were performed evaluating the predictability of the hepatic organ clearance from
hepatic uptake (CLh,int ≈ PSinf) or biliary secretion (CLh,int ≈ CLbile) (Abe et al., 2009; Webborn
et al., 2007). Results showed that the predictability of these methods was highly compound-
dependent and usually successful if the examined clearance pathway was the overall rate-limiting
step in the net hepatic clearance.
More recently, based on the extended hepatic clearance concept, mechanism-based hepatic IVIVE
methods were developed taking active transport and metabolic clearances into account (Shitara
et al., 2006; Kusuhara and Sugiyama, 2009; Umehara and Camenisch, 2012; Jones et al., 2012).
Thereby, Umehara and Camenisch (2012) demonstrated a significant improvement in predictability
when the model accounts for all processes driving the hepatic clearance (sinusoidal transport,
metabolism, canicular transport). In the following, this mechanism-based hepatic IVIVE approach
is described.
Step 1: In vitro determination of hepatic clearance processes.
As introduced in section 2.3.1 the in vivo hepatic clearance involves the hepatic drug uptake
followed by metabolism and/or biliary secretion. These three processes define the intrinsic hepatic
clearance. Mathematically, CLh,int can be expressed as follows (Kusuhara and Sugiyama, 2009):
CLh,int =
PSin f ,act + PSin f ,pas
PSe f f ,act + PSe f f ,pas + CLbile + CLmet
· (CLbile + CLmet) (2.11)
where PSinf,act and PSinf,pas are the active and passive hepatic drug uptake permeabilites over the
sinusoidal membrane, respectively; PSeff,act and PSeff,pas refers to the active and passive efflux from
the hepatocytes back into the blood (sinusoidal efflux); CLbile is the biliary secretion clearance and
CLmet refers to the metabolic clearance.
As introduced in section 2.4.1, in vitro cell systems based on primary hepatocytes provide useful
tools to study hepatic drug permeation. In vitro tools for assessing hepatic metabolism are isolated
hepatocytes and liver microsomes (Houston and Carlili, 1997; Obach, 1999). Thus, all processes
driving the intrinsic hepatic clearance can be assessed by established in vitro tools.
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Step 2: Upscaling of in vitro to human in vivo values and determination of the
intrinsic hepatic clearance.
The in vitro determined PS and CL values are normalized to either the protein amount or the number
of cells used in the respective in vitro systems. In order to extrapolate the in vitro data to organ
levels, species,-and in vitro system-specific scaling factors are applied : 99·106cells/(g liver) for
suspended hepatocytes; 53 (mg protein)/(g liver) for liver microsomes; 116 (mg protein)/(g liver)
for sandwich-cultured hepatocytes; and 25.7 (g liver)/(kg body weight) (Carlile et al., 1997; Swift
et al., 2010). Subsequently, using the upsclaled values equation 2.11 can be used to calculate the
human hepatic intrinsic clearance.
Step 3: Hepatic organ models.
Three liver models are mainly used for hepatic IVIVE: the well-stirred liver model, the dispersion
model, and the parallel-tube model. Among those, the well-stirred liver model is most frequently
applied (Lave et al., 2009; Ito and Houston, 2004). The approach is based on the assumption
that instantaneous and complete mixing occurs within the liver and only unbound drug is subject
to elimination. Mathematically, based on the well-stirred model the hepatic organ clearance is
assessed as follows (Pang and Rowland, 1977; Rowland and Tozer, 2011a):
CLh =
Qh · fu,b · CLh,int
Qh + fu,b · CLh,int (2.12)
where Qh is the hepatic blood flow rate (L·h-1) and fub is the fraction unbound of drug in blood
(-). Thus, if fub is available, the hepatic clearance can be calculated with the help of the upscaled
CLh,int values from equation 2.11 .
2.5.2 Renal IVIVE methods
As described in section 2.3.2, the net renal clearance involves glomerular filtration, tubular secretion,
renal metabolism, and tubular reabsorption. In contrast to IVIVE methods to predict human hepatic
clearances, renal IVIVE methods are less well established for multiple reasons including mainly the
lack of suitable in vitro systems to study secretive and reabsorptive processes and the complexity
of the underlying renal physiology. Thus, in contrast to hepatocytes where all hepatic clearance
processes occur, renal clearance involves multiple cell and tissue structures (glomerulus, proximal
tubule, distal, tubule; see section 2.3.2).
CHAPTER 2. INTRODUCTION | 24
Nevertheless, renal organ models were establish taking glomerular filtration, tubular secretion, and
tubular reabsorption into account (Kusuhara and Sugiyama, 2009; Watanabe et al., 2011):
CLr =
 fu,b · GFR︸ ︷︷ ︸
f iltration
+
Qr · fu,b · CLr,int
Qr + fu,b · CLr,int︸ ︷︷ ︸
secretion
 · (1− freab)︸ ︷︷ ︸
reabsorption
(2.13)
where GFR is the glomerular filtration rate (L·h-1), Qr is the renal blood flow rate (L·h-1), CLr,int
is the renal intrinsic clearance (L·h-1), and freab is the fraction of drug reabsorbed (-). In equation
2.13 the well-stirred liver model is adapted to describe the tubular secretion clearance. Following
this approach, the filtration clearance can be determined when fub of a drug is known while CLr,int
and freab require input data from in vitro studies. However, in vitro-based methods that allow the
determination of these values are lacking, thus limiting the application of equation 2.13 on renal
IVIVE.
2.5.3 Quantitative absolute targeted proteomics to assess transporter
protein abundance
Recently, novel technology based on liquid chromatography-linked tandem mass spectrometry
(LC-MS/MS) with multiple reaction monitoring has been established that allows the quantitative
assessments of drug transport proteins in cell samples (Ohtsuki et al., 2011). This method has been
shown to be a useful tool to characterize cell samples with respect to their absolute transporter
protein expression (Ohtsuki et al., 2012; Kamiie et al., 2008; Sakamoto et al., 2011; Uchida
et al., 2011). Moreover, protein abundance data have been used to investigate the quantitative
contribution of specific drug transporters to the net hepatic uptake of drugs by assuming a direct
transporter protein expression-activity relationship (Bi et al., 2013; Kimoto et al., 2012; Karlgren
et al., 2012). As illustrated above, active transport processes are determinants of the hepatic and
renal clearances. Thus, quantitative targeted absolute proteomics (QTAP) to determine transporter
protein abundances is expected to be a promising tool in the investigation of underlying clearance
processes. In the following, the methodology of QTAP for the assessment of drug transporter
protein levels is illustrated.
Quantitative assessment of transporter protein levels
Sensitive analysis of whole proteins by LC-MS/MS is limited by the size and solubility of the
protein (Steen and Mann, 2004; Ohtsuki et al., 2011). Therefore, QTAP is performed with selected
target peptides as surrogates for the respective proteins. Target peptides need to fulfill certain
requirements including a unique amino acid sequence, efficient tryptic digestions and good MS
sensitivity (Steen and Mann, 2004; Ohtsuki et al., 2011). Based on in silico investigations, Uchida
et al. published a list of suitable target peptides of most commonly investigated drug transporters
(Uchida et al., 2011). Once, target peptides are identified, stably isotope-labeled and unlabeled
peptides of the same amino acid sequence are synthesized, serving as internal standards. Conse-
quently, the internal standards are eluted at the same retention time as the target peptides but can be
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Figure 2.7: Methodology of quantitative targeted absolute proteomics (QTAP) analysis. A) Selection of
target peptides from the target protein. B) Synthesis of stably isotope-labeled and unlabeled target peptide
serving as internal standards. C) Extraction of the plasma membrane fractions of the cell or tissue samples.
D) Tryptic digestion of the plasma membrane fractions causes cleavage of the target proteins into peptides
including the target peptides. E) Addition of a fixed amount of labeled peptide (internal standard) to the
tryptic peptide sample followed by LC-MS/MS analysis. The absolute amount of the target peptide is
determined from the peak ratio obtained from the target peptide and internal standard. The figure was
adapted from Ohtsuki et al. (2011).
distinguished by MS due to the difference in mass (Ohtsuki et al., 2011).
The first step in the sample preparation is the isolation of the plasma membrane fractions from the
respective cell or tissue samples. Thereby, subcellular fragmentation is achieved following multiple
centrifugation and homogenization steps according to established protocols (Sakamoto et al., 2011;
Ohtsuki et al., 2012). Once the plasma membrane fractions are obtained they are subjected to
tryptic digestion thereby cleaving the transporter proteins into respective peptides, including the
selected target peptides. After adding a fixed amount of synthesized labeled target peptide (internal
standard) the solution is analyzed by LC-MS/MS with multiple reactions monitoring, thus allowing
simultaneous quantification of up to 37 proteins per assay. The absolute amount of target peptide
is quantified by calculating the peak ratios of the target peptides to those of the internal standards
(Steen and Mann, 2004; Ohtsuki et al., 2011). Figure 2.7 summarized the main steps of the QTAP
analysis.
2.6 Assessment of the Transporter-Mediated Drug-Drug
Interaction Potential from Cell-Based In Vitro Studies
As illustrated in the previous sections drug transporters exhibit a pivotal role in the human drug
elimination. Therefore, inhibition of renal and hepatic transporters due to co-medication can result
in a reduced drug clearance, potentially causing an increase in drug plasma concentrations and/or
systemic drug exposure of the victim drug.
During the last decade, several examples for transporter-mediated DDIs were described in liter-
ature. In 2001 the lipid-lowering drug cerivastatin was withdrawn from the market after causing
severe cases of myopathy and fatal rhabdomylysis. Thereby, an increased risk of side-effects
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was recognized following co-administration with gemfibrozil (Staffa et al., 2002). Cerivastatin
is primarily eliminated by the liver and retrospective analysis based on in vitro pharmacokinetic
data linked the clinically observed DDIs to the concomitant inhibition of OATP1B1 and metabolic
enzymes (Shitara et al., 2004). Furthermore, clinical studies reported severe adverse effects in-
cluding toxicity upon co-administration of methotrexate and non-steroidal anti-inflammatory drugs
(NSAIDs) (Liegler et al., 1969; Thyss et al., 1986). It was observed that NSAIDs lowered the renal
clearance of methotrexate. Based on in vitro studies it was shown that methotrexate is actively
renally secreted by OATs and MRPs and the clinically observed DDI are likely caused by inhibition
of these transporters due to co-medication (Uwai et al., 2000, 2004; El-Sheigk et al., 2007).
The examples above illustrate that drug transporter-mediated DDIs can have a significant impact
on a drugs safety and efficacy. Therefore, the assessment of the DDI potential of new molecular
entities is an important step in the drug development process. Static, in vitro based methods have
been established to predict the impact of transporter inhibition due to co-medication (pertrator drug)
on NMEs (victim drug). In the following, these methods are introduced.
2.6.1 Transporter inhibition and IC50 values
A measure of the inhibitory potential of a perpetrator substance on a drug transporter is given by the
IC50 value, representing the drug concentration that causes 50% inhibition of the maximal observed
transporter activity. The IC50 value can be assessed with the help of cell-based in vitro systems
introduced in 2.4.1. A commonly used approach is based on co-incubation of transporter-transfected
cells with a transporter-specific substrate and an increasing concentration of the perpetrator drug.
Following, the IC50 can be determined based on curve fitting using sigmoidal Hill kinetics:
%of control =
%max · In
ICn50 + In
(2.14)
where % of control is the observed transporter inhibition in the presence of a potent transporter
inhibitor, %max is the maximal observed transporter inhibition caused by a perpetrator, I is the
concentration of the perpetrator drug and n is the Hill coefficient which is a measure of the
cooperativity of the inhibition affinity to the active binding sites (n = 1, no cooperativity; n < 1,
negative coorperativity; n > 1 indicates positive cooperativity). The lower the IC50 value the higher
is the in vitro inhibitory potential of a perpetrator on the respective transporter.
2.6.2 R-value approach
Based on in vitro data, The R-value approach is used to assess the in vivo impact of transporter
inhibition on a drugs exposure. By that, estimates of the AUC ratio in the presence and absence of
a perpetrator drug (i) (AUCi/AUC) can be calculated as follows (Shitara et al., 2005; Barton et al.,
2013):
R =
AUCi
AUC
= 1+
I · (1+ S/Km)
IC50
(2.15)
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where I is the in vivo concentration of the perpetrator drug. The variables S and Km refer to the
transporter-specific probe substrate which was applied in the in vitro inhibition assay to determine
the IC50. If the substrate concentration is sufficiently below the Km (S « Km), the R-value can be
approximated as follows:
R = 1+
I
IC50
(2.16)
In contrast to the IC50 value which is only a measure of the inhibitory potential of a perpetrator on
a transporter the R-value approach predicts the clinical relevance of this inhibitory potential, as
given by the change in exposure. Thus, the higher the inhibitor concentration and the inhibitory
potential on drug transporters (indicated by a low IC50) the higher is the anticipated DDI potential.
However, due to its simplification the R-value approach rather provides a qualitative estimation if
transporter-effects are anticipated to be of clinical relevance than a quantitative prediction of the
DDI potential.
2.6.3 DDI assessment based on the mechanistic hepatic clearance model:
Introduction of the Extended Clearance Concept Classification
System (ECCCS)
For the liver, the hepatic clearance can be described with the well-stirred approach. Following oral
administration of a drug and its perpetrator and assuming that the liver is the only clearance organ
and that the fraction of drug absorbed, the hepatic blood flow rate, and the fraction of drug unbound
in blood does not change in the presence of the perpetrator, the AUC ratio can be determined as
follows (Einolf, 2007):
AUCi
AUC
=
CLh,int
CLh,int,i
(2.17)
Based on the mechanistic extended clearance concept, the intrinsic hepatic clearance is described
as a function of all governing processes, as stated in equation 2.11. A perpetrator can exhibit
inhibitory potential (fi) on all active processes driving the hepatic intrinsic clearance (Camenisch
and Umehara, 2012):
CLh,int =
[(1− fi,inf) · PSinf,act + PSinf,pas]
[(1− fi,eff) · PSeff,act + PSeff,pas] + [(1− fi,sec) · CLbile] + [(1− fi,met) · CLmet]
· [(1− fi,sec) · CLbile + (1− fi,met) · CLmet)] (2.18)
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Table 2.2: Characteristics of the ECCCS.
ECCCS rate-limiting clearance pathway anticipated DDI potential
Class 1 PSinf,pas metabolic enzymes
Class 2 CLbile, CLmet canicular efflux transporters and metabolic enzymes;
only metabolic enzymes (if CLsec « CLmet)
Class 3 PSinf,act, PSinf,pas sinusoidal uptake transporters
Class 4 all governing processes sinusoidal and canicular transporters, metabolic enzymes
ECCCS refers to the Extended Clearance Concept Classification System. PSinf,act and PSinf,pas refer to the active and passive
hepatic influx over the sinusoidal membrane; PSeff,act and PSeff,pas are to the active and passive hepatic efflux over the sinusoidal
membrane; CLbile is the biliary clearance, and CLmet refers to the metabolic clearance. The table was adapted according to
Camenisch and Umehara (2012).
Camenisch and Umehara recently reported an extended clearance concept classification system
(ECCCS) which allows the prediction of the DDI potential of drugs based on their rate-limiting
hepatic clearance pathway (Camenisch and Umehara, 2012). In contrast to the BDDCS, introduced
in section 2.3.3, the ECCCS does not require human in vivo data but is based on the incorporation
of in vitro parameters, driving the hepatic clearance as described by equation 2.18. According to the
ECCCS drugs are categorized into four classes whose characteristics are summarized in Table 2.2.
Metabolism is projected as the major hepatic DDI potential of highly permeable class 1 and 2
compounds. While passive hepatic uptake is the rate-limiting step for class 1 compounds, the
interplay between metabolism and transporter-mediated biliary secretion is predicted to be rate-
limiting for class 2 compounds. Hepatic uptake is predicted to be the rate-limiting step for class 3
compounds and major DDI effects are anticipated upon inhibition of hepatic uptake transporters.
For class 4 compounds, all processes driving the hepatic elimination (metabolism, uptake and
efflux) can be rate-limiting. Therefore, inhibition of metabolic enzymes as well as sinusoidal and
canicular drug transporters is anticipated as DDI potential of class 4 compounds. Thus, application
of the ECCCS allows for a compound-class dependent assessment of the DDI potential of drugs
based on the extended mechanistic clearance concept.
Chapter 3
Objectives
The development of new molecular entities is a step-wise process involving preclinical and clinical
phases. In this context, the early characterization of NMEs with respect to their safety and efficacy
is of major concern. Both components are influenced by the exposure of the drug within the body
which itself is affected by drug clearance processes. As introduced in chapter 2, drug transporters
play a pivotal role in the pharmacokinetics of absorption, distribution, metabolism, and excretion
(ADME). Thereby, transporters are now well recognized as major determinants of drug clearances.
Besides their involvement in the hepatobiliary and renally secretion of drugs they impact the access
of drugs to clearance organs and hence metabolic enzymes. Alterations in transporter activities
can therefore affect a drugs exposure and consequently its safety and/or efficacy (see section 2.6).
That is why the early characterization of the PK profile, including drug-transporter interactions, is a
key step in the development of NMEs. However, in preclinical drug development information of
human in vivo PK data are lacking. Therefore, as described in sections 2.4 and 2.5, in vitro-based
methods are commonly used to first assess PK properties of NMEs. Consequently, the development,
validation, and characterization of these methods is of major importance in drug development.
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It was the aim of this work to investigate the prediction of human renal and hepatic drug clearances
by IVIVE models that account for active drug transport processes. In a second step, the applicability
of in vitro-based methods to predict the DDI potential of drugs was assessed. Within this context,
the following objectives were defined:
• The establishment of a mechanistic IVIVE method to predict the human renal clear-
ance of drugs.
As introduced in sections 2.3, the renal clearance is a major elimination pathway of drugs and
thus an important parameter in the PK profile of NMEs. Current in vitro-based methods for
the early assessment of the human renal clearance are lacking (see 2.4 and 2.5). To overcome
this drawback, this study aimed to develop a novel physiologically based IVIVE method that
enables the prediction of the human renal drug clearance based on filtration, secretion, and
reabsorption. To gain mechanistic understanding of the renal excretion, the method should
allow the assessment of the contribution of the underlying clearance pathways to the net organ
clearance. This study further aimed to investigate, if the major renal drug clearance pathways
correlate with their assignment to the Biopharmaceutical Drug Disposition Classification
System.
• The investigation of the transporter protein expression- activity relationship to predict
the contribution of transporters involved in hepatic drug uptake.
Section 2.5.3 introduced the application of quantitative targeted absolute proteomics to inves-
tigate the drug transporter protein abundance. This method proved to be a promising tool
to characterize cell systems with respect to their quantitative transporter protein expression.
Moreover, QTAP was applied to investigate the contribution of transporter-specific drug
uptake into hepatocytes based on a transporter protein expression-activity correlation. An
objective of this study was to further investigate the transporter protein expression-activity
relationship. For this purpose the following hypothesis was questioned: If transporter protein
abundance directly translates into transporter activity, activities determined in cell lines
could be extrapolated into other tissues by using relative protein expression values as scaling
factors. This study aimed to investigate this hypothesis by assessing the predictability of the
contribution of OATP1B1- and OATP1B3-mediated transport in hepatocytes from activity
measurements in single-transporter expressing cell lines.
• The prediction of the DDI potential of statins based on an extended mechanistic hep-
atic clearance model.
Statins are lipid-lowering drugs that are widely prescribed for the prevention of cardiovas-
cular diseases. Therefore, patients treated with statins are likely under co-medication and
a multitude of clinical studies investigated the impact of co-medication on statin exposure.
As described above the characterization of NMEs in terms of their safety is crucial in early
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drug development. Section 2.6, introduced a recently established method that allows the
prediction of the DDI potential of compounds based on their rate-limiting hepatic clearance
pathways. In order to further validate this method, a direct comparison between the predicted
DDI potentials and clinically observed DDIs would be benificial. Moreover, a novel hepatic
IVIVE method has been recently reported that allows the prediction of the hepatic clearance
based on its governing processes (see section 2.5). The combination of both approaches
could be used in early drug development for a first risk assessment of NMEs. Using statins as
model drugs, this study therefore aimed to further validate the application of the mechanistic
clearance concept to predict the hepatic clearance of statins and subsequently assess their
DDI potential. In this context, the use of the Extended Clearance Concept Classification
System to anticipate the major DDI potential of statins was assessed.
• The assessment of the inhibitory potential of telaprevir on renal and hepatic drug trans-
porters.
In clinical studies telaprevir, a new marketed drug, has been shown to be involved in drug-
drug interactions as a perpetrator. In vitro studies demonstrated that telaprevir inhibits
metabolic enzymes but data on its interaction with drug transporters are lacking. As illus-
trated in section 2.6, DDIs can be the result of drug transporter inhibition. Therefore, the
purpose of this study was the application of cell-based in vitro systems to investigate the
inhibitory potential of telaprevir on major human renal and hepatic SLC transporters.
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4.1 Abstract
Renal clearance is a key determinant of the elimination of drugs. To date, only few in
vitro- in vivo extrapolation (IVIVE) approaches have been described to predict the renal
organ clearance as the net result of glomerular filtration, tubular secretion, and tubular
reabsorption. In this study, we measured in LLC-PK1 cells the transport of 20 compounds
that cover all four classes of the Biopharmaceutical Drug Disposition Classification System.
These data were incorporated into a novel kidney model to predict all renal clearance
processes in human. We showed that filtration and secretion were main contributors to
the renal organ clearance for all compounds, whereas reabsorption was predominant for
compounds assigned to classes 1 and 2. Our results suggest that anionic drugs were not
significantly secreted in LLC-PK1 cells, resulting in under-predicted clearances. When
all study compounds were included a high overall correlation between the reported and
predicted renal organ clearances was obtained (R2 = 0.83). The prediction accuracy in
terms of percentage within two-fold and three-fold error was 70% and 95%, respectively.
In conclusion, our novel IVIVE method allowed to predict the human renal organ clearance
and the contribution of each underlying process.
4.2 Introduction
Besides the liver, the kidney is the major organ responsible for the elimination of drugs
from the systemic circulation. Renal elimination of drugs is considered to be a major
clearance process, when the excretion of unchanged drug into the urine exceeds 25% of
the absorbed dose (Morrissey et al., 2013). As summarized by Morrissey et al, 32% of the
top 200 prescribed drugs in the United States in 2010 were cleared at least partially by
renal elimination (Morrissey et al., 2013). Therefore, renal clearance should be considered
as potentially important route of elimination for any new chemical entity.
Renal excretion describes the elimination process of unchanged drugs from the blood
circulation into the urine and is the net result of glomerular filtration, tubular secretion, and
tubular reabsorption. Glomerular filtration is a passive process and the filtration clearance
CLr,fil equals the product of the glomerular filtration rate (GFR) and the unbound fraction of
drug in blood fub. Tubular secretion describes the trans-epithelial permeation of drugs from
the blood into the tubular fluid and the secretion clearance (CLr,sec) is the sum of active
secretion and passive permeation. Active tubular secretion of drugs is mediated by organic
anion (OAT) and organic cation transport (OCT) systems. These systems contain various
drug transporters that mediate the active cellular uptake of drugs from the blood into the
proximal tubule and its subsequent efflux into the tubular fluid (Morrissey et al., 2013; Li
et al., 2006). For example, the secretion of cationic drugs is mediated by the organic cation
transporter OCT2, which is expressed at the basolateral membrane of proximal tubule cells,
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and the apically expressed multidrug and toxin extrusion proteins MATE1 and MATE2K
as well as the P-glycoprotein (P-gp) (Morrissey et al., 2013; Li et al., 2006). Weakly acidic
drugs are secreted by the organic anion transporters OAT1 and OAT3, which are expressed
at the basolateral membrane, and the multidrug resistance-associated proteins MRP2 and
MRP4 as well as the breast cancer-resistant protein (BCRP) (Morrissey et al., 2013). The
latter transporters are expressed at the apical membrane. Tubular reabsorption describes
the back-flux of drugs from the tubular fluid into the blood. Although active reabsorption
may occur (e.g. via the organic cation transporter proteins OCTN1 and OCTN2), this
process is mainly dependent on the passive permeability of a compound (Feng et al., 2010;
Masereeuw and Russel, 2001).
Tubular secretion and reabsorption involve both active, transporter-mediated processes,
and passive permeation across the tubular epithelium. Consequently, an in vitro model
that allows the determination of both processes is needed. The proximal tubule cell line
LLC-PK1, derived from pig (Sus scrofa) kidney, has been used in various studies to ex-
amine the renal disposition of compounds. When grown on permeable filter membranes,
LLC-PK1 cells form confluent, polarized cell monolayers that allow the the conduction
of trans-epithelial transport studies. LLC-PK1 cells were shown to be a suitable in vitro
system for studying the active secretion of cationic compounds (Masago et al., 2010;
Takaai et al., 2007; Urakami et al., 2005; Saito et al., 1992). Furthermore, expression of
endogenous P-gp, MRP2, and BCRP in LLC-PK1 cells was shown on mRNA and protein
level (Kuteykin-Teplyakov et al., 2010; Takada et al., 2005). Following standard protein
basic local alignment analysis (http://plast.ncbi.nlm.nih.gov) between S. scrofa and Homo
sapiens revealed over 80% identity for OAT3, OCT1, P-gp, MRP2, and OCTN1; and 79%
for BCRP.
The Biopharmaceutical Drug Disposition Classification System (BDDCS), established by
Benet et al., classifies drugs according to their in vivo reported extent of metabolism (ex-
tensive >70%, poor <30%) and solubility to predict the disposition and potential drug-drug
interactions of new chemical entities (Benet et al., 2011). Through in vitro studies, Ca-
menisch and Umehara demonstrated that the BDDCS class assignments correlate with the
major route of hepatic elimination of drugs (Umehara and Camenisch, 2012; Camenisch
and Umehara, 2012).
In the current study, we aimed to establish a novel physiological-based in vitro-in vivo
extrapolation (IVIVE) method to predict the human renal organ clearance based on filtra-
tion, secretion, and reabsorption processes. We used LLC-PK1 cells as an in vitro tool to
measure the bidirectional epithelial permeation of a set of 20 compounds with various phys-
iochemical properties covering all four BDDCS classes. The obtained permeability data
were incorporated in our model to predict CLr,fil, CLr,sec, the fraction of drug reabsorbed
(freab), and following the total renal organ clearance (CLr,org). We assessed the correlation
between the in vitro predicted and in vivo reported renal clearances. Specifically, we
investigated which underlying process is the major determinant for the overall renal organ
clearance for all four BDDCS classes.
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4.3 Materials and methods
Materials
[3H]desipramine (80 Ci/mmol), [3H]digoxin (40 Ci/mmol), [3H]imipramine hydrochlo-
ride (47.5 Ci/mmol),
[14C]D-mannitol (0.0588 Ci/mmol), [3H]propranolol (30 Ci/m-
mol), and
[3H]verapamil hydrochloride (65.6 Ci/mmol) were acquired from PerkinElmer
(Boston, MA).
[3H]amantadine hydrochloride (0.2 Ci/mmol), [3H]aten- olol (7.3 Ci/m-
mol),
[14C]creatinine hydrochloride (0.0573 Ci/mmol), [3H](R,S)-fexo- fenadine hy-
drochloride (0.29 Ci/mmol),
[3H]fluconazole (9.9 Ci/mmol), [3H]metho- trexate disodium
(25.9 Ci/mmol), and
[3H]tetracycline (17.1 Ci/mmol) were purchased from Moravek
Biochemicals, Inc (Brea, CA).
[3H]ketoconazole (10 Ci/mmol), [3H]atorva- statin cal-
cium (10 Ci/mmol),
[3H]chloroquine (20 Ci/mmol), [3H]cimeti- dine (80 Ci/mmol),[14C]metformin hydrochloride (80 Ci/mmol), [3H]pravastatin sodium (5 Ci/mmol), and[3H]quinidine (20 Ci/mmol) were obtained from American Radiolabeled Chemicals, Inc.
(St. Louis, MO).
[3H]cyclosporine A (20 Ci/mmol) was purchased from Amersham
(Buckinghamshire, UK) and
[14C]valsartan (39.6 Ci/mmol) was synthesized internally
(Isotope Laboratories, Drug Metabolism and Pharmacolinetics, Novartis Pharma AG, Basel,
Switzerland). All other compounds and reagents were of analytical grade and purchased
from commercial sources.
Cell culture
The LLC-PK1 cell line at passage 197 (ATCC CL-101TM) was obtained from the American
Type Culture Collection (ATCC, Manassas VA). The cells were cultivated in medium 199
(Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS), at
37◦C under a humidified atmosphere containing 5% CO2.The culture medium was changed
every second to third day. The cells were cultivated for a maximum period of 6 weeks and
were passaged 13 times.
Bidirectional permeability studies in LLC-PK1 cells
We conducted the bidirectional transport studies in Corning Transwell cell culture in-
serts (Corning Inc., Corning, NY). The LLC-PK1 cells were seeded on a microporous
poly-carbonate membrane (0.4 µm pore size; 0.33 cm2 surface area) at a density of
5·105 cells/cm2. The cells were maintained for four days as described above. On the day
of the experiment, we measured the trans-epithelial electrical resistance (TEER) with a
Millicell Electrical Resistance System (Millipore, Bedfor, MA) according to the manufac-
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turer’s recommendations. The transport studies were carried out only with cell monolayers
that exceeded a TEER value of 120 Ωcm2.
To account for physiological conditions, a pH difference between blood (basolateral)
and urine (apical) compartments was applied neglecting urinary pH variations. The ex-
periments were performed in modified Krebs buffer adjusted to pH 7.4 and 6.8 for the
basolateral (lower chamber, 1.0 mL) and apical compartment (upper chamber, 0.2 mL),
respectively (Brown et al., 2008). We replaced the cell culture medium with prewarmed
assay buffer (37◦C) and preincubated the cell monolayers for 30 min. Subsequently, the
buffer was aspirated and buffer containing the radio-labeled study compound was added
to the donor compartment. All study compounds were prepared as a mixture of labeled
and unlabeled substance to obtain a final concentration of 1 µM. The cell monolayers were
incubated for 20 min at 37◦C. Aliquots (0.1 mL) of both compartments were transferred
into scintillation vials and the radioactivity was determined by liquid scintillation counting
using a Packard Tri-Carb 2700TR (Westwood, MA). To evaluate the reproducibility of
data in terms of active compound transport, we studied the basolateral to apical transport
of creatinine (5 µM) in the presence and absence of N-methyl-4phenylpyridium acetate
(MPP+; 100 µM). Creatinine is known to be transported across the LLC-PK1 monolayers
by an active process which is inhibited by MPP+ (Urakami et al., 2005). Furthermore, we
measured the basolateral to apical transport of D-mannitol (1 µM) to evaluate the integrity
of the cell monolayers.
The apparent permeability Papp (cm/min) was calculated with:
Papp =
VR · CR
t · A · CD (4.1)
where VR determines the incubation volume (mL) in the receiver chamber, CR refers to
the substrate concentration (µM) in the receiver chamber at the end of the incubation time
t (min), A is the surface area of the transwell filter membrane (cm2), and CD determines
the initial substrate concentration (µM) in the donor chamber. From bidirectional transport
experiments Papp values were determined in basolateral to apical (Papp,BA) and apical to
basolateral (Papp,AB) directions.
Upscaling of in vitro parameters
The in vitro determined Papp,BA and Papp,AB values were upscaled to the human intrinsic
clearances [CLr,int,BA and CLr,int,AB, respectively; mL/(min· kg)] with:
CLr,int = Papp ·
pi · lPT · dPT · nnep · nkid
BW
(4.2)
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where the surface of the human proximal tubule is calculated as the product of its length
lPT (1.5 cm), its diameter dPT (7 · 10-3 cm), and the number pi ( = 3.141). nnep is the
number of nephrons per kidney (1.5 · 106), nkid the number of kidneys in human (2), and
BW is the average human body weight (70 kg) (Lote, 2012).
Determination of human renal clearance
The renal organ clearance (CLr,org), as descriptor of renal excretion, is a composed process
involving glomerular filtration clearance (CLr,fil), tubular secretion clearance (CLr,sec),
metabolic clearance, and reabsorption of a fraction of drug from the tubule fluid back into
the blood (freab). Assuming that the contribution of renal metabolic clearance is negligible
CLr,org can be expressed as (Okudaira and Sugiyama, 1996; Fagerholm, 2007; Kusuhara
and Sugiyama, 2009):
CLr,org =
(
CLr, f il + CLr,sec
) · (1− freab) (4.3)
The filtration clearance can be calculated as the product of GFR [1.79 mL/(min· kg)]
and the unbound fraction of drug in blood (fub) provided in Table 4.1 (Dewoskin and
Thompson, 2008):
CLr, f il = f ub · GFR (4.4)
In analogy to the well-stirred liver model, CLr,sec can be expressed as a function of the
renal blood flow rate Qr,b [17.14 mL/(min· kg)], fub, and the intrinsic clearance of tubular
secretion (Dewoskin and Thompson, 2008; Shitara et al., 2005). Assuming that secretion
occurs exclusively in the renal proximal tubules, the intrinsic clearance of tubular secretion
was approximated with CLr,int,BA (Eqs 4.1 and 4.2). Consequently, CLr,sec was calculated
as follows:
CLr,sec =
Qr,b · f ub · CLr,int,BA
Qr,b + f ub · CLr,int,BA (4.5)
Reabsorption can be determined analogous to the secretion clearance. As it occurs from the
tubule fluid into the blood, we substituted Qr,b in 4.5 with GFR, used CLr,int,AB instead of
CLr,int,BA, and assumed protein binding in the tubule fluid to be negligible (Dewoskin and
Thompson, 2008). Consequently, the fraction of drug reabsorbed was calculated as follows:
freab =
CLr,int,AB
GFR+ CLr,int,AB
(4.6)
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Finally, we obtained the predicted renal organ clearance (CLr,org,in vitro) by substituting the
variables from Eqs. (4.4-4.6) into Eq. 4.3.
Data analysis
We performed at least two independent bidirectional transwell experiments for each com-
pound. Each experiment consisted of triplicate incubations (n = 3). The permeability
(Papp,BA) of the reference compounds creatinine and mannitol was measured in 12 indepen-
dent experiments. Data were expressed as the mean of all incubations and the differences
between creatinine permeabilities in the presence and absence of MPP+ was calculated by
unpaired Student’s t-test. Differences were considered statistically significant when p was
< 0.05. The correlation between (in vitro) predicted and the (in vivo) observed clearances
was investigated by linear regression analysis using Microsoft Excel. As the clearance
values show a log-normal distribution, the linear regression analysis was performed with
log-transformed values to obtain the regression equation and the correlation coefficient
(R2). To indicated the predictive accuracy, average fold errors (afe) between the observed
and predicted clearances were calculated:
afe = 10| 1N ∑ log predictedobserved | (4.7)
A perfect prediction would be indicated by an afe value of one and a successful prediction
method is represented by an afe below two (Obach et al., 1997).
4.4 Results
Compound characteristics
We selected the 20 study compounds based on their physiochemical and pharmacoki-
netic properties, to generate a heterogeneous test set covering all four BDDCS classes as
summarized in Table 4.1. A further selection criterion was the availability of reported
clinical data such as protein binding, blood-to-plasma ratios, and renal clearances (Sup-
plementary Information Table 6.3). The relative contributions of the in vivo renal organ
clearance (CLr,org,in vivo) to the total body clearance (CLtot,in vivo) as reported in literature
are illustrated in Figure 4.1. For all classes 1 and 2 compounds, renal clearance is a
minor route of elimination with urinary excretion fractions (Ue) below 20%. In contrast,
the contribution of renal clearance to total body clearance exceeds 20% for all classes 3
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Table 4.1: Physiochemical and pharmacokinetic drug properties.
Compounds BDDCS pKa LogD7.4 fub Rb CLtot,in vivo [mL/(min·kg)] Ue (%)
Desipramine Class1 10.2 (b) 1.40 0.21 0.857 12.05 2
Imipramine Class1 9.5 (b) 2.20 0.13 1.100 9.92 2
Propranolol Class1 9.5 (b) 1.20 0.11 1.182 20.81 1
Quinidine Class1 4.3/8.5 (b) 1.82 0.27 0.444 7.30 19
Quinine Class1 4.1/8.4 (b) 1.82 0.18 0.733 2.62 16
Verapamil Class1 8.9 (b) 1.75 0.13 0.846 16.21 3
Atorvastatin Class2 4.5 (a) 1.53 0.08 0.630 14.17 1
Cyclosporine A Class2 n.a. (n) 2.92 0.03 2.333 4.88 1
Ketoconazole Class2 2.9/6.5 (b) 4.05 0.02 0.500 4.46 3
Amantadine Class3 10.1 (b) -0.69 0.14 2.660 1.22 70
Atenolol Class3 9.6 (b) -1.03 0.89 1.070 2.18 91
Chloroquine Class3 8.4 (b) 1.54 0.11 4.000 2.58 57
Cimetidine Class3 6.8 (b) 0.33 0.84 0.952 7.43 84
Digoxin Class3 n.a. (n) 1.26 0.82 0.915 3.58 66
Fexofenadine Class3 4.3/9.5 (a) 2.68 0.56 0.550 11.00 13
Metformin Class3 11.5 (b) -5.41 1.00 1.000 6.56 99
Methotrexate Class3 4.8/5.5 (a) -2.52 0.65 0.830 2.63 74
Pravastatin Class3 4.5 (a) -0.23 0.97 0.536 25.19 47
Tetracycline Class3 3.3/7.7/9.5 (a) -1.41 0.84 0.900 2.37 85
Valsartan Class4 3.9/4.7 (a) -0.34 0.09 0.556 0.94 29
BDDCS refers to the Biopharmaceutics Drug Disposition Classification System according to Benet et al. (2011) fub
refers tot he fraction of drug unbound in blood, CLtot, in vivo describes the total human body clearance, and Ue is the
fraction of drug excreted into urine (Ue = CLr,org,in vivo/CLtot,in vivo·100%). The letters b,a, and n refer to basic, acidic,
and neutral, respectively. All literature references for the given values are listed in Table 6.3 of the Supplementary
Information.
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Figure 4.1: Relative contributions of the renal (black bars) and nonrenal (white bars) clearance pathways
to the total body clearance for the study compounds according to Table 4.1. The line separates the study
compounds assigned to BDDCS classes 1,2 and classes 3,4.
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and 4 compounds except fexofenadine. For several class 3 compounds such as atenolol,
cimetidine, or tetracycline, renal clearance is the predominant or exclusive (metformin)
route of elimination with Ue above 80%. Literature references of all compounds including
human physiochemical and pharmacokinetic parameters are provided as supplementary
information.
Bidirectional permeability studies in LLC-PK1 cells
For all compounds, bidirectional transport studies were performed at a concentration
of 1 µM. It is assumed that this concentration is well below the Km values of relevant
basolateral uptake transporters allowing measurements of intrinsic transport properties for
compounds that are actively secreted across the LLC-PK1 monolayer (Morrissey et al.,
2013). In addition, sink conditions were verified at the end of the bidirectional transport
studies to assure linear transport conditions. For all study compounds, receiver chamber
concentrations were below 10% of the donor chamber concentrations except for three
compounds were deviations were assumed to be in an acceptable range (10%-13%).
To evaluate inter-assay variability of the LLC-PK1 cell system regarding monolayer in-
tegrity and reproducibility of Papp values, we performed eight independent transport assays
in basolateral to apical direction with creatinine and mannitol. We observed a mean Papp,BA
value of 28.6·10-5 ± 1.6·10-5 cm/min for creatinine in the absence of an inhibitor. In the
presence of MPP+, creatinine transport was significantly reduced to a mean Papp,BA of
16.5·10-5 ± 1.5·10-5 cm/min (p < 0.001). For mannitol, we obtained a mean Papp,BA value
of 6.5·10-5 ± 0.5·10-5 cm/min.
Table 4.2 lists the Papp values for all study compounds obtained from bidirectional transport
experiments as well as the corresponding efflux ratios (ERs). The ERs ranged from 0.51
for atorvastatin to 8.99 obtained for cimetidine. Out of 20 study compounds, 15 exhibited
ERs above 1, showing favored permeation in basolateral to apical direction. This might be
caused by transporter-mediated active secretion and/or favored passive permeation based
on lower degree of ionization of weak bases at pH 7.4 in the basolateral compartment
(compared with apical of 6.8).
Renal clearance prediction
For all study compounds, the clearances for the individual renal elimination process (CLr,fil,
CLr,sec, freab), as well as the overall renal organ clearances (CLr,org,in vitro) were calculated
as described in section 4.3. The resulting predictions are listed in Table 4.3.
For all BDDCS 1 and 2 study compounds with exception to quinidine, the reported in vivo
renal organ clearances in humans (CLr,org,in vivo) are below 1 mL/(min·kg). Our predicted
filtration (CLr,fil) and secretion (CLr,sec) clearances were below 1 mL/(min·kg) for all
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Table 4.2: Drug transmembrane permeation over the LLC-PK1 monolayers.
Compounds Papp,BA (10-5 cm/min) SD (10-5 cm/min) Papp,AB (10-5 cm/min) SD (10-5 cm/min) ER
Desipramine 199.82 2.72 89.38 5.05 2.24
Imipramine 273.75 9.08 142.15 7.46 1.93
Propranolol 408.82 53.31 241.75 11.54 1.69
Quinidine 178.10 10.10 39.11 6.14 4.55
Quinine 140.24 5.83 28.50 5.53 4.92
Verapamil 438.51 32.46 367.44 29.87 1.19
Atorvastatin 3.90 0.81 46.66 8.99 0.51
Cyclosporine A 165.18 31.37 81.94 4.6 2.02
Ketoconazole 138.44 3.90 96.78 13.09 1.43
Amantadine 128.17 6.38 15.86 1.02 8.08
Atenolol 7.92 0.43 9.49 1.12 0.83
Chloroquine 317.03 5.97 45.87 1.67 6.91
Cimetidine 201.59 18.22 22.43 1.26 8.99
Digoxin 41.42 2.55 15.46 1.89 2.68
Fexofenadine 12.04 1.11 13.05 3.02 0.92
Metformin 147.46 5.76 19.73 2.72 7.47
Methotrexate 10.27 0.62 10.13 2.09 1.01
Pravastatin 6.47 0.84 7.59 0.59 0.89
Tetracycline 106.25 4.54 97.29 11.09 1.09
Valsartan 30.46 1.62 40.73 1.15 0.75
Papp,BA and Papp,AB refer to the apparent permeabilities obtained from transport studies in basolateral to apical (BA) and
apical to basolateral (AB) as described by Eq.4.1. The efflux ratio (ER) was calculated as the quotient of Papp,BA and
Papp,AB.
classes 1 and 2 compounds as well. The determined fraction reabsorbed ranged between
0.18 obtained for quinine and 0.74 obtained for verapamil.
For classes 3 and 4 compounds, CLr,org, in vivo ranged between 0.27 mL/(min·kg) re-
ported for valsartan and 11.75 mL/(min·kg) reported for pravastatin. The predicted CLr,fil
covered a range between 0.16 and 1.79 mL/(min·kg) for valsartan and metformin, respec-
tively. The determined CLr,sec values ranged between 0.04 mL/(min·kg) for valsartan
and 2.10 mL/(min·kg) for cimetidine. The calculated fractions reabsorbed were generally
smaller for classed 3 and 4 compounds than observed for classes 1 and 2 with values below
0.2, except for valsartan (0.24), chloroquine (0.27), and tetracycline (0.43).
The correlation between the individual predicted clearance processes and CLr,org, in vivo
is illustrated in Figure 4.2. When CLr,org,in vivo was correlated exclusively with CLr,fil
(Fig. 4.2a), 14 compounds were within a three-fold error. Six compounds assigned to BD-
DCS classes 2 (namely ketoconazole) and 3 (namely amantadine, chloroquine, cimetidine,
metformin, and pravastatin) were underpredicted though. Including all compounds, an
afe of 1.94 was obtained, indicating a successful prediction of CLr,org, in vivo from CLr,fil.
When the dataset was separated into BDDCS classes 1/2 and 3/4, afe values of 1.40 and
2.54 were obtained, respectively. This analysis, indicated that BDDCS 1/2 compounds
were well predicted by filtration only, in contrast to classes 3/4 compounds.
In Figure 4.2b, CLr,org,in vivo was correlated with CLr,sec showing that nine compounds
(namely desipramine, imipramine, propranolol, quinidine, quinine, verapamil, cyclosporine
A, cimetidine, and tetracycline) were within three-fold error and 11 compounds were un-
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Table 4.3: Predicted human renal drug clearances from in vitro assays.
Compounds CLorg,in vivo CLr,fil CLr,sec CLr,fil+sec freab CLorg,in vitro
[mL/(min·kg)] [mL/(min·kg)] [mL/(min·kg)] [mL/(min·kg)] [mL/(min·kg)]
Desipramine 0.26 0.38 0.57 0.95 0.41 0.56
Imipramine 0.23 0.23 0.49 0.72 0.53 0.34
Propranolol 0.21 0.20 0.61 0.81 0.66 0.28
Quinidine 1.42 0.48 0.65 1.13 0.24 0.86
Quinine 0.42 0.32 0.35 0.67 0.18 0.55
Verapamil 0.48 0.23 0.77 1.00 0.74 0.26
Atorvastatin 0.14 0.14 0.03 0.17 0.27 0.12
Cyclosporine A 0.05 0.05 0.07 0.12 0.39 0.07
Ketoconazole 0.14 0.04 0.04 0.08 0.43 0.05
Amantadine 0.86 0.25 0.25 0.50 0.11 0.45
Atenolol 1.99 1.59 0.10 1.69 0.07 1.57
Chloroquine 1.47 0.20 0.48 0.68 0.27 0.50
Cimetidine 6.26 1.50 2.10 3.60 0.15 3.06
Digoxin 2.38 1.47 0.47 1.94 0.11 1.73
Fexofenadine 1.44 1.00 0.09 1.09 0.09 0.99
Metformin 6.49 1.79 1.86 3.65 0.13 3.18
Methotrexate 1.95 1.16 0.09 1.25 0.07 1.16
Pravastatin 11.75 1.74 0.09 1.83 0.06 1.72
Tetracyline 2.02 1.50 1.18 2.68 0.43 1.53
Valsartan 0.27 0.16 0.04 0.20 0.24 0.15
CLr,org,in vivo denotes the in vivo reported renal blood clearance, CLr,fil, CLr,sec, CLr,fil+sec, and CLr,org,in vitro denote
the determined renal filtration clearance, the renal secretion clearance, the su of filtration and secretion clearances,
and the predicted renal organc clearance according to Eqs.4.3-4.5. freab refers to the determined fraction of drug
reabsorbed according to Eq. 4.6.
derpredicted including the majority of BDDCS classes 2,3, and 4 compounds. Including
all compounds, an afe of 3.13 was obtained when CLr,org,in vivo was predicted from the
secretion clearance. A separate analysis of classes 1/2 and 3/4 showed an excellent predic-
tion for compounds assigned to classes 1/2 (afe = 1.04), whereas compounds, assigned to
classes 3/4 were poorly predicted with an afe of 7.72.
When CLr,org,in vivo was correlated with the sum of filtration and secretion clearance
(CLr,sec+fil), the prediction was improved and 16 out of 20 study compounds were within
a three-fold error (Fig. 4.2c). The BDDCS class 1 compounds desipramine, imipramine,
and propranolol were slightly overpredicted, whereas the BDDCS class 3 compound
pravastatin was underpredicted by more than six-fold. Following afe analysis including all
compounds, an excellent prediction was obtained when CLr,org,in vivo was predicted from
CLr,sec+fil (afe = 1.01). A separated analysis of classes 1/2 and 3/4 resulted in afe values of
1.80 (overpredicted) and 1.64 (underpredicted) for classes 1/2 and 3/4, respectively, thus
indicating a successful prediction.
Figure 4.2d shows the correlation of CLr,org,in vivo and CLr,org,in vitro. The incorporation
of all renal clearance processes improved the prediction significantly and 14 out of 20
compounds were within a two-fold error and 19 out of 20 study compounds were within
a three-fold error. Only pravastatin (class 3) was underpredicted. Including all study
compounds, the prediction accuracy in terms of the two-fold and three-fold error expressed
in percent was 70% and 95%, respectively. Afe analysis resulted in a value of 1.4 including
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Figure 4.2: Correlation of the in vivo reported and the in vitro predicted renal clearances according to 4.3.
CLr,org,in vivo was compared either with (a) the filtration clearance [log(CLr,org,in vivo) = 0.72·log(CLr,fil) - 0.31;
R2 = 0.80], (b) the tubular secretion clearance [log(CLr,org,in vivo) = 0.37·log(CLr,sec) - 0.55; R2 = 0.17], (c) the
sum of filtration and secretion clearance [log(CLr,org,in vivo) = 0.62·log(CLr,fil+sec) - 0.04; R2 = 0.71], or (d) the
predicted renal organ clearance taking all processes into account [log(CLr,org,in vivo) = 0.75·log(CLr,org,in vitro) -
0.19; R2 = 0.83]. Circles, triangles, diamonds, and squares refer to BDDCS class assignments 1,2,3, and 4,
respectively. White and gray represents BDDCS classes 1/2 and 3/4, respectively. The black line represents
the line of unity and the gray lines the three-fold errors.
all compounds, 1.03 for classes 1/2 and 1.96 for classes 3/4. Thus, a successful prediction
of CLr,org,in vivo from CLr,org,in vitro was obtained including all compounds as well as for
compounds assigned to classes 1/2 and 3/4.
4.5 Discussion
Our present study aimed to establish a novel IVIVE method to predict the human renal
organ clearance based on in vitro permeability studies in the LLC-PK1 cell line. We
performed bidirectional transepithelial permeation experiments for 20 compounds and
calculated the resulting ERs (Table 4.2). For all basic compounds, except atenolol, the ERs
were greater than 1.0 indicating secretion by an active transport process. The highest ER
values were obtained for amantadine, cimetidine, and metformin. These compounds are
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reported substrates for the OCT system and were shown to be actively secreted via OCT2
and MATE in humans (Morrissey et al., 2013; ITC, 2010). Moreover, we confirmed results
by Urakami et al. indicating that LLC-PK1 cells actively secrete creatinine (Urakami et al.,
2005). Thus, our data were in line with findings that the relevant transporters of the renal
OCT system are functionally active in the LLC-PK1 cell line (Urakami et al., 2005; Saito
et al., 1992). In contrast, the measured bidirectional permeabilities of the weakly acidic
drugs such as pravastatin, fexofenadine, methotrexate, tetracycline, and valsartan were not
significantly different resulting in ER values of approximately one or lower. As all of these
compounds are reported to be actively secreted by transporters of the renal organic anion
transport (OAT) system, including OAT1, OAT3, MRP2, and BCRP, our results appeared
to support previous data indicating limited OAT activity in the LLC-PK1 cell line (Hori
et al., 1993).
For our study dataset, we scaled the measured permeability values up to human intrinsic
clearances and incorporated these data into our new physiological-based model to deter-
mine CLr,sec and freab as well as CLr,org,in vitro (Table 4.3). Out of 20 compounds, nine are
assigned to the BDDCS classes 1 and 2. According to the BDDCS, the major route of
elimination for these compounds is hepatic metabolic clearance. Indeed, all classes 1 and
2 compounds in our dataset have reported CLr,org,in vivo below 1 ml/(min·kg). Because of
the high protein binding, CLr,fil was low and CLr,org,in vivo were well predicted exclusively
from CLr,fil for classes 1 and 2 compounds (Fig. 4.2a). Nevertheless, we could show that se-
cretion processes occurred also for these two BDDCS classes. Consequently, CLr,org,in vivo
was overpredicted for these compounds when predicted from either CLr,sec or CLr,fil+sec
(Fig. 4.2b and 4.2c). The inclusion of the reabsorption process increased the predictability
of classes 1 and 2 compounds and we obtained a good correlation between CLr,org,in vivo
and CLr,org,in vitro when taking all physiological processes driving renal clearance into
account (Fig. 4.1d). Extensive reabsorption is assumed to be a consequence of a high
passive permeation over the tubular epithelial of highly lipophilic compounds (Li et al.,
2006; Varma et al., 2009). Our study results confirmed that assumption and we predicted
extensive reabsorption for the highly lipophilic compounds assigned to BDDCS classes
1 and 2. Thus, despite the significant contribution of secretion, the overall renal organ
clearances for all classes 1 and 2 compounds were low. In conclusion, all renal clearance
processes of BDDCS 1 and 2 compounds were well described with our new model and in
line with literature data.
The major route of elimination for BDDCS 3 and 4 compounds is renal and biliary excre-
tion of unchanged drug (Benet et al., 2011). Our study included 11 compounds assigned
to the BDDCS classes 3 and 4. When CLr,org,in vivo was predicted either from CLr,fil or
CLr,sec, the majority of classes 3 and 4 compounds was underpredicted (Fig. 4.2a and
Fig. 4.2b). Moreover, a cluster of four class 3 compounds, including the three acidic drugs
methotrexate, pravastatin, and tetracycline, was strongly underpredicted when CLr,org,in vivo
was correlated to CLr,sec. As discussed above, the LLC-PK1 might not functionally express
major transporters of the OAT system. Consequently, our model might underpredict the
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contribution of CLr,sec to CLr,org,in vivo for compounds whose tubular secretion clearance
mainly depends on active secretion mediated by OAT. In contrast, we obtained highest
CLr,sec values for all the basic class 3 compounds in our dataset, indicating that active
secretion via OCT was contributing significantly to CLr,org,in vivo. Taking all classes 3 and
4 compounds of our dataset into account, regardless of their physiochemical properties,
we obtained a good correlation when CLr,org,in vivo was predicted from either CLr,fil+sec
(Fig. 4.2c) or CLr,org,in vitro (Fig. 4.2d). These results suggest that the contribution of
reabsorption to CLr,org,in vivo was negligible for most classes 3 and 4 compounds, which
is reflected by the low freab values determined for these compound classes. Again, our
new model well represented the underlying physiological determinants driving renal organ
clearance and showed an overall good correlation between CLr,org,in vivo and CLr,org,in vitro
for highly renally cleared classes 3 and 4 compounds.
Currently, reported IVIVE methods that allow the prediction of the overall renal organ
clearance for compounds with various physiochemical and pharmacokinetic properties are
limited. Recently, Neuhoff et al. introduced a new physiological-based pharmacokinetic
kidney model for the prediction of renal elimination that includes glomerular filtration,
secretion, reabsorption, and renal metabolism (Neuhoff et al., 2013). In comparison with
our IVIVE method, this approach requires a multitude of input parameters including physi-
ological, physiochemical, and in vitro data on drug transport and enzyme kinetics. Another
approach has been used by Watanabe et al. to predict CLr,sec for anionic drugs based on
in vitro uptake measurements in human kidney slices (Watanabe et al., 2011). A good
prediction was obtained for eight out of nine compounds within a three-fold error. The
predicted secretion clearance for valsartan was overestimated. Because of the experimental
setup, studies in kidney slices only allow the assessment of cellular uptake though and the
permeation over the epithelial layer cannot be determined. Consequently, IVIVE methods
using kidney slices are limited to compounds whose major renal clearance contributor is
active secretion and that do not undergo reabsorption. Major drawbacks of studies with
kidney slices and human primary tissue in general are the limited availability of suitable
donors and potential interdonor variability.
The ideal in vitro system would be a renal cell line of human origin, expressing all rele-
vant transporters and forming tight monolayers. Yet to our knowledge, no cell line was
reported to fulfill these requirements and therefore the LLC-PK1 cell line was considered
as the most suitable in vitro system. Our findings demonstrated that the LLC-PK1 cells
represented a valuable in vitro model to predict the renal organ clearance, especially for
neutral and cationic compounds. However, the lack of a functional OAT system limited the
predictability for anionic compounds that are mainly eliminated by tubular secretion.
As the distribution of of the 20 compounds had to fulfill a series of properties (described
in section 4.4), the proportion of neutral compounds was rather underrepresented. Future
application of this IVIVE approach to a larger set of compounds will be needed to inves-
tigate the predictability for neutral and zwitterionic compounds as well as for additional
cationic compounds that are actively secreted. Future work will also be required to validate
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the model in terms of its suitability for dynamic predictions. Although the present experi-
mental setup using only single concentrations allows static renal clearance and drug-drug
interaction predictions, concentration-dependent studies would allow the generation of
kinetic parameters that can be incorporated into physiologically based pharmacokinetic
models.
In summary, our novel IVIVE approach allows the prediction of all major renal clearance
processes of drugs and the assessment of the contribution of each process to the human
renal organ clearance. In this study, we demonstrated that our IVIVE method can be
applied to low and high renally cleared drugs with various properties independent of their
BDDCS class assignments. Moreover, our findings indicated that the contribution of the
underlying clearance processes to the total renal organ clearance correlates well with
the BDDCS class assignment. Consequently, renal clearance predictions based on the
mechanistic renal elimination model discussed in this paper can be used, at least for neutral
and cationic compounds, to identify the compound-class dependent rate-limiting step of
renal elimination and therefore for static or dynamic drug-drug interaction predictions in
the kidney.
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4.6 Supplementary Information
Table 4.4: Literature references for physiochemical and human pharmacokinetic properties of the study com-
pounds.
compound pka logD7.4 CLtot,invivo,p CLtot,invivo,p /F CLr,org,invivo,p fu fub Rb F Ue
(-) (-) (mL/min/kg) (mL/min/kg) (mL/min/kg) (-) (-) (-) (-) (%)
Amantandine 10.1 [1] -0.69 3.24 - 3.77 [2] 2.29 [2] 0.37 [1] 0.14 - 2.660 [1] 0.86 [1] 71 -
Atenolol 9.6 [3] -1.03 2.33 - 4.02 [4] 2.13 [4] 0.95 [4] 0.89 - 1.070 [5] 0.58 [6] 91 -
Atorvastatin 4.5 [7] 1.53 [7] 8.93 [7] 63.79 - 0.09 - 0.05 [8] 0.08 [9] 0.630 - 0.14 [7] 1 [7]
Chloroquine 8.4 [10] 1.54 10.31 [11] 11.58 - 5.89 [11] 0.43 [10] 0.11 - 4.000 [10] 0.89 [11] 57 -
Cimetidine 6.8 [12] 0.33 7.07 [12] n.o. 5.96 [12] 0.80 [12] 0.84 - 0.952 - n.o. 84 -
Cyclosporine A n.a. 2.92 11.39 [13]c) 25.77 - 0.11 - 0.07 [6] 0.03 [9] 2.333 - 0.22 [13] 1 [6]
Desipramine 10.2 [14] 1.40 10.33 [15] 27.18 - 0.22 [15] 0.18 [15] 0.21 [15] 0.857 - 0.38 [15] 2 -
Digoxin n.a 1.26 3.28 [16] 4.69 - 2.18 [16] 0.75 [6] 0.82 [9] 0.915 - 0.70 [6] 66 -
Fexofenadine 4.3/9.5 [17] 2.67 6.05 - 18.33 [18] 0.79 [18] 0.31 [8] 0.56 - 0.550 [8] 0.33 [17] 13 -
Imipramine 9.5 [14] 2.20 10.91 - 40.42 [19] 0.25 [19] 0.14 [20] 0.13 - 1.100 [21] 0.27 [20] 2 -
Ketoconazole 2.9/6.5 [22] 4.05 2.23 - 2.75 [23] 0.07 - 0.01 [23] 0.02 [9] 0.500 - 0.81 [23] 3 [24]
Metformin 11.5 [25] -5.41 6.56 [25] 12.62 - 6.49 [25] 1.00 [25] 1.00 - 1.000 [26] 0.52 [25] 99 -
Methotrexate 4.8/5.5 [27] -2.52 2.18 [28] 3.11 - 1.62 [28] 0.54 [6] 0.65 - 0.830 [8] 0.70 [6] 74 -
Pravastatin 4.5 [29] -0.23 13.50 [30] 75.00 - 6.30 [30] 0.52 [29] 0.97 [9] 0.536 - 0.18 [30] 47 -
Propranolol 9.5 [14] 1.20 24.61 - 94.61 [32] 0.25 - 0.13 [6] 0.11 [9] 1.182 - 0.26 [6] 1 [6]
Quinidine 4.3/8.5 [31] 1.82 3.24 - 4.05 [33] 0.63 [33] 0.12 [34] 0.27 [9] 0.444 - 0.80 [6] 19 -
Quinine 4.1/8.4 [31] 1.82 1.92 [35] 2.53 - 0.31 - 0.13 [6] 0.18 - 0.733 [36] 0.76 [6] 16 [6]
Tetracycline 3.3/7.7/9.5 [37] -1.41 2.13 [38] n.o. 1.82 [38] 0.76 [38] 0.84 - 0.900 [39] n.o. 85 -
Valsartan 3.9/4.7 [40] -0.34 [41]b) 0.52 [40] 2.26 - 0.15 [40] 0.05 [40] 0.09 [9] 0.556 - 0.23 [40] 29 -
Verapamil 8.9 [14] 1.75 [43] 13.71 [44] 52.73 - 0.41 - 0.11 [44] 0.13 [9] 0.846 - 0.26 [44] 3 [6]
Note: CLtot denotes the total body clearance, CLr,org,invivo refers to the renal organ clearance, F denotes the bioavailability, fu and fub
refer to the fraction of drug unbound in plasma and blood, respectively, Rb denotes the blood to plasma partition coefficient, and Ue
refers to the percentage of drug excreted in urine. If not indicated otherwise, all values refer to human plasma. Clearance values were
corrected for the average human body weight which was assumed to be 70 kg. The literature references are shown in squared brackets.
a) if not stated otherwise the values are obtained from Benet et al.
b) reported value refers to logD7.0
c) the reported value refers to blood
n.o. not obtained
n.a. not available (neutral compounds)
- calculated parameter
The calculated parameters reported in Table 6.3 were obtained according to the following
equations:
Rb = f u/ f ub = CL/CLb = Cb/C (4.8)
CLtot,invivo = CLtot,oral · F (4.9)
CLr,org,invivo = Ae/AUC (4.10)
CLr,org,invivo = Ue · CLtot (4.11)
(4.12)
where Rb denotes the blood to plasma partition coefficient, fu and fub denote the fraction
of drug unbound in plasma and blood, respectively, CL and CLb refer to clearance values
and C and Cb to concentrations obtained in plasma and blood, respectively, CLtot,invivo
denotes the total body clearance, CLtot,oral refers to the total body clearance reported
from oral administered drug studies, F denotes the bioavailability, CLr,org,invivo refers to
the renal organ clearance, Ae describes the amount of drug excreted unchanged in urine,
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AUC denotes the area under the curve, and Ue refers to the percentage of drug excreted
unchanged in urine. Equation 4.8 was used to convert the reported clearances from plasma
to blood values.
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5.1 Abstract
Organic anion transporting polypeptides (OATP)1B1 and OATP1B3 are drug transporters
mediating the active hepatic uptake of their substrates. Since they exhibit overlapping
substrate specificities the assessment of the contribution of each isoform to the net hep-
atic uptake needs to be considered when predicting drug-drug interactions. The relative
contribution of OATP1B1 and OATP1B3-mediated uptake of statins into hepatocytes was
estimated based on either relative transporter protein expression data or relative activity
data. Therefore, uptake kinetics of eight statins and OATP1B1 and OATP1B3-specific
reference substrates were determined in OATP1B1 and OATP1B3-expressing HEK293
cells and in human cryopreserved hepatocytes. Absolute OATP1B1 and OATP1B3 protein
abundance was determined by liquid chromatography-tandem mass spectrometry in all
expression systems. Transporter activity data generated in recombinant cell lines were
extrapolated to hepatocyte values using relative transporter expression factors (REF) or rela-
tive activity factors (RAF). Our results showed a pronounced OATP1B1 and comparatively
low OATP1B3 protein expression in the investigated hepatocyte lot. Based on REF-scaling,
we demonstrated that the active hepatic uptake clearance of reference substrates, atorvas-
tatin, pravastatin, rosuvastatin, and simvastatin was well predicted within two-fold error
demonstrating that OATP1B1 and OATP1B3 were major contributors. For other statins,
the net hepatic uptake clearance was underpredicted, suggesting the involvement of other
hepatic uptake transporters. Summarized, we showed that REF and RAF-based predic-
tions were highly similar indicating a direct transporter expression-activity relationship.
Moreover, we demonstrated that the REF-scaling method provided a powerful tool to
quantitatively assess the transporter-specific contributions to the net uptake clearance of
statins in hepatocytes.
5.2 Introduction
Human drug uptake transporters are membrane-bound proteins that facilitate the active
cellular uptake of compounds which due to their physiochemcial properties cannot cross
cellular membranes by passive diffusion. Expressed at the basolateral membrane of hepa-
tocytes, organic anion transporting polypeptides (OATPs) mediate the uptake of mainly
anionic drugs from the blood into the liver. OATP inhibition due to drug-drug inter-
actions (DDIs) can lead to increased plasma concentration levels of drugs thus posing
a potential risk for toxicity in peripheral organs. Following co-medications involving
hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), muscle
toxicity and severe myopathy are reported risks that have been partially attributed to the in-
hibition of OATPs (Staffa et al., 2002; Shitara and Sugiyama, 2006; Neuvonen et al., 2006).
Thus, predicting the transporter-mediated DDI risk is a necessity for the development of
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new molecular entities.
Cryopreserved human hepatocytes are a common tool to assess the hepatic uptake of com-
pounds. Hepatocytes express various uptake transporters including OATP1B1 (SLCO1B1),
OATP1B3 (SLCO1B3), OATP2B1 (SLCO2B1), the organic anion transporter 2 (OAT2;
SLC22A7), the organic cation transporter 1 (OCT1; SLC22A1), and the sodium taurocholate
co-transporting polypeptide (NTCP; SLC10A1). Since a variety of compounds including
statins exhibit an overlap of transporter specificity, compound uptake in hepatocytes reflects
the sum of all transporter-specific contributions (Shitara and Sugiyama, 2006; Neuvonen
et al., 2006; Noe et al., 2007; Shitara et al., 2013; Kalliokoski and Niemi, 2009; Knauer
et al., 2010; Bi et al., 2013).
To assess the relative contribution of specific transporters to the net hepatic uptake, meth-
ods based on relative transporter expression and activity have been introduced. Hirano
et al., established a method that allows the estimation of the contribution of OATP1B1
and OATP1B3 mediated uptake in hepatocytes based on relative activity factors (RAF)
(Hirano et al., 2004). Determined as ratios of the uptake of transporter-specific substrates
in hepatocytes relative to the uptake in recombinant cell lines, the RAF method has been
widely used to estimate the contribution of OATP1B1 and OATP1B3 to the hepatic uptake
of various compounds (Shitara and Sugiyama, 2006; Hirano et al., 2004; Shimizu et al.,
2005; Kitamura et al., 2008). In addition, Hirano et al. used protein expression data from
Western Blot analysis to estimate relative expression factors (REFs) to determine the contri-
bution of OATP1B1, OATP1B3, and OATP2B1 to the net hepatic uptake of pitavastatin and
estradiol 17β-D-glucuronide (Hirano et al., 2004, 2006). While the predicted transporter
contributions based on RAFs and REFs were within a comparable range, net hepatic
uptake clearances estimated from REFs were significantly over-predicted compared to
observed values. Recently, the contribution of OATP1B1-mediated hepatic uptake of five
substrates was investigated using a gene knockdown approach (Williamson et al., 2013).
Compared with a RAF-based method highly similar results were obtained in predicting the
transporter-specific contributions to the net hepatic uptake. Yet, extending the described
approaches to any transport protein of interest is challenging due to practical limitations,
such as the need for specific antibodies for Western Blots, transporter-specific substrates
for RAFs, and genespecific knockdown. Moreover, the RAF-based and siRNA-based
approaches are restricted to investigated cell systems (i.e. hepatocytes) and do not allow
the extrapolation of transporters activities to any tissue based on in vitro experiments.
Recently, novel established quantitative targeted absolute proteomics (QTAP) methods,
based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) have been used
to determine the absolute transporter amount in plasma membrane samples of various hu-
man tissues including liver and brain (Ohtsuki et al., 2012; Kamiie et al., 2008; Sakamoto
et al., 2011; Uchida et al., 2011; Schaefer et al., 2012). Moreover, REFs determined by
LC-MS/MS based approaches are used in first studies to determine the specific contribution
of hepatic uptake transporters in cryopreserved hepatocytes and human liver (Karlgren
et al., 2012; Kimoto et al., 2012; Bi et al., 2013; Vildhede et al., 2014).
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It was the aim of the present study to determine the contribution of OATP1B1 and
OATP1B3 to the net hepatic uptake clearance of atorvastatin, cerivastatin, fluvastatin,
lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. For this purpose protein
expression levels of OATP1B1 and OATP1B3 were measured in cryopreserved human
hepatocytes and in recombinant HEK293 cell lines. Subsequently, we determined the
uptake clearances of statins and used REFs derived from QTAP analysis to extrapolate
OATP1B1 and OATP1B3 activities obtained in recombinant cells to hepatocyte values.
Finally, in order to further validate the REF-based scaling method, we assessed the correla-
tion between uptake transporter activity and their relative protein abundance by comparing
RAF and REF-based predictions.
5.3 Materials and Methods
Compounds
[3H]atorvastatin calcium (0.37 MBq/nmol), [3H]cerivastatin sodium (0.19 MBq/nmol),[3H]cholecystokinin octapeptide (CCK8; 3.65 MBq/nmol), [3H]fluvastatin sodium (0.74
MBq/nmol),
[3H]lovastatin acid (0.37 MBq/nmol), [3H]rosuvastatin calcium (0.37 MBq/n-
mol),
[3H]pitavastatin calcium (0.37 MBq/nmol), and [3H]simvastatin acid (0.37 MBq/n-
mol) were obtained from American Radiolabeled Chemicals, Inc. (Saint Louis, MO).[3H]estrone-3-sulfate ammonium (E3S; 1.67 MBq/nmol) was purchased from PerkinElmer
(Boston, MA). All other compounds and reagents were of analytical grade and purchased
from commercial sources.
Cell systems
LiverPoolTM cryopreserved human hepatocytes (lot PQP) were obtained from Celsis, In
Vitro Technologies (Brussels, Belgium). The hepatocyte pool was derived from non-
transplantable fresh liver tissues of twenty donors (gender: 10 male and 10 female; age:
17-75, average age: 52; ethnic background: 16 Caucasians, 2 Blacks, and 2 Hispanics).
A HEK293 cell line stably expressing human OATP1B3 (polybrene transfection method)
was purchased from DKFZ (Deutsches Krebsforschungszentrum; Heidelberg, Germany)
(König et al., 2000). A recombinant HEK293 cell line with stable expression of human
OATP1B1 was generated in-house using the Flp-InTM system (Invitrogen by Life Technolo-
gies, Paisley, United Kingdom) as previously described (Kunze et al., 2012). All HEK293
cell lines were cultivated in DMEM supplemented with 10% FBS, 1% L-glutamine, and 1%
penicillin/streptomycin. For HEK293 cells expressing OATP1B1 or OATP1B3, 100 ng/µL
hygromycin B or 800 ng/µL geneticin, respectively, was added to the cultivation medium.
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The protein content of solubilized cells (solved in 0.2 N NaOH) was determined using
the Bio-Rad Protein Assay kit (Bio-Rad Laboratories AG, Hercules, CA) according to the
manufacturer’s recommendations.
Determination of absolute transporter protein abundance
Absolute protein expression levels of human OATP1B1 and OATP1B3 in the membrane
fractions of recombinant HEK293 cells and human cryopreserved hepatocytes were deter-
mined by peptide-based LC-MS/MS. The preparation of the membrane fractions as well
as the QTAP analysis was performed by BertinPharma (Montigny le Bretonneux, France)
according to established methods by the group of Terasaki, Sakamoto, and Ohtsuki et al.
(Ohtsuki et al., 2012; Sakamoto et al., 2011).
Three samples containing each approximately 80 million HEK293-OATP1B1 or HEK293-
OATP1B3 cells were quickly harvested in ice-cold lysis buffer [Tris-HCl 10 nM, 250 mM
sucrose, Complete Protease Inhibitor (Roche, Basel, Switzerland)]. Subsequently, the
samples were centrifuged (537 g, 4◦C, 5 min) and the supernatant was aspirated. Two
samples of human cryopreserved hepatocytes (approximately 30 million cells per sample)
were thawed and immediately resuspended in InVitroGROTM HT Medium (Bioreclam-
mationIVT; Baltimore, MD). Samples were then centrifuged (50 g; 4◦C; 5 min) and the
supernatant was aspirated. All cells were stored as dry pellet at 80◦C and were shipped to
BertinPharma on dry ice.
All samples were processed by BertinPharma following the published protocols from
the Terasaki group (Ohtsuki et al., 2012; Sakamoto et al., 2011). The cell pellets were
suspended in lysis buffer followed by homogenization. Thereafter, sub-mitrochondrial
fractions were isolated by centrifugation (25 min; 10’800 g; 4◦C). The supernatant was
collected and the microsomal fractions were obtained by centrifugation (60 min; 100’000 g;
4◦C). The microsomal pellet was suspended in 10 mM Tris-HCl buffer (pH 7.4; 250 mM
sucrose). The plasma membrane fractions were obtained by ultracentrifugation of the
microsomal fractions through a 38% (w/v) sucrose solution (Ohtsuki et al., 2012; Sakamoto
et al., 2011).
Total protein contents were determined by Lowry’s method before and after each fractiona-
tion step. The absolute transporter protein abundance in the respective plasma membrane
fractions were determined using simultaneous QTAP based on LC-MS/MS with multiple
reactions monitoring (MRM) (Ohtsuki et al., 2012; Sakamoto et al., 2011). The same
reference peptides were selected as previously published by Uchida et al. : LNTVGIAK
for OATP1B1; IYNSVFFGR for OATP1B3; VLLQTLR for OATP2B1; NVALLALPR for
OAT2M LSPSFADLFR for OCT1; and GIYDGDLK for NTCP (Uchida et al., 2011).
The respective transporter protein expression (exp) was obtained as the amount of trans-
porter protein (fmol) per amount of plasma membrane protein (µg protmem). To determine
the transporter expression per amount of total protein [fmol/(µg prot)], exp was multi-
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plied with the amount of plasma membrane protein obtained per amount of total sample
protein.
Uptake studies in suspended human hepatocytes
Hepatocyte uptake of reference compounds (E3S; CCK8) and the statins was assessed
by the oil spin method as previously described (Umehara and Camenisch, 2012). Frozen
hepatocytes were thawed and directly suspended in InVitroGroTM HT Medium. After
centrifugation (537g, 5 min, low brakes), the supernatant was aspirated and the cells
were immediately suspended in 1 mL of prewarmed Krebs-Henseleit-Buffer (KHB). Sub-
sequently, cells were counted and the suspension was adjusted to a concentration of
1.0 - 1.5·105 viable cells/mL (viability: 83-95%).
Hepatocyte uptake studies initiated by adding 50 µL of hepatocyte suspension to 100 µL
of a substrate solution (KHB containing a mixture of radiolabeled and non-labeled study
compound at specific concentrations). All incubations were carried out at 37◦C and 4◦C
following preincubation times of 5 min and 15 min at 37◦C and 4◦C, respectively. At
designated time-points incubations were terminated transferring the sample to a mineral
oil/NaOH containing tube [Hepatocyte Transporter Suspension Assay Kit (BD Biosciences,
Woburn MA)], followed by immediate centrifugation (10’000 rpm; 1 min). The tubes were
cut and the radioactivity in the cell pellets as well as in the supernatants (for mass balance
studies) was analyzed by liquid scintillation counting (LSC; Packard Tri-Carb 2700TR;
PerkinElmer Inc, Waltham MA).
All hepatocyte incubations were performed for 90 s. In time-dependent uptake experiments
(1, 2, 3, 5 min) for E3S (0.1 µM), pitavastatin (0.5 µM, CCK8 (0.5 µM), and rosuvastatin
(0.5 µM), the rate of uptake was found to lie in a time linear-uptake phase and was conse-
quently applied to all statin incubations. For concentration-dependent kinetic studies, a
broad concentration range was defined for all substrates (0.01–300 µM; 5-10 concentration
points). To demonstrate uptake transporter activity, E3S (0.03 µM) uptake was measured
in the absence and presence of an OATP inhibitor cocktail [a combination of atorvastatin
(10 µM) and rifamycin (20 µM)] in all hepatocyte studies.
Uptake studies in human HEK293-OATP1B1 and HEK293-OATP1B3
expressing cell lines
Cellular uptake studies using plated HEK293-OATP1B1, HEK293-OATP1B3 cells, and
HEK293 parental cells, were performed as previously described (Kunze et al., 2012).
Uptake studies at 37◦C were initiated by incubating the cells with the substrate solution
at the respective concentrations (mix of radiolabeled and unlabeled study compound in
KHB). To determine mass balances of the study compounds, aliquots of the incubation
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solution were taken from each well prior to the termination of the incubation. Afterwards,
the incubation was terminated by aspirating the remaining incubation solution followed by
washing the cells twice with ice-cold PBS. Subsequently, the cells were lysed in NaOH
(0.2 N). The protein contents of the solubilized cells were determined as described above.
The amount of radiolabeled compound in the cell samples and in the incubation solution
was quantified using LSC as described in the previous section.
Time-dependent experiments in OATP1B1 and OATP1B3-expressing HEK293 cells were
performed to define the time-linear range for subsequent concentration-dependent studies
(0.01-300 µM; 6-9 concentration points). An incubation time of 3 min was chosen for
all cell lines and compounds, except for E3S (1 min). Uptake of each study compound
(0.01 µM) was measured in the absence and presence of an OATP inhibitor cocktail
[a combination of atorvastatin (10 µM) and rifamycin (20 µM)]. Functional activity of
OATP1B1 and OATP1B3 in the recombinant cell lines was confirmed in each experiment
as previously described (Kunze et al., 2012).
Data analysis
The uptake kinetics of the investigated compounds were calculated by normalizing the
measured radioactivity to the incubation time and protein content. Consequently, these
uptake rates (Vapp; pmol·min-1·mg-1) were divided by the applied substrate concentrations
to obtain the apparent uptake clearances (PSapp; µL·min-1·mg-1). Results are presented as
uptake clearances throughout the whole manuscript to simplify the visualization of kinetic
data.
As previously described, PSapp values determined in suspended hepatocytes are potentially
affected by nonspecific binding (NSB) of the compound to plastic surfaces of the assay
device or to cellular structures (Umehara and Camenisch, 2012). To account for plastic
binding, total compound recoveries were calculated for all incubations and PSapp values
were multiplied by a respective correction factor (total theoretical recovery divided by
obtained recovery). In a second step, control incubations were performed at 4◦C to correct
PSapp obtained at 37◦C (PSapp,tot,37◦C) for saturable NSB processes to cells (Umehara and
Camenisch, 2012):
PStot = PSapp,tot,37◦C − (PSapp,tot,4◦C,Cmin − PSapp,tot,4◦C,Cmax) (5.1)
where the difference between the apparent clearances determined from 4◦C incubations
at the lowest and highest substrate concentrations (PSapp,tot,4◦C,Cmin and PSapp,tot,4◦C,Cmax,
respectively) was used to describe saturable nonspecific cell binding. For incubations
with OATP1B1 and OATP1B3 expressing HEK293 cells, none of the studied compounds
showed significant NSB to plastic (recoveries > 90%). Moreover, no relevant saturable
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NSB to cells was observed in control incubations using HEK293 parental cells. Conse-
quently, no correction of uptake clearances was required for studies with cell lines and
PStot equals PSapp. The different experimental setups between HEK293 cells (plated) and
hepatocytes (suspension) and the resulting difference in cell surface exposed to the incuba-
tion medium might explain the lack of saturable NSB in HEK293 parental cells. Moreover,
as discussed previously, a difference in NSB between HEK293 cells and hepatocytes could
be a result of different cell membrane compositions (e.g. lipids and protein contents),
between HEK293 cells and hepatocytes (Mateus et al., 2013).
The total uptake clearance (PStot) is the sum of the active uptake clearance for saturable,
transporter-mediated and passive permeation processes (PSact and PSpas, respectively):
PStot = PSact + PSpas =
PSact,max · Km
Km+ S
+ PSpas (5.2)
where the active transporter-mediated process is following Michaelis-Menten kinetics with
Km and S representing the Michaelis-Menten constant (µM) and the substrate concen-
tration µM), respectively. For initial uptake rates and clearances at very low substrate
concentration (S « Km), PSact can be approximated with PSact,max representing a measure
of the transporter activity. Kinetic parameters were estimated by fitting Eq. 5.2 to the
measured data using a nonlinear least square method.
Estimation of OATP contribution in human hepatocytes
The relative contribution of OATP1B1 and OATP1B3 to the hepatic uptake of compounds
can be assessed by determining a relative activity factor (RAF) or a relative expression
factor (REF) for a specific transporter. In brief, RAFs for OATP1B1 and OATP1B3 were
determined by comparing the transporter activities of transporter specific reference sub-
strates (E3S for OATP1B1; CCK8 for OATP1B3) in recombinant cell lines and hepatocytes,
as described by Hirano et al. (2004); Kimoto et al. (2012):
RAF1B1 =
PSact,max,ES HEP
PSact,max,ES HEK OATP1B1
(5.3)
RAF1B3 =
PSact,max,CCK8 HEP
PSact,max,CCK8 HEK OATP1B3
(5.4)
Subsequently, RAF1B1 and RAF1B3 were applied to predict the combined uptake trans-
porter activity of OATP1B1 and OATP1B3 co-substrates into hepatocytes (PSact,max,HEP)
based on the transporter activities measured in recombinant cells (PSact,max,1B1;1B3):
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PSact,max,HEP = PSact,max,HEK OATP1B1 · RAF1B1 +
PSact,max,HEK OATP1B3 · RAF1B3 (5.5)
Alternatively, we used absolute OATP1B1 and OATP1B3 protein expression data in hepa-
tocytes and recombinant HEK293 cells to derive the REFs for OATP1B1 and OATP1B3:
REF1B1 =
expOATP1B1,HEP
expOATP1B1,HEK OATP1B1
(5.6)
REF1B3 =
expOATP1B3,HEP
expOATP1B3,HEK OATP1B3
(5.7)
where exp represents the specific transporter expression [fmol/(µg prot)] determined as
described in section 5.3. In analogy to equation 5.5, the net transporter activity of com-
pounds in hepatocytes was calculated from recombinant cells using the REF values:
PSact,max,HEP = PSact,max,HEK OATP1B1 · REF1B1 +
PSact,max,HEK OATP1B3 · REF1B3 (5.8)
Statistics
All incubations for kinetic studies were performed in triplicates (n = 3) where values are
given as the mean and standard deviation. Statistical significance for the differences in
uptake clearances obtained in incubations in the presence and absence of transporter in-
hibitors was assessed by unpaired, two-tailed Student’s t-test. Differences were considered
to be statistically significant for p-values below 0.05. For parameter estimation based on
data fitting the coefficients of determination (R2) were determined to assess the goodness
of fit. Moreover, fold-error deviations between the observed and predicted hepatic PSact,max
values were calculated to assess the performance of the REF and RAF-based prediction
methods.
5.4 Results
Transporter abundance
The transporter protein abundance in plasma membrane fractions of HEK293-OATP1B1
and HEK293-OATP1B3 cells and pooled human cryopreserved hepatocytes (lot PQP) was
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Table 5.1: Absolute transporter protein expression.
expression system transporter protein protein expression
(fmol/µg protmem) (fmol/µg prot)
human hepatocytes OATP1B1 15.85 0.230
human hepatocytes OATP1B3 0.35 0.005
human hepatocytes OATP2B1 1.57 0.022
human hepatocytes OAT2 1.03 0.014
human hepatocytes NTCP 2.62 0.036
human hepatocytes OCT1 6.94 0.095
HEK OATP1B1 OATP1B1 23.97 0.269
HEK OATP1B3 OATP1B3 1.44 0.028
The absolute transporter protein expression was normalized to the amount of plasma mem-
brane protein (fmol/µg protmem) or total protein (fmol/µg prot) in the respective expression
system.
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Figure 5.1: Transporter protein expression in
plasma membrane fractions of pooled cryopre-
served human hepatocytes. The bars represent
mean values of two independent measurements
performed in triplicates and errorbars represent
standard deviations.
determined by the QTAP method. Figure 5.1 and Table 5.1 show the measured abundances
of the uptake transporters OATP1B1, OATP1B3, OATP2B1, NTCP, OAT2, and OCT1 in
cryopreserved human hepatocytes. Significant differences in expression levels were found
between the specific transporters, ranging from 0.35 fmol/(µg protmem) for OATP1B3 to
15.85 fmol/(µg protmem) for OATP1B1. OATP2B1, NTCP, and OAT2 showed similar
expression levels [1.03 to 2.62 fmol/(µg protmem)] while the expression of OCT1 was
comparatively higher [6.94 fmol/(µg protmem)]. In plasma membranes of recombinant
HEK293 cells, the protein expression levels of OATP1B1 and OATP1B3 were measured
at 23.97 fmol/(µg protmem) and 1.44 fmol/(µg protmem) (Table 5.1). Transporter protein
expression levels shown in Table 5.1, are either normalized to the amount of total plasma
membrane (µg protmem) or to the total sample protein (µg prot).
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Determination of pharmacokinetic parameters
We performed concentration-dependent incubations in HEK293-OATP1B1 and OATP1B3
over-expressing cells, and in suspended hepatocytes to subsequently estimate pharmacoki-
netic parameters of our study compounds. Control incubations in the presence of the OATP
inhibitors atorvastatin and rifamycin resulted in a significant decrease in PStot values in
recombinant cell lines and hepatocytes, confirming transporter functionality in all uptake
experiments (data not shown).
Figure 5.2 shows the uptake clearances of the OATP1B1 and OATP1B3-specific ref-
erence compounds E3S and CCK8, respectively, into recombinant cell lines and sus-
pended hepatocytes. E3S uptake clearances in HEK293-OATP1B1 were decreased in a
concentration-dependent manner and PStot was significantly reduced in the presence of the
OATP inhibitors. Also HEK293-OATP1B3 cells showed transport activity for E3S, which
however, was significantly lower compared to HEK293-OATP1B1 cells (Fig.5.2A). For
CCK8, a concentration dependent decrease in uptake clearances and inhibition in presence
of OATP inhibitors were found in recombinant HEK293-OATP1B3 but not in HEK293-
OATP1B1 cells (Fig.5.2B).
Compound recoveries in hepatocytes studies above 85% were obtained for E3S, CCK8,
atorvastatin, lovastatin, pitavastatin, and rosuvastatin. In contrast, substantial concentration-
dependent NSB to the experimental device was found for cerivastatin (69%), fluvastatin
(79%), pravastatin (56%), and simvastatin (71%).
As illustrated in Figures 5.2C and 5.2D, experiments with E3S and CCK8 using human
hepatocytes showed a concentration-dependent decrease in PSapp values at 4◦C incubations.
As previously described, such a profile indicates saturation of temperature-independent
NSB of the compound to cellular structures. Consequently, uptake clearances determined
from 37◦C incubations were corrected according to Equation 5.1. The resulting PStot
values showed a concentration-dependent decrease for E3S and CCK8 indicating that both
compounds were actively transported into hepatocytes. The observed PStot value for E3S
was more than ten-fold higher than the value observed for CCK8.
Figure 5.3 shows representative kinetic profiles for rosuvastatin and cerivastatin. For both
compounds, OATP1B1 or OATP1B3 uptake clearances were significantly reduced in the
presence of the OATPs inhibitors (Figure 5.3A and 5.3B). Moreover, saturation of trans-
porter activities at high concentrations of both statins were observed in HEK293-OATP1B1
and HEK293-OTAP1B3 cells. However, in both cell lines the concentration-dependent
decrease in PStot was more pronounced for rosuvastatin than for cerivastatin, probably due
to the comparatively high passive uptake clearance obtained for the latter compound.
Atorvastatin, fluvastatin, pravastatin and pitavastatin were also actively transported by
OATP1B1 and OATP1B3, while lovastatin was found to be a substrate for only OATP1B1
but not for OATP1B3. The simvastatin uptake clearances decreased in a concentration-
dependent manner in OATP1B1 and OATP1B3 cells but co-incubation with the OATP
inhibitors did not affect the total uptake clearance in either cell line.
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Figure 5.2: Uptake clearance of reference compounds in recombinant HEK293-OATP1B1 (HEKOATP1B1)
or HEK203-OATP1B3 (HEKOATP1B3)cells (a,b) and human CCK8 (b) in recombinant cell lines in the
presence and absence of OATP inhibitors atorvastatin and rifamycin (AR). The total uptake clearance of
E3S (c) and CCK8 (d) and apparent clearances determined from 4◦C and 37◦C incubations, (PSapp,tot, 7◦C
and PSapp,tot,4◦C, respectively). Data are presented as triplicates with the error bars representing the standard
deviation.
Hepatocyte uptake profiles of rosuvastatin and cerivastatin are shown in Figure 5.3C
and 5.3D. The uptake clearances of both compounds were decreased in a concentration-
dependent manner. Compared to the PStot value of rosuvastatin observed at initial con-
centrations, a very high PStot of cerivastatin was obtained. However, at high substrate
concentrations, PStot of cerivastatin was significantly higher compared to the value deter-
mined for rosuvastatin, indicating a high contribution of the passive uptake clearance to
the total cerivastatin uptake clearance.
Table 5.2 summarizes the estimated maximal activities (PSact,max), the ratios between
active to passive compound clearances, and the global goodness of fit (R2) for parameter
estimations according to equation 5.2. In recombinant cell lines highest PSact,max val-
ues were obtained for E3S and CCK8 in HEK293-OATP1B1 and OATP1B3-expressing
cells, respectively. While E3S also exhibited the highest PSact,max value in hepatocytes,
active CCK8 transport was comparatively low. For the statins, comparable activities
(PSact,max) of OATP1B1 and OATP1B3 were derived from recombinant cells while higher
activities were generally obtained in human hepatocytes. The ratios between active and
passive uptake clearances (PSact,max/PSpas) represent a measure of the contribution of the
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Figure 5.3: Uptake clearance of statins in recombinant HEK293-OATP1B1 (HEKOATP1B1) or HEK293-
OATP1B3 (HEKOATP1B3) cells (a,b) and human cryopreserved hepatocytes (Hep; c,d). The total clearance
(PStot) of rosuvastatin (a,c) and cerivastatin (b,d) in recombinant cell lines in the presence and absence of
OATP inhibitors atorvastatin and rifamycin (AR) (a,b) or cryopreserved human hepatocytes (c,d). Data are
presented as triplicates with the error bars representing the standard deviation.
transporter-mediated process to the total uptake clearance. E3S exhibited the highest
ratios in HEK293-OATP1B1 cells and in hepatocytes. Among the statins, the highest ratio
was measured for pravastatin in hepatocytes. Together with atorvastatin and rosuvastatin,
pravastatin also showed highest ratios in recombinant cell lines. Ratios below one were
obtained for simvastatin, fluvastatin, and cerivastatin in all expression system, indicating
an extensive contribution of passive permeation to the total uptake clearance for these
compounds.
REF and RAF based prediction of compound uptake in suspended
hepatocytes
Table 5.3 lists the observed and predicted hepatic PSact,max values as well as the determined
scaling factors. We obtained very similar transporter specific scaling factors with values of
0.853 and 1.112 for REF1B1 and RAF1B1 (1.3-fold deviation), respectively, and of 0.181
and 0.113 for REF1B3 and RAF1B3 (1.6-fold deviation), respectively. Consequently, the
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Table 5.3: Observed and predicted hepatic PSact,max values.
observed REF-based scaling RAF-based scaling
PSact,max PSact,max PSact,max
total 1B1 1B3 1B1 + 1B3 1B1 1B3 1B1 + 1B3
(µL/min/mg) (µL/min/mg) (µL/min/mg)
E3S 157.7 117.8 1.2 119.0 n.a. n.a. n.a.
CCK8 7.4 0.0 13.8 13.8 n.a. n.a. n.a.
Atorvastatin 45.1 22.4 5.8 28.2 30.0 3.1 33.1
Cerivastatin 54.4 7.0 1.6 8.6 9.4 0.8 10.2
Fluvastatin 53.7 17.5 5.4 22.8 23.4 2.9 26.3
Lovastatin 40.6 7.6 0.0 7.6 10.2 0.0 10.2
Pitavastatin 89.5 28.6 2.6 31.2 38.3 1.4 39.7
Pravastatin 13.4 8.8 0.4 9.2 11.8 0.2 12.0
Rosuvastatin 6.7 4.5 0.7 5.3 6.1 0.4 6.5
Simvastatin 28.5 12.3 2.6 14.9 16.5 1.4 17.9
PSact,max refers to the maximal observed or predicted active uptake in hepatocytes. 1B1 and 1B3 determine
OATP1B1 and OATP1B3, respectively. According to Eqs. 5.3 and 5.4 for RAFs and Eqs. 5.6 and 5.7 for REFs
the followig scaling factors were applied: REF1B1 = 0.853; REF1B3 = 0.181; RAF1B1 = 1.142; RAF1B3 = 0.097.
PSact,max values predicted from the RAF and REF-methods were highly comparable. Given
the high similarity between the two scaling methods, only the results for REF-based scaling
are discussed in the following.
PSact,max values in hepatocytes were predicted from the extrapolated sum of OATP1B1
and OATP1B3 activities (Equation 5.8). A good resulting prediction accuracy between
the observed and predicted values for E3S, CCK8, atorvastatin, pravastatin, rosuvastatin,
simvastatin was obtained with errors below two-fold. In contrast, poor predictability was
observed for cerivastatin, fluvastatin, lovastatin, and pitavastatin with errors between two
to six-fold, thus indicating a significant under-prediction.
Figure 5.4 illustrates the contribution of OATP1B1 and OATP1B3 to the observed active
uptake clearance of statins in suspended hepatocytes predicted from REF-scaling. For all
statins, OATP1B1-mediated uptake into hepatocytes was significantly higher than active
uptake by OATP1B3. Moreover, the contribution of OATP1B1 and OATP1B3 to the
hepatic uptake clearance of atorvastatin, pravastatin, rosuvastatin, and simvastatin was
above 50% indicating that both isoforms were the major contributors to the hepatic uptake
of these compounds. In contrast, OATP1B1 and OATP1B3-mediated uptake of cerivastatin,
fluvastatin, lovastatin, and pitavastatin was not the major determinant of the active hepatic
uptake clearance determined in hepatocyte lot PQP.
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Figure 5.4: Fractional contribution of
OATP1B1 (gray) and OATP1B3 (black)
to the observed active uptake clear-
ance of statins in suspended hepato-
cytes (lot PQP), where PSact,max mea-
sured in hepatocytes represents 100%.
The transporter contributions were pre-
dicted with the REF-method based on
data listed in Table 5.1 and Table 5.2.
5.5 Discussion
In the present study we determined the OATP1B1 and OATP1B3-mediated uptake clear-
ances of statins in single-transporter expressing HEK293 cells. Based on relative trans-
porter protein expression data, we used the transporter activities to estimate the OATP1B1
and OATP1B3-mediated uptake of statins into hepatocytes.
Recently, QTAP methods were established to quantify low abundant proteins, and first
expression levels in cryopreserved hepatocytes and liver samples were reported for the
major hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1, OAT2, OCT1, and
NTCP (Bi et al., 2012; Kimoto et al., 2012; Ohtsuki et al., 2012; Bi et al., 2013). Literature
data on OATP transporter expression show high inter-individual differences. For OATP1B1
values between 2-12 fmol/(µg protmem) in human liver samples and 2-7 fmol/(µg protmem)
in cryopreserved hepatocytes are reported (Karlgren et al., 2012; Kimoto et al., 2012;
Ohtsuki et al., 2012; Vildhede et al., 2014).
For OATP1B3 reported values vary between 1-6 fmol/(µg protmem) in human liver samples
and 1-2 fmol/(µg protmem) in cryopreserved hepatocytes (Karlgren et al., 2012; Ohtsuki
et al., 2012; Vildhede et al., 2014). Reported values for other uptake transporters in human
liver tissues vary between 1-4 (OATP2B1), 1-10 (NTCP), 1-3 (OAT2), and 3-15 fmol/(µg
protmem) (OCT1) (Karlgren et al., 2012; Kimoto et al., 2012; Ohtsuki et al., 2012; Vildhede
et al., 2014).
In the present study, transporter protein expression was quantified for pooled (20 donors)
human cryopreserved hepatocytes. Measured protein expression levels were within the
range of reported values, with 16 (OATP1B1), 0.4 (OATP1B3), 2 (OATP2B1), 3 (NTCP),
1 (OAT2), and 7 fmol/(µg protmem) for OCT1 (Table 5.1). In the tested lot of human hepa-
tocytes, OATP1B1 protein was found to be expressed at a substantially higher level than
OATP1B3. Such a pronounced OATP1B1 abundance with a concomitant low OATP1B3
expression has not yet been reported for protein levels in cryopreserved hepatocytes. In
contrast, comparatively high differences in OATP1B1 and OATP1B3 expression levels
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were observed in human liver samples (Vildhede et al., 2014). Thus, the level of OATP1B1
protein expression is in agreement with reported values in human liver samples while
generally lower values are reported in human cryopreserved hepatocytes.
On a functional level, high variability in active uptake values determined in different
cryopreserved hepatocytes is shown for statins and our reference substrates (Hirano et al.,
2004; Watanabe et al., 2010; Kimoto et al., 2012). Hirano et al. reported maximum
transporter activities between 36-84 µL·min-1·mg-1 for E3S and 1-5 µL·min-1·mg-1 for
CCK8 in three different cryopreserved human hepatocyte lots (Hirano et al., 2004). While
our CCK8 results were comparable, we obtained a significantly higher maximal activity
for E3S uptake in hepatocytes. These findings are in-line with the high OATP1B1 protein
expression level obtained in the hepatocyte lot PQP.
Differences in reported transporter activities and protein expression levels might be a
result of substantial inter-individual variation in transporter protein abundances observed
in human liver samples (Nies et al., 2013; Vildhede et al., 2014). Furthermore, differences
in hepatocyte isolation or transporter protein quantification procedures, as well as in the
selection of reference peptides for QTAP analysis were attributed to impact determined
transporter protein abundances (Balogh et al., 2012; Lundquist et al., 2014). All studied
statins are reported substrates of OATP1B1, and fluvastatin, rosuvastatin, pravastatin,
and pitavastatin are substrates of OATP1B3 (Hirano et al., 2004; Neuvonen et al., 2006;
Noe et al., 2007; Kalliokoski and Niemi, 2009). Our results confirmed that all statins
were substrates of OATP1B1. Only lovastatin was not identified as an OATP1B3 sub-
strate. Simvastatin demonstrated concentration-dependent uptake kinetics in OATP1B1
and OATP1B3 cells but no significant inhibition was observed upon co-administration with
OATP inhibitors. We assume that its extensive passive permeation might have masked the
contribution of the active transport process.
To investigate the correlation between transporter activity and expression level, we pre-
dicted the OATP1B1 and OATP1B3 activities in hepatocytes from studies in cell lines
expressing the respective transporter, using RAF and REF based methods. In the ideal
case, where measured activity of a specific transporter is directly proportional to its protein
expression level, the transporter specific REF, would be equal to the respective RAF. Our
determined REF and RAF values for OATP1B1 (0.853 and 1.112) and for OATP1B3 (0.181
and 0.113) showed a high similarity indicating a direct correlation between expression
levels and activity for OATP1B1 and OATP1B3. These results should neither be affected
by individual variation in transporter protein expression, nor by variation in the hepatocyte
preparation as absolute protein abundance measurements, as well as kinetic experiments,
were performed for the same batch of human hepatocytes. Thus, even if transporter protein
expression in cryopreserved hepatocytes would not represent transporter expression levels
in freshly-isolated or human liver samples, as indicated in studies by Kimoto et al. and
Lundquist et al., the correlation between transporter protein expression and activity should
not be affected as protein abundances and transporter activities were determined for the
same lot of hepatocytes in the present study (Lundquist et al., 2014). In contrast, given the
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substantial variation in reported transporter protein abundances between different hepato-
cyte lots or liver samples, it is crucial to characterize transporter expression in hepatocytes
in order to compare with the respective activities.
Using protein expression based REF-scaling, the observed hepatic PSact,max for the ref-
erence compounds E3S and CCK8 were predicted within two-fold error. For statins, the
REF-based predicted PSact,max values were in good agreement with the observed values
with fold error deviation below two for atorvastatin, pravastatin, rosuvastatin, and sim-
vastatin, indicating that their active hepatic uptake was mainly described by OATP1B1
and OATP1B3 mediated transport. In contrast, the active hepatic uptake of cerivastatin,
fluvastatin, lovastatin, and pitavastatin was under-estimated.
Within the scope of this study, the hepatic uptake activities were only extrapolated using
OATP1B1 and OATP1B3 values. Therefore, a potential explanation could be the involve-
ment of other transporters in the hepatic uptake of these compounds. Recently, Bi et al.
showed that NTCP is significantly involved in the hepatic uptake of fluvastatin, pitavastatin,
and rosuvastatin (Bi et al., 2013). NTCP protein abundance in our hepatocyte pool was
about two-fold higher than the reported value by Bi et al. Hence a significant contribu-
tion of NTCP to the net hepatic uptake of the respective statin is likely to be expected
for our investigated hepatocyte lot. Moreover, atorvastatin, fluvastatin, pravastatin and
rosuvastatin, as well as E3S, were shown to be substrates of OATP2B1 (Noe et al., 2007;
Kalliokoski and Niemi, 2009; Knauer et al., 2010). OATP2B1 was found to be expressed
at a comparable level to reported human liver data (Kimoto et al., 2012; Vildhede et al.,
2014). Therefore, we assumed that OATP2B1 might has contributed to the uptake of statins
in the studied hepatocyte lot. Thus, comparing REF-based extrapolation of specific hepatic
transporter activities with measured hepatic net uptake provides information about the
potential involvement of other transporters in the net hepatic uptake activity.
It is expected that REF-based scaling will represent a powerful tool for in vitro-in vivo
extrapolation of OATP1B1 and OATP1B3 activities to subsequently predict their con-
tribution to the net hepatic uptake clearance and to assess the impact of OATP1B1 and
OATP1B3-mediated DDIs. Recently Karlgren et al. and Vildhede et al. predicted the
contribution of OATP1B1, OATP1B3, OATP2B1, and NTCP to the atorvastatin uptake
clearance based on protein expression data determined for human liver samples and re-
combinant cell lines by an LC-MS method. Subsequently, the impact on isoform-specific
inhibition to the atorvastatin clearance was assessed (Karlgren et al., 2012; Vildhede et al.,
2014). Based on the substantial variation in transporter protein abundance among the
investigated liver samples (twelve donors), the predicted transporter-specific uptake clear-
ances showed high inter-individual variability ranging between 26-89% and 1.8-60% for
OATP1B1 and OATP1B3, respectively. Moreover, Nies et al., demonstrated that genetic
polymorphism significantly contributed to variation in OATP1B1 protein expression and
functionality, observed among 82 individuals (Nies et al., 2013). The high inter-individual
variability in transporter-protein expression observed in these studies clearly needs to
be considered when REF-based methods are used for in vitro-in vitro extrapolation of
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transporter activities. This aspect becomes especially important when results from DDI
studies with relatively small numbers of subjects are compared with IVIVE approaches.
In summary we demonstrated as a proof-of-concept that the OATP1B1 and OATP1B3
activity in hepatocytes can be extrapolated from recombinant cell lines based on abso-
lute transporter protein measurements. We further assessed the relative contribution of
OATP1B1 and OATP1B3 to the total hepatic uptake. Moreover, in contrast to RAF-based
scaling methods, this approach is expected to allow scaling of transporter activities from
in vitro incubations in recombinant cell lines to any tissues, given the respective trans-
porter abundance is known. Therefore, future research will be required to strengthen the
evidence that scaling of transporter activities based on absolute protein abundance data
represents a powerful tool to predict transporter-mediated in vivo clearance processes and
DDI effects.
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6.1 Abstract
During drug development, it is an important safety factor to identify the potential of any
new molecular entity to become a victim of drug-drug interactions (DDI). Especially
in preclinical development, anticipation of clinical DDIs remains a difficult challenge
mainly because of the lack of in vivo human pharmacokinetic data. We therefore applied a
recently developed in vitro-in vivo extrapolation method, including hepatic metabolism
and transport processes, to predict the human hepatic clearance and the DDI potential
of eight statins. For atorvastatin, cerivastatin, fluvastatin, lovastatin acid, pitavastatin,
pravastatin, rosuvastatin, and simvastatin acid all processes driving the hepatic clearance
were determined in vitro. Application of the recently established Extended Clearance
Concept Classification System (ECCCS), demonstrated a good predictability of the human
hepatic clearance with six out of eight statins projected within a two-fold deviation to
reported values. Furthermore, the DDI potential of the statins was assessed with respect
to the impact of possible perpetrator drugs on hepatic uptake, metabolism, and biliary
secretion and subsequently compared with reported clinical DDI effects. The predicted
AUC ratios for statins showed excellent quantitative correlations with clinical observations.
In addition, the mechanistic interplay of hepatic transport and metabolism processes was
well-reflected by our model. The ECCCS thus represents a powerful tool to anticipate the
DDI potential of victim drugs based on in vitro drug metabolism and transport data.
6.2 Introduction
Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors in-
dicated for the treatment of hypercholesterolemia (Shitara and Sugiyama, 2006). They are
widely used to lower the risk of cardiovascular disease. In 2012, rosuvastatin, simvastatin,
and atorvastatin were among the 15 most prescribed drugs in the United States. Myotoxic-
ity and rare cases of severe rhabdomyolysis are reported adverse events following statin
treatment though. In 2001, cerivastatin was therefore withdrawn from the market due to
incidents of fatal rhabdomyolysis, which were partially attributed to drug-drug interactions
(DDI) following comedication with gemfibrozil (Staffa et al., 2002). For several statins
hepatic elimination is described as interplay of drug transport and metabolism processes.
Expressed at the basolateral membrane of hepatocytes, the organic anion transporting
polypeptides (OATP) 1B1, 1B3 and 2B1 as well as the organic anion transporter (OAT)
2 and the sodium taurocholate co-transporting polypeptide (NTCP) are known to be in-
volved in the hepatic uptake of various statins. Subsequent biliary secretion is mediated
by apically expressed efflux transporters including P-glycoprotein (P-gp), the multidrug-
resistance associated protein (MRP) 2, and the breast cancer resistance protein (BCRP) (Li
et al., 2011). Hepatic metabolism of statins is predominantly mediated by enzymes of the
CHAPTER 6. DDI PREDICTION OF STATINS | 72
cytochrome P450 (CYP) family including CYP3A4, CYP2C8, and CYP2C9 (Shitara and
Sugiyama, 2006). Moreover, glucuronidation mediated by UDP-glucuronosyltransferase
(UGT) is involved in the metabolism of several statins (Prueksaritantont et al., 2002a).
Thus, each statin exhibits a unique and complex pharmacokinetic profile due to specific
transporter- and/or enzyme-mediated clearance mechanisms. Inhibition of one or several
of these clearance pathways upon co-medication of the statins (so-called victim drug) with
a perpetrator compound might therefore ultimately result in alterations of drug exposure.
Recently, our group established a novel method to predict the human hepatic drug
clearance based on a mechanistic in vitro-in vivo extrapolation (IVIVE) model (Umehara
and Camenisch, 2012; Camenisch and Umehara, 2012). The approach is based on incor-
poration of in vitro data for all physiological hepatic drug elimination processes into the
extended mechanistic hepatic clearance model, allowing the determination of the rate-
limiting hepatic clearance step. Based on this approach, drugs can be classified according
to their in vitro determined major clearance mechanism, referred as Extended Clearance
Concept Classification System (ECCCS). Similar to the Biopharmaceutics Drug Disposi-
tion Classification System (BDDCS), which is based on the extent of in vivo observed drug
metabolism and in vitro solubility data (Benet et al., 2008), the ECCCS categorizes drugs
into four classes. For highly permeable class 1 and 2 compounds, metabolism is projected
as the major hepatic clearance process. While passive hepatic uptake is the rate-limiting
step for class 1 compounds, the sum of metabolism and efflux transporter-mediated biliary
elimination is predicted to be rate-limiting for class 2 compounds. Active hepatic uptake
is predicted to be the rate-determining step for class 3 compounds, while the clearance
of class 4 compounds is dependent on the interplay of all processes involved in hepatic
elimination (namely metabolism, uptake, and efflux). Thus, based on the extended mecha-
nistic clearance concept, application of the ECCCS allows for a compound-class dependent
assessment of the DDI potential of (new) chemical entities. In this study, we used statins as
model drugs to further validate our new in vitro data-based extended mechanistic hepatic
clearance model. Human hepatic clearances were predicted for all marketed statins: ator-
vastatin, fluvastatin, lovastatin acid, pitavastatin, pravastatin, rosuvastatin, and simvastatin
acid as well as for cerivastatin. Subsequently, we assessed the DDI potential of each statin
by simulating inhibition of the relevant hepatic clearance processes. The predicted DDI
effects were compared with reported AUC changes from clinical studies (Sharma et al.,
2012; Yoshida et al., 2012; Neuvonen et al., 2006) and the underlying mechanisms driving
the DDI potential for each statin were discussed within the frame of the ECCCS.
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6.3 Materials and Methods
Compounds
[3H]atorvastatin calcium (0.37 MBq/nmol), [3H]cerivastatin sodium (0.19 MBq/nmol).[3H]fluvastatin sodium (0.74 MBq/nmol), [3H]lovastatin acid (0.37 MBq/nmol), [3H]pi-
tavastatin calcium (0.37 MBq/nmol),
[3H]pravastatin sodium (0.19 MBq/nmol), [3H]ro-
suvastatin calcium (0.37 MBq/nmol), and
[3H]simvastatin acid (0.37 MBq/nmol) were
obtained from American Radiolabeled Chemicals, Inc. (Saint Louis, MO).
[3H]taurocholic
acid (TCA; 1.67 MBq/nmol) was purchased from PerkinElmer (Boston, MA). All other
compounds and reagents were of analytical grade and purchased from commercial sources.
Human sandwich-cultured hepatocytes were purchased as B-CLEARr kits from Qualyst,
Inc. (Durham, NC).
Hepatic clearance prediction
According to the extended mechanistic clearance concept, the overall apparent hepatic
intrinsic clearance can be described as follows (Camenisch and Umehara, 2012):
CLh,int =
(PSin f ,act + PSin f ,pas) · (CLint,sec + CLint,met)
(PSe f f ,act + PSe f f ,pas + CLint,sec + CLint,met)
(6.1)
Where PSinf,act and PSinf,pas are the active and passive hepatic influx clearances from the
blood, respectively, CLint,sec is the intrinsic biliary secretion clearance, and CLint,met is
the intrinsic metabolic clearance. PSeff,act and PSeff,pas describe the active and passive
sinusoidal efflux from the hepatocytes back into the blood, respectively.
All above parameters can be determined experimentally (Umehara and Camenisch, 2012;
Camenisch and Umehara, 2012). For present assessment, all in vitro transport and
metabolism data for atorvastatin and pravastatin were taken from a previous work (Ca-
menisch and Umehara, 2012). For the other statins, we used PSinf,act and PSinf,pas data
as recently assessed in suspended hepatocytes (Kunze et al., 2014a). CLint,sec was deter-
mined in human sandwich-cultured hepatocyte incubations using the B-CLEARr assay
(single concentration determinations at 0.1 µM) assuming that metabolism was negligible
(Camenisch and Umehara, 2012). All values for CLint,met determined in human liver
microsomal incubations were taken from literature (Table 6.1). Moreover, we assumed that
efflux over the sinusoidal membrane from hepatocytes back into the blood occurred via
passive diffusion only (i.e. PSeff,act = 0) and that the passive sinusoidal efflux was equal
to the passive influx (i.e. PSeff,pas = PSinf,pas). Subsequently, the hepatic in vivo clearance
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(CLh) was predicted based on the "well-stirred liver" model as follows (Camenisch and
Umehara, 2012):
CLh =
Qh · fu,b(PSin f ,act + PSin f ,pas) · (CLint,sec + CLint,met)
Qh · (PSin f ,pas + CLint,sec + CLint,met) + fu,b · (PSin f ,act + PSin f ,pas) · (CLint,sec + CLint,met)
(6.2)
Where Qh is the hepatic blood flow [20.7 mL/(min·kg)] and fu,b is the unbound fraction of
drug in blood as reported in literature (Table 6.1).
DDI assessment
A perpetrator drug may inhibit all active clearance pathways contributing to the total
hepatic elimination of a substrate compound. Accordingly, based on equation 6.1, the
overall apparent hepatic intrinsic clearance in the presence of a perpetrator (CLh,int,i) can
be expressed as follows (Camenisch and Umehara, 2012):
CLh,int,i =
((1− fi,in f ) · PSin f ,act + PSin f ,pas) · ((1− fi,sec) · CLint,sec + (1− fi,met) · CLint,met)
(PSin f ,pas + (1− fi,sec) · CLint,sec + (1− fi,met) · CLint,met)
(6.3)
Where fi,inf, fi,sec, and fi,met denote the inhibited fractions of active influx, secretion, or
metabolism, respectively. A value of zero thereby indicates no inhibition whereas a value
of one refers to complete inhibition. Based on this relationship the hepatic in vivo clearance
in the presence of any perpetrator compound (CLh,i) can be calculated in accordance with
equation 6.2.
Following oral administration of a drug and its perpetrator, assuming the presence of
hepatic and a non-hepatic (e.g. renal) elimination pathways and that the perpetrator drug
only affects active processes in the liver, the exposure (AUC) fold-change (expressed as
AUCpo,i/AUCpo) can be described as follows (Boulenc and Barberan, 2011):
AUCpo,i
AUCpo
=
Fh,i
Fh
· 1
fn,h · CLh,i/CLh + 1− fn,h (6.4)
Where, fn,h is the fractional contribution of hepatic clearance to overall clearance. Fh
(= 1-CLh/Qh) and Fh,i (= 1-CLh,i/Qh) are the fractions of the oral dose escaping hepatic
first-pass in the absence and presence of a perpetrator, respectively.
Under the additional assumption that the liver is the only clearance organ (i.e. fn,h = 1)
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equation 6.4 simplifies with (Einolf, 2007):
AUCpo,i
AUCpo
=
CLh,int
CLh,int,i
(6.5)
Statistical Analysis
Linear correlation analysis were performed to obtain the regression equation and the
correlation coefficient (R2) using Microsoft Excel. Average fold errors (afe), predicting
the accuracy between the observed and predicted parameters were calculated accordingly:
= 10
1
N ∑ log
predicted
observed (6.6)
Where a value below two indicates a good prediction accuracy (Kunze et al., 2014b).
Table 6.1: In vitro pharmacokinetic parameters.
measured in house obtained from literaturea
compounds PSinf,act,invitro PSinf,pas,invitro CLint,sec,invitro CLint,met,invitro fu,b
(µL·min-1·106cells) (µL·min-1·106cells) (µL·min-1·mgprot-1) (µL·min-1·mgprot-1) (-)
lovastatin acid 64.88 57.17 bld 337.00 0.08
simvastatin acid 45.63 117.09 0.50 564.71 0.11
cerivastatin 87.07 95.82 bld 34.40 0.02
fluvastatin 85.95 127.94 bld 107.79 0.04
pitavastatin 143.18 101.70 bld 12.96 0.07
atorvastatin 55.15 22.69 3.75 47.41 0.08
pravastatin 22.78 14.13 0.71 0.68 0.97
rosuvastatin 10.69 9.73 1.90 1.13 0.17
a) Literature references are provided as "Supplementary Information" (Supplementary Table 6.3)
bld) below limit of detection (zeroed for all subsequent calculations)
6.4 Results and Discussion
The experimentally determined in vitro parameters for hepatic influx, metabolism, and
biliary secretion are listed in Table 6.1. The up-scaled process parameters, the projected
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overall apparent hepatic intrinsic clearances according to equation 6.1 and the predicted in
vivo hepatic organ clearances (CLh,pre) according to equation 6.2 are given in Table 6.2.
Moreover, Table 6.2 lists the in vivo observed hepatic clearances (CLh,obs) which were
derived from human mass balance studies taking the in vivo determined renal clearances
into account.
As shown in Table 6.2, the values for the different physiological processes driving hepatic
elimination differ significantly for the eight statins in our dataset. Highest net hepatic
influx values, exceeding 500 mL/(min·kg), were obtained for pitavastatin and fluvastatin,
while pravastatin and rosuvastatin showed comparatively low values [< 100 mL/(min·kg)].
Simvastatin acid, cerivastatin, and fluvastatin exhibited a high contribution of passive
influx to the total net influx (PSinf,pas > PSinf,act). The up-scaled CLint,met ranged from
0.9 mL/(min·kg) for pravastatin to 769.2 mL/(min·kg) for simvastatin acid. Up-scaled
CLint,sec was highest for atorvastatin [11.8 mL/(min·kg)] whereas no biliary secretion at
all could be experimentally determined for lovastatin acid, cerivastatin, fluvastatin and
pitavastatin. The predicted intrinsic clearances ranged from 7.4 mL/(min·kg) measured for
pravastatin to 298.6 mL/(min·kg) obtained for simvastatin acid.
Anticipation of hepatic clearance
The correlation between the in vitro predicted and in vivo observed hepatic clearances is
illustrated in Figure 6.1. Six out of eight statins (atorvastatin, fluvastatin, lovastatin acid,
pitavastatin, pravastatin, and simvastatin acid) were predicted within two-fold deviation
from the clinically observed value, while cerivastatin and rosuvastatin were under-predicted
by more than two- and six-fold, respectively. Excluding rosuvastatin a good overall ac-
Table 6.2: Predicted pharmacokinetc parameters
compounds ECCCS PSact PSpas CLint,met CLint,sec CLh,int CLh,pred CLh,obsa
mL/(min·kg) mL/(min·kg) mL/(min·kg) mL/(min·kg) mL/(min·kg) mL/(min·kg) mL/(min·kg)
lovastatin acid class 1 165.1 145.5 459.0 0.0 235.8 9.9 11.4
simvastatin acid class 1 116.1 297.9 769.2 1.7 298.6 12.7 25.2
cerivastatin class 2 221.5 243.8 46.9 0.0 75.0 1.4 3.4
fluvastatin class 2 218.7 325.5 146.8 0.0 169.2 5.1 7.0
pitavastatin class 2 364.3 258.7 17.7 0.0 39.8 2.5 3.5
atorvastatin class 4 140.4 7.7 64.6 11.8 112.9 6.5 5.9
pravastatin class 4 57.9 36.0 0.9 2.2 7.4 5.4 10.4
rosuvastatin class 4 27.2 24.8 1.5 5.7 11.8 1.8 12.2
Notes: Up-scaling of the in vitro clearances (Table 6.1) to human in vivo organ level was performed with the help of the fol-
lowing scaling factors: 1.6 (mg protein)/(1·106 cells) and 99·106 cells/(g liver) for suspended hepatocytes; 53 (mg protein)/(g
liver) for liver microsomes; 116 (mg protein)/(g liver) for sandwich-cultured hepatocytes and 25.7 (g liver)/(kg body weight)
for liver weight (Carlile et al., 1997; Swift et al., 2010). CLh,int and CLh,pred were calculated according to equations 6.1 and
6.2, respectively. Compound categorization according to the ECCCS was performed as previously described (Camenisch and
Umehara, 2012).
a) Literatur references and calculation details are provided as "Supplementary Information" (Supplementary Table 6.4).
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Figure 6.1: Correlation between the predicted
(CLh,pred) and observed (CLh,obs) hepatic
clearances. Abbreviations: ato, atorvas-
tatin; cer, cerivastatin, flu, fluvastatin; lov,
lovastatin acid; pit, pitavastatin; pra, pravas-
tatin; ros, rosuvastatin, and sim, simvastatin
acid. The black and gray lines represent
the line of unity and the two-fold deviations,
respectively.
curacy of prediction was indicated by an average fold error (afe) of 1.5. However, a
trend towards a slight under-estimation of the in vivo observed hepatic clearances was
observed (linear regression slope: 0.47, intercept: 1.72, R2 = 0.80). Down-regulated trans-
porter/enzyme expression in our in vitro systems and/or intracellular pH effects potentially
impacting the basolateral passive efflux out of hepatocytes are possible mechanistic/physi-
ological explanations for this general observation as discussed in more detail elsewhere
(Umehara and Camenisch, 2012; Camenisch and Umehara, 2012). Possible other reasons
eventually leading to significant IVIVE disconnects are discussed below.
Drug-drug interaction potential projections
Figure 6.2 depicts the predicted DDI potential of all statins in our dataset following oral
administration according to equation 6.5, generally assuming significant (almost complete)
process inhibition of 90% (i.e. fi,inf = fi,met = fi,sec = 0.9) (Camenisch and Umehara, 2012).
As illustrated, the impact of simultaneous inhibition of multiple clearance processes can for
some statins (such as cerivastatin, fluvastatin, lovastatin acid, pitavastatin, and simvastatin
acid) be anticipated from the product of the AUC ratios of the individual processes (i.e.
inhibition of only influx, metabolism, or biliary secretion) whereas for another category
of statins (such as atorvastatin, pravastatin, and rosuvastatin) the projected overall AUC
change increases over-proportionally compared to the single process contributions. The
power of the extended hepatic clearance model for providing mechanistic insight into the
(rate-limiting) processes driving hepatic elimination and, ultimately, for assessing qualita-
tively and quantitatively the compound-dependent DDI risks is subsequently discussed for
each statin separately.
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Figure 6.2: Prediction of the hepatic DDI potential of statins. Using equation 6.5, the AUC fold-change
was determined for the following scenarios (Camenisch and Umehara, 2012): black, total hepatic inhibition
(fi,inf = fi,met = fi,sec = 0.9); white, inhibition of active hepatic influx (fi,inf = 0.9); dark gray, inhibition of
metabolism (fi,met = 0.9); light gray, inhibition of biliary secretion (fi,sec = 0.9).
Lovastatin acid and simvastatin acid
Lovastatin and simvastatin are both administered as lactone pro-drugs, which are rapidly
converted to their active acid forms either by spontaneous chemical reactions or by
carboxylesterase-mediated metabolism in the intestine, liver, and plasma (Neuvonen et al.,
2006; Elsby et al., 2012). Renal clearance represents a minor elimination pathway for both,
lovastatin acid and simvastatin acid, with 10% and 13% parent drug excreted in urine,
respectively. Both drugs are mainly eliminated by metabolism via CYP3A4, CYP2C8,
and UGTs (Prueksaritantont et al., 2002a; Neuvonen et al., 2006; Elsby et al., 2012).
Lovastatin acid was in vitro identified to be transported by OATP1B1 and simvastatin acid
is a substrate of OATP1B1 and OATP1B3 (Kunze et al., 2014a).
Following co-medication with gemfibrozil in clinics, AUC ratios of 2.8 and 2.9 were
reported for lovastatin acid and simvastatin acid, respectively (Backman et al., 2000; Kyrk-
lund et al., 2001). Gemfibrozil is a well-known inhibitor of OATP1B1, NTCP, CYP2C8,
and UGTs (Prueksaritantont et al., 2002b; Shitara et al., 2004). Accordingly, applying
equation 6.5 with fi,inf = fi,met = 0.9, AUC ratios of 6.1 and 4.7 are predicted for lovastatin
acid and simvastatin acid, respectively (Figure 6.2). Both projections slightly over-predict
the in vivo findings though (2.2-fold for lovastatin acid and 1.6-fold for simvastatin acid).
However, static DDI prediction methods are generally expected to be over-predictive for
the in vivo situation as they do not account for the real inhibitor concentration and conse-
quently for partial inhibition effects at the sites of interaction (i.e. any process inhibition
fractions below 0.9 in this study). In addition, recent studies in our laboratories have
revealed the involvement of at least one additional not yet identified transporter system in
the hepatic uptake of both compounds (its contribution to overall active uptake is estimated
with about 80% and 40% for lovastatin acid and simvastatin acid, respectively) (Kunze
et al., 2014a). Provided that gemfibrozil is not inhibiting this additional transport system,
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the fractional contributions for active OATP1B1-mediated influx would be significantly
lower than assumed above (fi,inf = 0.2 and 0.6 for lovastatin acid and simvastatin acid, re-
spectively) and, as a consequence, a lower DDI potential following simultaneous inhibition
of OATP1B1-mediated hepatic uptake and overall metabolism is projected (3.5-fold for
lovastatin acid and 4.2-fold for simvastatin acid).
Nevertheless, based on their high passive permeability characteristics, both compounds
were assigned to ECCCS class 1. In this class the uptake into the hepatocytes becomes
the rate-limiting step of hepatic elimination and metabolism is anticipated to be the major
source for DDIs. Applying the mechanistic extended hepatic clearance model, inhibition
of only metabolism resulted in AUC ratio projections of 3.2 and 3.5 for lovastatin acid
and simvastatin acid, respectively. This DDI prediction is in excellent agreement with the
in vivo interaction results (less than 1.2-fold over-predictive for both lovastatin acid as
well as simvastatin acid). Consequently, in alignment with the ECCCS class 1 assignment,
transporter effects (if any) are projected to be minimal and the product of the individual
AUC ratio changes driving hepatic elimination (namely hepatic uptake and metabolism)
can be used to anticipate the overall DDI risk following simultaneous inhibition of both
processes together (Figure 6.2).
Cerivastatin
Cerivastatin, administered as free acid, is exclusively eliminated in the liver where pri-
mary OATP1B1 ( 20%) and a yet unknown transporter system (probably NTCP, 80%)
are involved in its active hepatic uptake (Kunze et al., 2014a). Metabolism is the only
reported clearance pathway of cerivastatin, with a contribution of 61% CYP2C8 and 37%
of CYP3A4 (Shitara et al., 2004; FDA, 2014).
As shown in Table 6.2, cerivastatin was assigned to ECCCS class 2. In this class the sum
of metabolism and biliary clearance represents the rate-limiting step of hepatic elimination
and inhibition of metabolism is generally projected as the major source of drug-drug inter-
actions (Figure 6.2). In clinical studies, an AUC-ratio of 5.6 has been observed following
co-administration of cerivastatin and gemifbrozil (Yoshida et al., 2012). Based on in vitro
studies gemfibrozil inhibits the OATP1B1- and NTCP-mediated hepatic uptake as well as
the CYP2C8-mediated metabolism of cerivastatin while its inhibitory effect on CYP3A4
is expected to be of minor clinical relevance (Shitara et al., 2004; Prueksaritantont et al.,
2002c). Thus, taking into account above inhibitory potential of gemfibrozil (fi,inf = 0.9,
fi,met = 0.61) the liver-based static DDI model (equation 6.5) predicted an AUC ratio of
4.1. Furthermore, in clinics, cyclosporine A (CsA, an OATP family, NTCP and CYP3A4
inhibitor with no relevant CYP2C8 effect) was shown to increase the AUC of cerivastatin
by 3.8-fold (Yoshida et al., 2012). Accordingly, with fi,inf = 0.9 and fi,met = 0.37, an AUC
ratio of 2.6 is anticipated from in vitro data. Consequently, for both scenarios DDI effects
within a comparable range to the observed AUC ratios were predicted with a general trend
towards a slight under-prediction (about 1.5-fold) of the effective DDI potential. One
reason for systematic under-predictions with the extended clearance concept approach is
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the possibility that the fractional process contributions as estimated from in vitro inves-
tigations might not absolutely reflect the ultimate in vivo situation correctly (e.g. wrong
fractional contributions of known pathways, existence of additional not yet identified path-
ways and/or time-dependent changes of pathway contributions as e.g. observed following
auto-induction/inhibition). And indeed, being a prominent CYP3A4, BCRP and P-gp
substrate (Matsuhima et al., 2005), for cerivastatin a possible existence of an extra-hepatic
elimination pathway such as pre-systemic intestinal metabolism and/or efflux ultimately
contributing to the overall clinical DDI risk in the range of our under-predictions was
discussed in literature (Yoshida et al., 2012). Nevertheless, similar to ECCCS class 1,
transporter effects for ECCCS class 2 drugs are anticipated to contribute minimally to their
hepatic interaction risk and the overall DDI potential as victim drug in the liver can easily
be projected from the AUC changes of the individual processes (Figure 6.2).
Fluvastatin
Fluvastatin is predominately cleared by the liver. Administered as free acid, about 90% of a
fluvastatin dose undergoes metabolism while only 2% and 6% of parent drug are recovered
in feces and urine, respectively. In vitro studies indicate that metabolism is primarily
mediated by CYP2C9 (75%) and to a lower extent by CYP3A4 (20%) and CYP2C8 (5%)
(Scripture and Pieper, 2001). Moreover, OATP1B1, OATP2B1, OATP1B3, and NTCP
contribute to the active hepatic uptake of fluvastatin (Kunze et al., 2014a; Bi et al., 2013;
Fujino et al., 2003).
Fluvastatin was assigned to ECCCS class 2 and, in agreement with this classification,
the overall DDI potential can be projected from the individual process contributions as
discussed above (Figure 6.2). Inhibition of metabolism is predicted as the major pathway
causing DDIs while inhibition of hepatic uptake transporters is expected to have a minor
impact. This conclusion is supported by a clinical observation demonstrating that co-
administration of the OATP transporter family inhibitor erythromycin (no CYP inhibition
potency) did not significantly alter the exposure of fluvastatin (predicted and observed
AUC) ratio of 1.6 and 1.2, respectively) (Scripture and Pieper, 2001).
As illustrated in Figure 6.2, an AUC ratio of 11.3 was projected assuming simultaneous
inhibition of active uptake and metabolism (fi,inf = fi,met = 0.9). In clinical trials, maximal
DDI effects resulted generally in AUC ratios below four though. However, as multiple
transporters and metabolic enzymes are involved in the hepatic elimination of fluvastatin,
it is likely that perpetrators used in clinical studies did not concomitantly inhibit all active
clearance processes involved in its elimination. For example, AUC-increases of up to 3.5-
fold have been reported for co-administration of fluvastatin with CsA (potent inhibitor of
OATPs, NTCP, BCRP, and CYP3A4 (Yoshida et al., 2012)). Assuming inhibition of hepatic
uptake (fi,inf = 0.9) and simultaneously of only CYP3A4-mediated metabolism (fi,met = 0.2)
the anticipated change in AUC is 1.8-fold which, in contrast to above projections, slightly
under-predicts the in vivo observed value. Thus, the discrepancy between the predicted
and observed clinical DDI effect could eventually be attributed to an additional (partial)
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inhibition of CYP2C8 and/or CYP2C9 by CsA. Recent investigations, however, are more
supportive for the hypothesis that BCRP-mediated intestinal efflux might have a significant
role in modulating the absorption of fluvastatin (Elsby et al., 2012). Integrating into above
assessment an experimentally determined in vivo exposure increase of 72% (1.72-fold)
following complete BCRP inhibition, the overall static DDI risk projection for fluvastatin
in the presence of CsA would be 3.1-fold which is in excellent compliance with the clinical
observations.
Pitavastatin
Administered as free acid, pitavastatin is exclusively eliminated via the liver, and 79% of
the dose is recovered in feces as unchanged parent drug, indicating direct biliary secretion
(Elsby et al., 2012). Thus, metabolism of pitavastatin, mainly mediated by CYP2C9 (45%)
and UGT (55%), is a minor hepatic elimination pathway (Shitara and Sugiyama, 2006;
Fujino et al., 2003). Moreover, pitavastatin is an in vitro substrate of OATP1B1, OATP1B3,
NTCP, and BCRP (Kunze et al., 2014a; FDA, 2014; Bi et al., 2013; Hirano et al., 2005).
In contrast to the described clinical observations, no active biliary secretion of
pitavastatin was measured in our in vitro experiments which is in alignment with recent
clinical findings that pitavastatin disposition is not influenced by BCRP in vivo (Elsby
et al., 2012). Metabolism was predicted as the predominant hepatic elimination pathway
of pitavastatin (Table 6.2) and the anticipated hepatic clearance based on the extended
clearance concept equation was similar to the measured clinical data. This observation
suggests that the reported value for biliary parent drug secretion (79%) might not correctly
reflect the effective mechanism of pitavastatin elimination (Elsby et al., 2012). In vitro
studies demonstrated that direct glucuronidation contributes significantly to pitavastatin
metabolism providing evidence that in vivo pitavastatin might be substantially biliary
secreted as its direct glucuronide metabolite (Shitara and Sugiyama, 2006; Fujino et al.,
2003). Since glucuronide metabolites are often found to be cleaved in the gastrointestinal
tract (e.g. by enterobacteria), the amount of unchanged pitavastatin found in human feces
might consequently not fully represent the actual amount of secreted parent drug. The
contribution of direct biliary pitavastatin secretion in vivo might therefore be significantly
overestimated while hepatic metabolism is in fact representing the most relevant clearance
mechanism.
Using the ECCCS categorization approach pitavastatin was assigned to class 2. Inhibiting
all hepatic pitavastatin clearance mechanisms as a worst-case scenario (i.e. fi,inf = fi,met= 0.9)
we predicted an AUC ratio of 19.9 (Figure 6.2). In a clinical study, co-administration with
CsA led to a 4.6-fold increased AUC of pitavastatin (Yoshida et al., 2012). Based on in
vitro inhibition data, CsA is expected to inhibit active hepatic uptake and UGT-mediated
metabolism of pitavastatin while it has no clinically significant inhibitory potential on
CYP2C9 (Yoshida et al., 2012; Liu et al., 2011). Thus, applying the known inhibitory
properties of CsA (fi,inf = 0.9 and fi,met = 0.55) we forecast an AUC increase of 4.5-fold. In
a different study, co-administration of pitavastatin with erythromycin (inhibitor of OATPs
CHAPTER 6. DDI PREDICTION OF STATINS | 82
but not of CYPs) resulted in an observed AUC increase of 380% (Elsby et al., 2012).
Assuming inhibition of active hepatic influx only (fi,inf = 0.9) we project an AUC ratio of
2.1-fold. Our predictions indicate that clinically observed DDI effects are mechanistically
well-reflected by our model. These observations further support the above mentioned hy-
pothesis that clinical data might represent an over-estimation of the actual in vivo observed
biliary pitavastatin clearance.
Atorvastatin
In clinics, atorvastatin is administered as pharmacologically active acid. About 70% of
administered atorvastatin is metabolized (mainly by CYP3A4), and about 28% are actively
biliary secreted. With 2% of unchanged drug recovered in urine, renal elimination is a
minor excretion pathway for atorvastatin. In vitro studies demonstrated that atorvastatin
is a substrate for OATP1B1, OATP1B3, P-gp, BCRP, and MRP2 (Li et al., 2011; Kunze
et al., 2014a; Lau et al., 2006).
Based on in vitro data, atorvastatin was assigned to ECCCS 4 (Table 6.2). As shown in
Figure 6.2, inhibition of either active influx (fi,inf = 0.9) or metabolism (fi,met = 0.9) is
predicted to result in moderate AUC changes of about 2- to 3-fold, while no significant
increase in AUC was anticipated when only biliary clearance was inhibited (fi,sec = 0.9).
Upon simultaneous inhibition of all hepatic clearance processes, an AUC change of 13.5-
fold is projected. Clinical studies, following oral co-administration of atorvastatin with
CsA, reported AUC changes of up to 15-fold (Yoshida et al., 2012; Elsby et al., 2012).
CsA is a well-known (in vitro) inhibitor of OATP1B1, OATP2B1, OATP1B3, NTCP, P-gp,
BCRP and MRP2 transporters, as well as of CYP3A4 and UGT metabolic enzymes (Liu
et al., 2011; Cummins et al., 2002; El-Sheikh et al., 2013; Ho et al., 2006; Xia et al.,
2007). Hence, the present total hepatic worst case DDI prediction of about 14-fold is in
excellent agreement with the reported clinical observations. Similarly, when clinically
co-administered with a combination of lopinavir and ritonavir a 5.9-fold AUC increase of
atorvastatin was observed (Yoshida et al., 2012; Elsby et al., 2012). Lopinavir is a potent
OATP1B1 and OATP1B3 inhibitor while ritonavir also inhibits CYP3A4 metabolism
(Annaert et al., 2010; Eagling et al., 1997). Assuming concomitant significant inhibition of
active influx and metabolism (fi,inf = fi,met = 0.9), the extended clearance concept anticipates
an exposure increase of around 6.5-fold. Moreover, an AUC ratio of 3.3 was reported for
atorvastatin when given together with the potent CYP3A4 inhibitor itraconazole (has no
effect on OATPs), which is also in good agreement with the projected value of 2.4-fold
(Yoshida et al., 2012; Elsby et al., 2012).
In contrast to the ECCCS class 1 and 2 compounds discussed before, the overall DDI
potential for atorvastatin cannot be projected from the AUC changes of the individual
processes though, as nicely illustrated in Figure 6.2. Hence, for ECCCS class 4 compounds
the substantial over-proportional increase in AUC upon simultaneous inhibition of uptake,
efflux and metabolism derives from the essential interplay and inter-dependencies of all
hepatic elimination pathways together. It is noteworthy to mention here, that in current
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DDI risk assessment potential involvement of basolateral hepatic and/or apical intestinal
efflux transporters as well as of intestinal enzymes was not considered and that significant
coincidental in vivo inhibition of any of these active processes by perpetrators drugs would
ultimately result in over-predictions of the effective interaction potential for this ECCCS
class 4 compound.
Pravastatin
Administered as free acid, the major route of hepatic pravastatin elimination is biliary
secretion of parent drug mediated by BCRP and MRP2. Hepatic oxidative metabolism
via CYPs is considered to be of minor importance since less than 10% of the dose are
recovered as metabolites in feces (Elsby et al., 2012; Hirano et al., 2005; Everett et al.,
1991; Sasaki et al., 2002). Furthermore, active hepatic uptake of pravastatin is mediated by
OATP1B1, OATP1B3, and OATP2B1 (Shitara and Sugiyama, 2006; Kunze et al., 2014a).
Applying equation 6.4, inhibition of all hepatic clearance processes (fi,inf = fi,met =
fi,sec = 0.9) resulted in a maximal AUC increase projection of more than 20-fold (Figure
6.2). However, in contrast to other statins, pravastatin exhibits a unique pharmacokinetic
profile due to a significant contribution of renal clearance (47%) to the total body clearance
which represents a significant deviation from the assumptions made for equation 6.5
(Elsby et al., 2012). Hence, the fractional contribution of the hepatic pathway to overall
pitavastatin elimination is only about 53% (fn,h = 0.53) and, as a consequence according to
equation 6.4, complete blockage of the hepatic elimination pathway is not expected to result
in AUC changes beyond 2.6-fold. Clinical DDI studies with pravastatin and gemfibrozil, a
selective OATP inhibitor, reported 2-fold AUC changes (Nakagomi-Hagihara et al., 2007).
Assuming only inhibition of active hepatic influx (fi,inf = 0.9), we calculated an AUC ratio
of 1.6 with equation 6.4. Furthermore, no significant AUC increases were observed in
clinics following co-administration of pravastatin with either itraconazole or fluconazole
both compounds potent CYP3A4 and CYP2C9 inhibitors (Yoshida et al., 2012). This
observation was also reflected by our model since inhibition of metabolism alone did not
predict any relevant AUC changes (1.1-fold).
However, in clinics an AUC ratio of 23 was reported upon co-administration of pravastatin
with CsA (inhibitor of OATPs, NTCP, CYP3A4, UGTs, MRP2, and BCRP) exceeding
the theoretically possible hepatic DDI potential by about 9-fold (Yoshida et al., 2012).
Yet, in human the renal excretion process is known to involve active transporter-mediated
secretion as indicated by the estimated renal clearance (9.2 mL/(min·kg) corresponding
to 47% of total clearance) significantly exceeding (about 5-6-fold) the projected renal
filtration clearance [ ˜ 1.7 mL/(min·kg)] calculated from the product of glomerular filtration
rate [1.8 mL/(min·kg)] and the fraction unbound in blood (fu,b = 0.97) (Kunze et al., 2014b).
The most likely reason for the obvious contradiction in data is therefore the contribution
of a transporter mediated active tubular secretion pathway coincidentally also inhibited
by CsA. In literature, OAT3 has been suggested to be responsible for the basolateral
uptake of pravastatin, whereas the transporter involved in its luminal efflux is yet to be
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identified (Nakagomi-Hagihara et al., 2007). MRP2 and/or BCRP are likely candidate
transporters though, both well-known to be effectively inhibited by CsA. Assuming a
80% simultaneous inhibition of both hepatic as well as renal elimination pathways the
anticipated overall exposure increase can be estimated with around 9-fold (details are
given as "Supplementary Information" (equation 6.16, Table 6.5)). Following a 90%
inhibition of the overall clearance the AUC increase is projected with already 19-fold
("Supplementary Information" (equation 6.16, Supplementary Table 6.6)). This would
be in excellent agreement with the observed in vivo DDI effect (measured in vivo AUC
ratio/predicted in vitro AUC ratio ≈ 1.2). Owing the complex inhibition profile of CsA
a final assessment is difficult to develop though notably because of a potentially reduced
pravastatin absorption due to intestinal MRP2 as discussed in literature (Elsby et al.,
2012). The restriction of pravastatin absorption was quantified with 67% reflecting the
observed AUC increase in individuals with a synonymous c1446C > G single nucleotide
polymorphism in the ABCC2 (MRP2) gene (Niemi et al., 2006). In any case, the hepatic
DDI projections according to equation 6.5 provided above are therefore just accidentally
reflecting the in vivo observations stressing out the need for a careful and integrated
(pre)clinical data analysis for more complex chemical entities such as the ECCCS class 4
compound pravastatin.
Rosuvastatin
Rosuvastatin is administered as free acid. The hepatic clearance of rosuvastatin accounts
for approximately 70% (fn,h = 0.7) of the net body clearance while 30% are attributed
to renal secretion of unchanged drug. Direct biliary secretion of unchanged rosuvastatin
is reported as the major hepatic route of elimination. Thereby, OATP1B1, OATP1B3,
OATP2B1, and NTCP are assumed to mediate active hepatic uptake, while secretion of
rosuvastatin into bile is primary mediated via BCRP (Elsby et al., 2012; Martin et al.,
2003a). Metabolic clearance, mainly by CYP2C9 and UGTs, is considered to play a minor
role in rosuvastatin elimination (Elsby et al., 2012; Prueksaritantont et al., 2002c; Martin
et al., 2003a).
A clinical AUC ratio of 2.1-fold was reported when co-administering rosuvastatin together
with lopinavir (OATP family inhibitor) and ritonavir (CYP3A4 inhibitor) (Yoshida et al.,
2012). Since rosuvastatin is not metabolized by CYP3A4, the observed DDI effect is ex-
pected to result exclusively from inhibition of active hepatic uptake. Assuming significant
inhibition of hepatic influx (fi,inf = 0.9) and applying due to a significant renal clearance
contribution equation 6.4, we foresee an 1.5-fold AUC change with this static model
approach. Moreover, a triple combination of rosuvastatin, azatanavir (OATP inhibitor) and
ritonavir (OATP and CYP inhibitor) resulted in vivo in a 3.1-fold increased rosuvastatin
AUC (Yoshida et al., 2012). Both perpetrators do not affect canalicular efflux of rosuvas-
tatin. The corresponding static DDI projection predicts an AUC ratio of 1.7. Furthermore,
maximum clinical AUC increases of 7.1-fold were observed upon co-administration of
rosuvastatin with CsA, which is expected to inhibit all active hepatic elimination processes
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of rosuvastatin (Yoshida et al., 2012). Simulating inhibition of all possibly involved hepatic
clearance processes in our model, using equation 6.5 (which neglects the clearance pathway
via the kidney), an exposure increase of up to 15-fold is projected (Figure 6.2). Also taking
into consideration a renal clearance contribution according to equation 6.4, we predict a
3.1-fold AUC increase though. BCRP eventually plays a relevant role in the absorption
of rosuvastatin in humans which was demonstrated to be 50% (Elsby et al., 2012; Keski-
talo et al., 2009). With that, the maximal exposure increase following intestinal BCRP
inhibition is two-fold (probably significantly less though as the physiochemical properties
of this hydrophilic statin are unlikely accounting for a complete absorption even in the
absence of any efflux transporter activity). Consequently, the static DDI projection for CsA,
taking into account DDI effects in the liver and intestine, would be 6.2-fold maximum,
which is in good agreement with the clinical observations. However, also for rosuvastatin a
substantial active tubular secretion via the OAT1, OAT3, MRP2, BCRP as well as P-gp was
demonstrated (Verhulst et al., 2008; Windass et al., 2007). Accounting for such an active
tubular secretion pathway, similar to the pravastatin case above (i.e. 80% inhibition of
overall systemic clearance without considering a potential intestinal interaction on BCRP),
the overall DDI risk would be only slightly over-estimated ( 1.5-fold) (details are given as
"Supplementary Information" [equation 6.16, Supplementary Table 6.5)].
Rosuvastatin was assigned to ECCCS class 4. This is in line with clinical observations,
demonstrating that concomitant inhibition of sinusoidal uptake, biliary secretion as well
as metabolism pathways significantly define the complex hepatic DDI potential of rosu-
vastatin. Although the mechanism-based DDI assessment for the liver seems to reflect
the clinical observations pretty well (all hepatic projections based on equation are only
slightly under-predictive (1.6-fold maximum)), the experimentally determined in vivo
hepatic clearance of rosuvastatin was significantly under-predicted (> 6-fold) by the ex-
tended clearance concept model (Figure 6.1). One possible explanation for this IVIVE
disconnect would be an overestimation of the in vivo hepatic clearance pathway as derived
from experimental clinical data. Hypothetically, the presence of an additional extra-
hepatic/extra-renal elimination pathway (such as e.g. active BCRP-mediated intestinal
secretion) could have resulted in such an over-estimation of the effective hepatic clearance
without really impacting above static DDI assessments for the unspecific cross-reactive
inhibitor CsA (Martin et al., 2003b). Yet, present hypothesis is in partial contradiction
to above discussed (major) involvement of BCRP in rosuvastatin absorption as it would
rather support a significant involvement of this efflux pump in hepatic, renal and intestinal
systemic elimination, largely accounting for the 2.4-fold exposure difference observed
in healthy volunteers and BCRP-deficient individuals (Keskitalo et al., 2009). Fractional
process contributions as experimentally determined from in vitro investigations not cor-
rectly reflecting the ultimate in vivo situation might provide an alternative explanation
for the observed data discrepancy. Recently, Jamei et al. developed an IVIVE-based
PBPK model for rosuvastatin (Jamei et al., 2014). Since experimental hepatic uptake data
did not accurately predict the reported in vivo clearance of rosuvastatin the authors used
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a top-down (fitted) value [PSinf,act = 222 µL/(min·106 cells)] which was 21-fold higher
compared to our experimental data (Table 6.1). Replacing our in-house active hepatic
uptake results with this tailored value the current IVIVE model (equation 6.2) would have
predicted a hepatic clearance of 10.8 mL/(min·kg) being in excellent agreement with the
observed in vivo clearance (Table 6.2). In addition, using equation 6.4 (i.e. not considering
a possible interaction on the active renal tubular secretion pathway and not taking into
account a possible intestinal BCRP inhibition), static DDI predictions including this new
data point would have provided DDI estimations reflecting above in vivo observations very
well (8.8-fold following complete process inhibition as observed with CsA, 4.1-fold for an
OATP and CYP inhibition profile as seen with the azatanavir/ritonavir combo, and 3.8-fold
following OATP inhibition with lopinavir). But, although intriguing prima facie, the
potential role of renal and/or intestinal transporter inhibition as discussed above remains to
be clarified. In addition, this hypothesis would need to be substantiated by the involvement
of a not yet identified sinusoidal active solute-carrier system (as most other statins can
reasonably well predicted with current approach the candidate transporters are unlikely
OATP1B1, OATP1B3 or NTCP) which in course of the isolation and/or preparation process
is ultimately heavily down-regulated in the in vitro hepatocyte systems and which in vivo
is similarly subject to inhibition by above perpetrators.
6.5 Conclusion
In agreement with previous findings, by applying the extended mechanistic hepatic organ
model, a very good in vitro-in vivo projection of the effective hepatic clearances for all
marketed statins could be demonstrated. Similarly, using clinical in vivo observations
and in vitro information about drug transport and metabolism characteristics, the DDI
potential of these statins was successfully assessed and quantitatively evaluated in several
retrospective analysis. The correlation between observed and predicted AUC ratios for
different combinations of the investigated statins and perpetrator drugs is given in Figure 6.3
summarizing all relevant DDI predictions according to equations 6.4 and 6.5 as discussed
above. Overall, the observed interaction effects were well-predicted by the extended
mechanistic hepatic clearance model as indicated by an afe of 1.3. Out of 16 DDIs 14
were predicted within a two-fold error and linear regression analysis revealed an almost
1-to-1 correlation (slope: 0.857, intercept: -0.2677, R2: 0.84). Excluding the interaction
predictions for the ECCCS class 4 compounds pravastatin and rosuvastatin in the presence
of CsA as perpetrator (legitimated by the evident and significant under-prediction of
the overall DDI risk due to cross-reactivity with renal and/or intestinal transporters as
discussed above) all clinical DDI effects were projected within a two-fold error maximum
(R2 of 0.89) underlying the validity of this static DDI prediction approach to appropriately
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Figure 6.3: Correlation of all observed
(AUCpo,obs,i/AUCpo,obs) vs. predicted
(AUCpo,pred,i/AUCpo,pred) DDIs between
statins and different perpetrator drugs accord-
ing to equation 6.4 [applied for pravastatin
(black diamonds) and rosuvastatin (black
circles)] and equation 6.5 [used for lovas-
tatin acid (black squares), simvastatin acid
(gray squares), fluvastatin (gray diamonds),
cerivastatin (black triangles), pitavastatin
(gray triangles) and atorvastatin (gray cir-
cles)]. For effective numbers please refer
to text. Predictions prone to misjudgment of
the effective DDI potential while underlying
some vital assumptions (such as the presence
of alternative renal and/or intestinal active
processes as discussed in the manuscript)
were not considered. The black and gray
lines represent the line of unity and the two-
fold deviations, respectively.
anticipate the DDI potential of victim drugs in the liver.
For the five statins assigned to ECCCS class 1 (lovastatin acid, and simvastatin acid) and
ECCCS class 2 (fluvastatin, cerivastatin and pitavastatin) metabolism was anticipated
as major clearance mechanism primary responsible for causing DDIs. For compounds
assigned to these classes the overall DDI potential can easily be anticipated from the
product of the AUC changes of the individual process. A similar overall DDI behavior
would be anticipated for ECCCS class 3 statins with sinusoidal transporter inhibition
being the major mechanism causing the interaction though. However, none of the statins
in this study could be assigned to this ECCCS class which, besides a significant active
uptake contribution, is characterized by a low passive permeability and a comparatively
high intrinsic (metabolic and/or sinusoidal efflux) clearance. For the three ECCCS class
4 compounds in the dataset (pravastatin, rosuvastatin and atorvastatin), we predicted
highest AUC changes upon concomitant inhibition of hepatic uptake, biliary secretion and
metabolism whereas inhibition of the single clearance pathways results in comparatively
moderate AUC ratios. This concept was well reflected by our DDI predictions and is in
good agreement with clinical DDI data. Nevertheless, it noteworthy to mention at this point
that present analysis bases on transport and metabolism data determined in pools of human
hepatocytes and liver microsomes from multiple donors (Camenisch and Umehara, 2012;
Kunze et al., 2014a). Differences in protein expression levels due to genetic polymorphism
were therefore not actively taken into consideration. As polymorphism for some variants
ultimately translates into activity changes, it is evident, that such alterations might impact
the ECCCS class categorization, hepatic clearance prediction and/or the DDI projections
for some statins in our dataset. Susceptibility towards this effect was e.g. reported for
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atorvastatin (144% greater mean AUC for the SLCO1B1 (OATP1B1) c.521CC genotype
(Pasanen et al., 2007)), fluvastatin (up to 3-fold differences in mean AUC according to the
number of CYP2C9*3 alleles (Kirchheiner et al., 2003), or rosuvastatin (AA haplotype
individuals on ABCG2 (BCRP) c.421 exhibited 2.4-fold higher AUC compared with
individuals carrying the control (CC) haplotype (Keskitalo et al., 2009)).
In summary, we have demonstrated the validity of the ECCCS as a bottom-up assessment
for hepatic clearance and as a static model for DDI predictions purely from in vitro data.
The ECCCS is therefore expected to be of great value for preclinical Drug Development,
at a time when no human pharmacokinetic data are available. In addition, in combination
with clinical (DDI) data applying a top-down approach, the ECCCS concept can be
extremely helpful in identifying IVIVE disconnects and in revealing alternative elimination
pathways. As such pathways are passively (by altering the individual fractional pathway
contributions) and/or actively (by involvement of metabolism and/or transporter processes
likewise being subject to interferences) contributing to the ultimate drug-drug interaction
risk of victim drugs their quantitative integration into static or even dynamic (e.g.with help
of the population-based simulator Simcypr) pharmacokinetic models might be crucial for
an appropriate assessment and final interpretation of clinical study results.
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6.6 Supplementary Information
Literature references for reported in vitro data and calculations of
pharmacokinetic parameters
In order to obtain intrinsic secretion clearances CLint,sec,invitro (provided in Table 6.1 of
the manuscript), the measured apparent secretion clearances from sandwich-cultured
hepatocyte incubations (CLapp,sec,invitro) were corrected for the unbound fraction of drug in
hepatocytes (fu,hep, Supplementary Table 6.3) as described previously [1]:
CLint,sec,invitro = CLapp,sec,invitro/fu,hep (6.7)
with:
log(fu,hep) = 0.9161− 0.2567 · logD7.4 (6.8)
Similarly, the intrinsic metabolic clearances CLint,met,invitro were calculated from reported
apparent metabolic clearances from liver microsomal incubations (CLapp,met,invitro) taking
the unbound fraction of drug in microsomes (fu,mic; Supplementary Table 6.3) into account
[1]:
CLint,met,invitro = CLapp,met,invitro/fu,mic (6.9)
Table 6.3: Physiochemical and pharmacokinetic parameters of statins.
compound logD7.4 fu,hep fu,mic fu,p Rb CLapp,met,invitro CLapp,sec,invitro
(-) (-) (-) (-) (-) (µL·min-1mgprot-1) (µL·min-1mgprot-1)
lovastatin acid 1.51 [2]a) 0.050 0.096 [3] 0.05 [2] 0.57 [4] 32.35 [2] bld [m]
simvastatin acid 1.88 [2] 0.040 0.051 [3] 0.06 [2] 0.57 [4] 28.80 [2] 0.02 [m]
cerivastatin 1.90 [5] 0.039 0.689 [3] 0.01 [6] 0.60 [7] 23.70 [2] bld [m]
fluvastatin 1.60 [8] 0.047 0.308 [9] 0.02 [6] 0.52 [7] 33.20 [2] bld [m]
pitavastatin 1.50 [10] 0.050 0.432 [9] 0.04 [7] 0.58 [7] 5.60 [2] bld [m]
atorvastatin 1.30 [5] 0.056 0.510 [1] 0.05 [1] 0.63 [-] 24.18 [1] 0.21 [1]
pravastatin -0.40 [11] 0.154 0.880 [1] 0.52 [1] 0.54 [-] 0.60 [1] 0.11 [1]
rosuvastatin -0.89 [10] 0.205 0.975 [3] 0.12 [9] 0.69 [9] 1.10 [12] 0.40 [m]
Notes: fu,p refers to the fraction of unbound drug in plasma, Rb denotes the blood-to-plasma partition coefficient. The
literature references are shown in brackets. [-], calculated parameter, [m], parameter determined in this study. bld, below
limit of detection.
a) the reported value refers to logD7.0
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Table 6.4: Literature references for the human pharmacokinetic properties of statins.
compound CLtot,obs,p CLtot,obs,oral,p CLh,obs,p CLr,obs,p Ue F
(mL/min/kg) (mL/min/kg) (mL/min/kg) (mL/min/kg) (-) (-)
lovastatin acid 7.20 [13] 144.00 [-] 6.48 [-] 0.72 [-] 0.10 [2] 0.05 [2]
simvastatin acid 16.53 [-] 330.69 [14] 14.39 [-] 2.15 [-] 0.13 [6] 0.05 [6]
cerivastatin 2.04 [-] 3.04 [2] 2.04 [-] 0.00 [-] 0.00 [7] 0.60 [6]
fluvastatin 3.88 [-] 16.17 [15] 3.65 [-] 0.23 [-] 0.06 [15] 0.24 [6]
pitavastatin 2.02 [-] 3.97 [2] 2.02 [-] 0.00 [-] 0.00 [7] 0.51 [6]
atorvastatin 3.73 [-] 26.62 [-] 3.69 [1] 0.04 [-] 0.01 [16] 0.14 [16]
pravastatin 10.60 [-] 58.89 [-] 5.62 [1] 4.98 [-] 0.47 [16] 0.18 [16]
rosuvastatin 11.64 [17] 58.02 [-] 8.40 [-] 3.24 [17] 0.28 [-] 0.20 [2]
Notes: Clearance values were corrected for the average human body weight assuming 70 kg.
The literature references are shown in brackets. [-], calculated parameters.
Literature references for clinical data
Supplementary Table 6.4 provides the literature references for all described clinical phar-
macokinetic parameters. All reported clearances in supplementary Table 6.4 represent
plasma clearances. Hepatic clearances (CLh,obs,p) were obtained from reported total body
clearances after oral (CLtot,obs,oral,p ) or i.v. (CLtot,obs,p) administration according to the
following equations:
CLtot,obs,p = CLtot,obs,oral,p · F (6.10)
CLr,obs,p = Ue · CLtot,obs,p (6.11)
CLh,obs,p = CLtot,obs,p − CLr,obs,p (6.12)
(6.13)
where F denotes the absolute oral bioavailability, CLr,obs,p refers to the renal organ clear-
ance, and Ue refers to fraction of drug excreted unchanged in urine.
In the main manuscript all pharmacokinetic parameter are referring to blood, in order to
compare with predicted hepatic blood clearances. Consequently, plasma-based parameters
in Supplementary Table 6.4 were converted to the respective blood parameters by the
following equation:
Rb = fu,p/ fu,b = CLp/CLb = Cb/Cp (6.14)
where Rb denotes the blood-to-plasma partition coefficient, fu,p and fu,b denote the fraction
of drug unbound in plasma (p) and blood (b), respectively, CLp and CLb refer to clearance
values and Cp and Cb to concentrations obtained in plasma and blood, respectively.
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DDI predictions taking into account inhibition of renal secretion
The degree of change in AUC caused by drug-drug interaction following oral (p.o.)
administration can be expressed as follows:
AUCpo,i
AUCpo
=
Fa·Fg,i·Fh,i·D
CLh,i+CLr,i
Fa·Fg·Fh·D
CLh+CLr
(6.15)
where Fa, Fg and Fh represent the fraction of drug absorbed, the fraction of drug escaping
gut-wall metabolism and the fraction of drug escaping hepatic extraction. D represents the
administered dose. The corresponding parameters in the presence of a perpetrator drug are
denoted "i".
Assuming that: (i) the substrate is not metabolized and/or transported in the intestine
(Fg = 1), and (ii) Fa does not change in the presence of inhibitor, the AUCpo,i/AUCpo ratio
can be described as follows:
AUCpo,i
AUCpo
=
Fh,i · (CLh + CLr)
Fh · (CLh,i + CLr,i) (6.16)
Equation 6.16 was be applied for the two statins in our dataset (pravastatin, rosuvastatin),
which are subject to concomitant hepatic as well as renal process inhibition by CsA. The
corresponding input parameters assuming 80% or 90% process inhibition on hepatic and
renal clearance and DDI anticipations are summarized in Supplementary Table 6.5 and 6.6,
respectively.
Table 6.5: Hepatic and renal elimination contributions in clinics in absence and presence of a 80% process
inhibitor.
compound CLh,obs Fh CLr,obs CLh,i,pre Fh,i CLr,i,pre AUCpo,i/AUCpo
(mL/min/kg) (-) (mL/min/kg) (mL/min/kg) (-) (mL/min/kg) (-)
pravastatin 10.4 [1] 0.50 [-] 9.2 [-] 2.08 [-] 0.90 [-] 1.84 [-] 9.0
rosuvastatin 12.2 [17] 0.42 [-] 5.2 [7] 2.44 [-] 0.88 [-] 1.04 [-] 10.5
Notes: All clearance parameters represent human blood clearances. [-], calculated parameters.
Table 6.6: Hepatic and renal elimination contributions in clinics in absence and presence of a 90% process
inhibitor.
compound CLh,obs Fh CLr,obs CLh,i,pre Fh,i CLr,i,pre AUCpo,i/AUCpo
(mL/min/kg) (-) (mL/min/kg) (mL/min/kg) (-) (mL/min/kg) (-)
pravastatin 10.4 [1] 0.50 [-] 9.2 [-] 1.04 [-] 0.95 [-] 0.92 [-] 19.0
rosuvastatin 12.2 [17] 0.42 [-] 5.2 [7] 1.22 [-] 0.94 [-] 0.52 [-] 22.4
Notes: All clearance parameters represent human blood clearances. [-], calculated parameters.
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7.1 Abstract
Telaprevir is a new, direct-acting antiviral drug that has been approved for the treatment of
chronic hepatitis C viral infection. First data on drug-drug interactions with co-medications
such as cyclosporine, tacrolimus, and atorvastatin have been reported recently. Drug trans-
porting proteins have been shown to play an important role in clinically observed drug-drug
interactions. The aim of this study was therefore to systematically investigate the potential
of telaprevir to inhibit drug transporting proteins. The effect of telaprevir on substrate
uptake mediated by drug transporters located in human kidney and liver was investigated
on a functional level in HEK293 cell lines that over-express single transporter. Telaprevir
was shown to exhibit significant inhibition of the human renal drug transporters OCT2
and MATE1 with IC50 values of 6.4 µM and 23.0 µM, respectively, whereas no inhibitory
effect on OAT1 and OAT3 mediated transport by telaprevir was demonstrated. Liver drug
transporters were inhibited with an IC50 of 2.2 µM for OATP1B1, 6.8 µM for OATP1B3,
and 20.7 µM for OCT1. Our data show that telaprevir exhibited significant potential to
inhibit human drug transporters. In view of the inhibitory potential of telaprevir, clinical
co-administration of telaprevir together with drugs that are substrates of renal and hepatic
transporters should be carefully monitored.
7.2 Introduction
Hepatitis C (HVC) is a major burden to public health in industrialized as well as developing
countries. The prevalence of HCV infection is estimated to 2-3% worldwide, affecting
130-170 million people (Lavanchy, 2009; Shepard et al., 2005). In 2011 a new class of com-
pounds, direct acting-antiviral agents (DAA), such as telaprevir were approved by the FDA.
Triple therapy with these new protease inhibitors in combination with pegylated inteferon
(peg-IFN) and ribavirin has significantly increased the sustained virologic response (SVR)
rates in patients with HCV genotype 1. Combining peg-IFN with ribavirin increased the
SVR by about 50%, whereas triple therapy resulted in an increase in SVR about 70%
(Asselah and Marcellin, 2011). This combination therapy is therefore a promising new
tool to treat chronic hepatitis C infections and is expected to lead to increased usage in the
future.
Patients treated with these new DDA are often co-medicated with several other drugs.
The potential for drug-drug interactions (DDI) due to these compounds should therefore
be carefully investigated. DDIs with telaprevir and co-medications such as cyclosporine,
tacrolimus, and atorvastatin were recently reported, demonstrating significant increases
in blood concentrations of the co-administered drugs (Garg et al., 2011; Lee et al., 2011).
Co-administration with steady-state telaprevir increased dose-normalized cyclosporine
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exposure by 4.6-fold and tacrolimus 70-fold. In an open-label clinical study with 21 healthy
volunteers, co-administration of telaprevir increased the Cmax of atorvastatin 10.6-fold and
its AUC 7.88-fold.
Cyclosporine, tacrolimus, and atorvastatin were reported to be substrates of P-glycoprotein
(P-gp). Furthermore, atorvastatin is known to be a substrate of breast cancer resistance
protein (BCRP), of the organic anion transporting polypeptide 1 (OATP1B1), and of the
organic anion transporting polypeptide 2B1 (OATP2B1) (Fricker et al., 1996; Grube et al.,
2006; Keskitalo et al., 2009; Lau et al., 2006; Wu et al., 2000). The fact that DDI led to
changes in the pharmacokinetics of co-medications with telaprevir was attributed mainly
to cytochrome P450 enzymes (Kiser et al., 2012). However, besides metabolic enzymes,
interactions with drug transporters should not be neglected and can also play an important
role.
Drug transporters expressed in the kidney mediate the cellular transport of endogenous and
exogenous organic anions and cations. Tubular section of many organic cations is mediated
by uptake across the basolateral membrane by organic cation transporter 2 (OCT2) and by
efflux across the apical membrane by multidrug and toxin extrusion transporters (MATE)
(Nakamura et al., 2010). Human organic anion transporter 1 (OAT1) and human organic
anion transporter 3 (OAT3) have been localized at the basolateral membrane of renal
proximal tubule cells, where they mediate the cellular uptake of a number of drugs such
as thiazides, cephalosporin antibiotics, and loop diuretics as well as toxic compounds
(Nigam et al., 2007; Ueo et al., 2005). OAT1, OAT3, OCT2, and MATE1 are expressed
predominantly in the kidney. Organic anion transporting polypeptides (OATPs) such as
OATP1B1 and OATP1B3 are liver-specific drug transporters selectively expressed at the
basolateral membrane of hepatocytes, where they mediate the cellular uptake of several
drugs, including statins (Hagenbuch and Meier, 2004; König et al., 2006; Matsushima
et al., 2008). Expressed at the basolateral membrane as well, the organic cation transporter
1 (OCT1) has been shown to transport HIV drugs and anti-diabetic drugs (Jung et al., 2008;
Shu et al., 2008).
Telaprevir is reported to be a substrate and inhibitor of P-gp (Vertex, 2011). To date, no
information is available on potential interactions of telaprevir with other drug transporters
located in kidney or liver. It was therefore the aim of the present study to test in vitro
the inhibitory effect of telaprevir on drug transporters and quantify the specific impact
on each transporter by determining corresponding IC50 values. In particular, using cell
lines transfected with single transporters of the solute carrier (SLC) family, the effect
of telaprevir on cellular uptake of substrates of OCTs, MATE1, OATs, and OATPs was
systematically investigated.
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7.3 Materials and methods
Materials
[3H]aminohippuric acid (PAH; 4.53 Ci/mmol), [3H]estradiol 17β-D-glucuronide (34.3 Ci/m-
mol) were acquired from PerkinElmer (Waltham, MA).[3H]atorvastatin calcium (10 Ci/m-
mol), [3H]N-methyl-4-phenyl pyridinium iodide (MPP+; 85 Ci/mmol), and [14C]metformin
HCl were purchased from American Radiolabeled Chemicals, Inc. (Saint Louis, MO). Met-
forfmin HCl, estradiol 17β-D-glucuronide sodium salt, 1,1’-diethyl-2,2’-cyanine iodide
(decynium), probenecid, phenoxybenzamine hydrochloride, MPP+ iodide, PAH, dimethyl
sulfoxide (DMSO), formic acid, and acetonitirle were purchased from Sigma-Aldrich
(Saint Louis, MO). Atorvastatin calcium was obtained from AKScientific (Union City,
CA) and telaprevir (VX 950) was purchased from APIchem Chemical Technology Co.
(Shanghai, China). Irgarsafe Plus liquid scintillator was purchased from Zinsser Ana-
lytic (Frankfurt, Germany). Trypsin-EDTA (0.05%), DMEM, GlutaMAXTM, Dulbecco’s
phosphate-buffered saline (PBS), fetal bovine serum (FBS), geneticin (50 mg/mL), Hank’s
balanced salt solution (HBSS), and hygromycin B (50 mg/mL) were obtained from Invitro-
gen by Life Technologies (Paisly, UK). Penicilin/streptomycin (10,000 IU/mL Str) was
acquired from BioConcept (Allschwil, Switzerland). All unlabeled solid compounds were
dissolved in DMSO.
Mass spectrometry
According to the certificate of analysis provided by the manufacturer, telaprevir used for
the present study had a purity of 99.2% as determined by HPLC-analysis. In addition,
identity of telaprevir (10 µg/mL) used as a freshly prepared stock solution in 0.1% (v/v)
formic acid in acetonitrile, was confirmed by mass spectrometry. Mass spectra were
recorded by direct infusion at a rate of 10 µL/min (infusion pump 11, Harvard Apparatus,
MA) into an API 365 triple-quadrupole mass spectrometer (PE Biosystems, Foster City,
CA) equipped with a turbo ion spray interface, operated in positive or negative ionization
mode (Duthaler et al., 2011). The analyte was detected by either single-quadrupole mode
or selected reaction monitoring (SRM). Instrumentation control and data analysis were
performed with Analyst 1.4.2. software (PE Biosystems). Results were in accordance with
published data (Farnik et al., 2009): Positive mode, protonated molecular [M+H]+ ions at
m/z 680; negative mode, deprotonated [M-H]- at 678; mass transition (collision energy of
15eV) m/z 680 ≥ 322. The mass spectrometer was operated in unit resolution mode with a
precision of ± 0.1 mass units.
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Cell culture
Recombinant HEK293 cell lines with stable expression of human OATP1B1, OCT1, OCT2,
OAT1, OAT3, or MATE1 were generated by using the Flp-InTM system according tho the
manufacturer’s recommendations (Invitrogen by Life Technologies, Paisley, UK). Briefly,
HEK293 Flp-In cells were transfected with human OATP1B1, OCT1, OCT2, OAT1, OAT3,
or MATE1 cDNAs subcloned into pFRTV5-Dest plasmid vector and pOG44 or with the
respective vector alone using FuGene according to the manufacturer’s recommendations
(Roche, Basel, Switzerland). Transporter-expressing clones were obtained following hy-
gromycin B selection. Selective transporter function was determined and an evaluation of
stable transporter-expressing cell lines was carried out according to published data (Abe
et al., 1999; Cha et al., 2001; Chen et al., 2005; Gorboulev et al., 1997; Ho et al., 2000;
Koepsell et al., 2007; König et al., 2000; Liang et al., 1995; Takeda et al., 2001; Tamai et al.,
2001; Tanihara et al., 2007; Vavricka et al., 2002). Recombinant HEK293 cells express-
ing human OATP1B3 were purchased from DKFZ (Deutsches Krebsforschungszentrum,
Heidelberg, Germany). HEK293 stably transfected with OATP1B1, OCT1, OCT2, OAT1,
OAT3, or MATE1 were grown and maintained in DMEM supplemented with 10% FBS, 1%
L-glutamine and 1% penicillin/streptomycin, and 100 ng/µL hygromycin B at 37◦C with
5% CO2. HEK293 cells stably transfected with OATP1B3 were grown and maintained in
DMEM supplemented with 10% FBS, 1% L-glutamine and 1% penicilline/streptomycin
and 800 ng/µL geneticin.
Cytotoxicity assay
The cytotoxicity of telaprevir was assessed by the in vitro toxicology assay kit, sulforho-
damin B based (Sigma-Aldrich, Saint Louis, MO) as described previously by Skehan et al.
(1990). The assay was performed under the same conditions as the incubation studies, with
telaprevir at its highest concentration of 200 µM and an incubation time of 5 min.
Transporter inhibition assays
The transporter expressing HEK293 cells were seeded on BD poly-D-lysine 96-well
microplates with a density of approximately 0.2·106 cells per well in DMEM supplemented
with 10% FBS. OATP1B1 and OATP1B3 uptake studies were performed 72 h after seeding,
whereas all other uptake studies were performed after 24 h. On the day of the study,
the cultivation medium was replaced by the final incubation solution (buffer containing
a probe substrate and telaprevir or a positive control inhibitor). Transporter substrates
were [3H]estradiol 17β-D-glucuronide (1 µM) for OATP1B1 and OATP1B3, [3H]MPP+
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(0.0025 µM) for OCT1 and OCT2, [3H]PAH (1µM) for OAT1, [3H]estrone sulfate (1 µM)
for OAT3, and [14C]metformin (1 µM) for MATE1 uptake studies. Positive control
inhibitors were a combination of atorvastatin and rifamycin (20 µM and 10 µM) for
OATP1B1 and OATP1B3, decynium (10 µM) for OCT1, probenecid (100 µM) for OAT1
and OAT3, phenoxybenzamine (50 µM) for OCT2, and pyrimethamine (10 µM) for MATE1
uptake studies. For concentration-dependent inhibition studies, telaprevir was used in the
following concentrations: 0.2 µM, 0.4 µM, 0.6 µM, 0.8µM, 1 µM, 2 µM, 4 µM, 6 µM,
8µM, 10 µM, 20 µM, 40 µM, 60 µM, 80 µM, 100 µM, 125 µM, 150 µM, 175 µM, and
200 µM. Organic solvent (DMSO) concentrations were limited to 1% of the total incubation
volume (V/V). Uptake experiments were performed in HBSS supplemented with 12.5 mM
HEPES (pH 7.4) for OAT1, OAT3, OCT1, and OCT2, or in HBSS supplemented with
12.5 mM HEPES (pH 7.0) for OATP1B1 and OATP1B3. MATE1 uptake was performed
as described by Tanihara et al. (2007). For each incubation 200 µL of incubation solution
were added per sample. Incubation times were 3 min (OATP1B1, OCT1, and OCT2) or
5 min (OATP1B3, OAT1, OAT2, and MATE1). After removal of the incubation solution,
cells were washed twice with ice-cold PBS buffer and lysed in NaOH solution (0.2 N).
Quantitation of radio-labeled test compounds was performed by scintillation counting.
Radioactivity was determined in 5 mL Irgarsafe plus scintillation cocktail using Packard
Tri-Carb 2700TR liquid scintillation counter. The protein contents of the solubilized cells
were determined using the Bio-Rad Protein Assay kit (Bio-Rad Laboratories AG, Hercules,
CA) according to the manufacturer’s recommendations.
Data analysis
Cellular substrate uptake (pmol/min/mg protein) was given as the amount of radioactivity
associated with the cells (dpm) divided by its concentration (dpm/pmol substrate) in the
incubation medium and normalized to the incubation time (min) and the amount of protein
(mg protein) inside the wells. Uptake data were converted into relative inhibition values
given as % of control according to Eq.7.1:
% of control = 100%
Uptake0% −UptakeX
Uptake0% −Uptake100%
(7.1)
Uptake0% refers to the cellular substrate uptake in the absence of an inhibitor or test
compound, Uptake100% states the substrate uptake in the presence of the positive control
inhibitor, and UptakeX refers to substrate uptake in the presence of the test compound.
The IC50 values (inhibitor concentration causing 50% inhibition of the maximal drug
effect) were calculated using sigmoidal Hill kinetics according to Eq. 7.2.
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% of control =
%max · In
ICn50 + In
(7.2)
where n states the slope factor (Hill coefficient), I refers to the inhibitor concentration
(µM), and %max is the maximal transporter inhibition. Eq.7.2 was fitted to the data to
obtain estimates of the IC50 and %max.
Statistics
Uptake experiments were performed in triplicate, where values are given as the mean
of these replicates with error bars representing the standard deviation (SD). Statistical
significance was calculated by unpaired Student’s t-test. Differences were considered
statistically significant when p was < 0.05. Parameter estimations were performed by
data fitting with non linear least square method using SigmaPlot2008. The coefficients of
determination, R2, were calculated for each fit. Figures were created using MatlabR2009.
7.4 Results
All results presented in the following section were performed with telaprevir of high
purity (99.2%). Identity of telaprevir was confirmed by mass spectroscopy according to
Farnik et al. (2009). Direct infusion of the analyte confirmed the molecular mass and
fragmentation pattern of telaprevir.
To rule out non-specific toxicity as the cause of observed inhibitory effects, we investigated
whether telaprevir exhibited a cytotoxic potential at the concentrations used in this study.
No cytotoxicity was observed in HEK293 cells over-expressing single drug transporters up
to the highest concentration investigated (200 µM) (data not shown).
Inhibition of the renal transporters OAT1, OAT3, OCT2, and MATE1 by
telaprevir
Cellular uptake of known renal transporter substrates was compared in the presence and ab-
sence of telaprevir. Functional expression of recombinant transporters was examined using
transporter substrates in the presence and absence of specific inhibitors. The results were
compared to incubations with telaprevir. As shown in Figure 7.1a, the uptake of 0.025 µM
MPP+ in OCT2 expressing cells was significantly reduced from 1.2± 0.1 pmol/min/mg pro-
tein to 0.6± 0.1 pmol/min/mg protein in the presence of 200 µM telaprevir. Co-application
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Figure 7.1: Inhibition of renal solute carriers by telaprevir. Inhibitory effect of telaprevir on the uptake of
0.025 µM [3H]MPP+ in OCT2 (a,b) and 1 µM [14C]metformin in MATE1 (c,d) over-expressing HEK293
cells. Substrate uptake is shown in the absence (Tela-) and presence of 200 µM telaprevir (Tela+) or the
reference inhibitors phenoxybenzamine (Phe; 50 µM) or pyrimethamine (Pyr; 10 µM), respectively (a,c).
Concentration-dependent inhibition of substrate uptake normalized to transporter inhibition by the reference
inhibitors (b,d). Shown are the average values of three independent incubations with the error bars represent-
ing the sample standard deviation. The stars indicate the significance level of the inhibitory effect derived
from t-test comparing Tela+ as well as positive control against Tela- incubations(**p < 0.01, ***p < 0.001).
The coefficient of determination, R2, was calculated for each fit (R2 = 0.96 (b), R2 = 0.98 (d)).
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Figure 7.2: Interaction of telaprevir with renal organic anion transporters. Effect of telaprevir on the uptake of
1 µM [3H]PAH in OAT1 (a) and 1 µM [3H]estrone sulfate in OAT3 (b) over-expressing HEK293 cells. Sub-
strate uptake is shown in the absence (Tela-) and presence of 60 µM telaprevir (Tela+) or 100 µM probenecid
(Pro), respectively. Shown are the average values of three independent incubations with error bars represent-
ing the sample standard deviation.The stars indicate the significance level of the inhibitory effect derived
from t-test comparing Tela+ as well as positive control against Tela- incubations(**p < 0.01, ***p < 0.001).
of 50 µM phenoxybenzamine (positive control) resulted in a reduction of substrate uptake
to 0.2 ± 0.0 pmol/min/mg protein. Moreover, the uptake of 1 µM metformin was signifi-
cantly reduced from 4.0 ± 0.3 pmol/min/mg protein to 0.5 ± 0.0 pmol/min/mg protein
in MATE1 expressing cells (Fig. 7.1b). The inhibitory effect observed was in a similar
range as the transporter inhibition caused by co-incubation with 10 µM pyrimethamine
(0.5 ± 0.1 pmol/min/mg protein; positive control). In a subsequent step, the IC50 values
were determined by co-application of the specific transporter substrate with increasing
concentrations of telaprevir. As shown in Figure 7.1b and d telaprevir inhibited the uptake
of reference substrates in a concentration-dependent manner with resulting IC50 values of
6.4± 3.5 µM and 23.0 ± 6.7 µM for OCT2 and MATE1, respectively. As shown in 7.2, no
inhibitory effect on the uptake of 1 µM PAH and 1 µM estrone sulfate in OAT1 and OAT3
expressing cells was demonstrated in the presence of 60 µM telaprevir, whereas 100 µM of
probenecid (positive control) significantly reduced the substrate uptake. Determined IC50
values as well as the maximal transporter inhibition (%max) are summarized in Table 7.1.
Inhibition of the hepatic transporters OATP1B1, OATP1B3, and OCT1 by
telaprevir
Inhibitory effects of telaprevir on substrate uptake in cells expressing the hepatic up-
take transporters OATP1B1, OATP1B3, and OCT1 are shown in Fig. 7.3. The up-
take of 1 µM estradiol 17β-D-glucuronide, a typical substrate for OATPs (König et al.,
2000; Tamai et al., 2001), in OATP1B1 and OATP1B3 expressing cells was signifi-
cantly reduced from 4.8 ± 0.1 pmol/min/mg protein for OATP1B1 (FIg. 7.3a) and
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1.0± 0.1 pmol/min/mg protein for OATP1B3 (Fig. 7.3c) to 0.4± 0.1 pmol/min/mg protein
and 0.3 ± 0.0 pmol/min/mg protein, for OATP1B1 and OATP1B3, respectively. Moreover,
inhibitory effects were comparable to inhibition by a combination of atorvastatin (20 µM)
and rifamycin (10 µM), resulting in a reduction of estradiol 17β-D-glucuronide uptake
to 0.5 ± 0.0 pmol/min/mg protein and 0.4 ± 0.1 pmol/min/mg protein for OATP1B1
and OATP1B3, respectively. Co-administration of estradiol 17β-D-glucuronide and
telaprevir demonstrated a concentration-dependent inhibition, with resulting IC50 val-
ues of 2.2 ± 0.1 µM and 6.8 ± 0.9 µM for OATP1B1 and OATP1B3 (Fig.7.3b and
d). Furthermore, the uptake of the OCT1 substrate MPP+ (0.025 µM) was significantly
reduced in the presence of 200 µM telaprevir from 1.3 ± 0.0 pmol/min/mg protein to
0.5 ± 0.0 pmol/min/mg protein. This effect was comparable to the inhibition of MPP+ up-
take in the presence of the reference inhibitor decynium (10 µM; 0.4± 0.0 pmol/min/mg pro-
tein) as shown in Figure 7.3e. Telaprevir inhibited MPP+ uptake in OCT1 expressing cells
in a concentration-dependent manner with an IC50 of 20.7 ± 7.7 µM (Fig. 7.3f). IC50
values as well as the maximal transporter inhibition (%max) compared to positive control
are summarized in Table 7.1.
7.5 Discussion
Telaprevir was recently registered; therefore, data on clinically observed drug-drug interac-
tions of telaprevir with metabolizing enzymes and transporters are still sparse. However,
first clinical data have been published by Lee and Garg, indicating that telaprevir exhibits
the potential to change the pharmacokinetics of co-administered drugs such as atorvastatin,
amlodipine, cyclosporine, and tacrolimus (Lee et al., 2011). Telaprevir has a molecular
formula of C36H53N7O6 with a molecular weight of 679.85 (Vertex, 2011). Telaprevir is
optically active and possesses six chiral centers. It exhibits an acidic pKa of 11.8 and a
basic pKa at 0.31 with 13 H bond acceptors and 4 H bond donors. Its physiochemical
Table 7.1: IC50 and maximal inhibition (%max) of telaprevir for different drug transporters.
localization transporter IC50 %max
value (µM) SD (µM) P value (%) SD (%) P
Kidney OCT2 6.35 3.45 0.0856 62.29 6.91 <0.001
Kidney MATE1 22.98 6.72 0.0033 111.76 9.95 <0.001
Liver OATP1B1 2.15 0.13 <0.001 100.90 2.31 <0.001
Liver OATP1B3 6.77 0.87 <0.001 105.39 3.88 <0.001
Liver OCT1 20.67 7.74 < 0.0175 98.59 10.68 <0.001
Note: No inhibition of OAT1 and OAT3. Model parameter were estimated from nonlinear least square fit to the data,
consisting of 17-19 datapoints with each datapoint corresponding to the mean value of three independent incubatins.
Coefficient of determination, R2, was > 0.96 for all fits. The p-values were calculated under asymptotic normality of the
least squares fit estimates from t-test against the null hypothesis that the corresponding coefficient is equal to zero.
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Figure 7.3: Inhibition of hepatic solute carriers by telaprevir. Inhibitory effect of telaprevir on the uptake of
1 µM [3H]estradiol 17β-D-glucuronide (a-d) in OATP1B1 (a,b) and OATP1B3 (c,d) over-expressing cells,
and 0.025 µM [3H]MPP+ in OCT1 (e,f) over-expressing HEK293 cells. Substrate uptake is shown in the
absence (Tela-) and presence of 200 µM telaprevir (Tela+) or the reference inhibitors 20 µM atorvastatin
co-applied with 10 µM rifamycin (A/R) or 10 µM decynium (Dec), respectively (a,c,e). Concentration-
dependent inhibition of substrate uptake normalized to transporter inhibition by the reference inhibitors
(b,d,f). Shown are the average values of three independent incubation with error bars representing the
sample standard deviation.The stars indicate the significance level of the inhibitory effect derived from
t-test comparing Tela+ as well as positive control against Tela- incubations(**p < 0.01, ***p < 0.001). The
coefficient of determination, R2, was calculated for each fit (R2 = 0.98 (b), R2 = 0.97 (d), R2 = 0.98 (e)).
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properties indicate that its charge is neutral at pH 7.4 (EMBL, 2012). Telaprevir has been
described as a substrate as well as an inhibitor of CYP3A4 and P-gp (Vertex, 2011). To
our knowledge, the interaction of telaprevir with drug transporters besides P-gp has not yet
been investigated. In this study, the inhibitory potential of telaprevir on drug transporters
located in kidney and liver was therefore characterized.
We examined the inhibitory effect of telaprevir on the transport of substrates of renal drug
transporters OCT2, MATE1, OAT1, and OAT3. In the kidney, renal tubular secretion of
several drugs such as cimetidine, metformin, and acyclovir is mediated by uptake through
OCT2 into proximal tubular cells and subsequent excretion through MATEs (Nies et al.,
2009). The IC50 value of telaprevir with respect to inhibition of renal solute carriers (OCT2
and MATE1) is in the µ- molar range. Because telaprevir concentrations in plasma have
been described as 5.5 µM at steady state with a free concentration of 2.1 µM, there is a sig-
nificant potential for telaprevir to inhibit transport of co-medications transported by OCT2
(Vertex, 2011). Clinical data on the effect of telaprevir on co-medications transported by
OCT2 are currently not available, but it might be useful to monitor the effect of telaprevir
on drugs excreted by OCT2 in clinical studies in the future.
Information on drug-drug interactions involving MATEs is currently sparse. First data
suggest that clinically observed inhibition of tubular metformin secretion is not only caused
by inhibition of OCT2-mediated tubular uptake, but also by inhibition of MATE1-mediated
luminal secretion (Tsuda et al., 2009). However, telaprevir is extensively metabolized in
the liver and after oral administration only 1% of the administered radioactive dose has
been found in urine (Vertex, 2011). It can therefore be assumed that active excretion of
unchanged telaprevir leading to high concentrations inside renal proximal tubular cells is
unlikely. Inhibition of transporters located at the apical membrane, such as MATE1, can
be predicted to be of minor clinical relevance.
The inhibitory effect of telaprevir on OAT1 and OAT3 seems to be negligible. Telaprevir
exhibited no interaction with substrates transported by these transporters. Therefore, the
likelihood of clinical DDI due to inhibition of renal OAT mediated drug transport is ex-
pected to be low.
Lee et al. conducted a clinical study in healthy volunteers in which they examined the
effect of telaprevir on atorvastatin and amlodipine pharmacokinetics (Lee et al., 2011).
The mean maximal concentration (Cmax) and the area under the curve (AUC) of amlodip-
ine were increased 1.3-fold and 2.8-fold, respectively, by co-administration of telaprevir.
Telapreivr also exhibited a pronounced effect on atorvastatin pharmacokinetics, leading to
an increase in Cmax and AUC of 10.6-fold and 7.9-fold, respectively. The author attributed
the observed effects mainly to CYP3A4 inhibition, because amlodipine and atorvastatin
are substrates of this enzyme and telaprevir has been shown previously to be a susbtrate
as well as an inhibitor of CYP3A4. However, they also speculated that telaprevir might
exhibit an inhibitory effect on OATP1B1- mediated atorvastatin uptake. Our data showed a
significant reduction of OATP1B1 and OATP1B3-mediated transport by co-administration
of telaprevir, which exhibited an IC50 of approximately 2 µM for OATP1B1 and 7 µM for
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OATP1B3. Thus, our data confirmed the assumption by Lee et al., that telaprevir is an
inhibitor of OATP1B1.
In humans, telaprevir reaches a Cmax at steady state of 5.2 µM with a free concentration of
2.1 µM when given as a 750 mg dose three times a day, indicating that in vivo inhibition
of OATP1B1 and OATP1B3 is likely (Vertex, 2011). Hirano et al. introduced calcula-
tion of R-values, which represent the ratio of the uptake clearance in the absence of the
inhibitor to that in its presence (Hirano et al., 2006). According to the FDA guideline on
drug-drug interactions, R-values for OATPs should be estimated by using the total plasma
concentrations Cmax (R = 1 + Cmax/IC50)(FDA, 2012). Using this guideline, R-values
can be estimated 3.75 for OATP1B3 and 1.75 for OATP1B3. Since the maximal concen-
tration at the inlet of the liver is generally higher than in plasma, R-values calculated for
concentrations at the inlet of the liver are expected to be even higher (Huang et al., 2010).
To our knowledge, amlodipine has not been described as a substrate for OATPs, whereas
atorvastatin is transported by OATP1B1 (Kameyama et al., 2005). The observed inhibition
of OATP1B1 and OATP1B3 by telaprevir might explain the finding that telaprevir exhibited
a greater effect on the Cmax of atorvastatin compared to amlodipine (10.6-fold compared to
1.3-fold). This is in line with predictions by Camenisch et al. that inhibition of CYP3A4
alone leads to a maximal increase in the atorvastatin AUC of 3.6-fold, whereas additional
inhibition of transporter increases the atorvastatin AUC in the range of 5- to -fold 28
(Camenisch and Umehara, 2012). Furthermore, we showed that telaprevir inhibited OCT1,
with an IC50 of approximately 20.7 µM. Assuming a total concentration of 5.2 µM and
a free concentration of 2.1 µM after oral administration of clinical relevant doses, the
likelihood of an in vivo interaction of telaprevir with substrates of OCT1 such as metformin
or HIV drugs cannot be ruled out entirely (Shu et al., 2008). Boceprevir a second member
of the class of direct acting-antiviral agents has been described to increase kinetics of single
dose pravastatin and has been found to inhibit OATP1B1 with an IC50 of 18 µM (Chu,
2011; Hilskotte et al., 2011). Comparison of telaprevir with other protease inhibitors used
in HIV therapy such as ritonavir, saquinavir, lopinavir, inidnavir, and nelfinavir indicate
that this class of compounds has besides its inhibitory potential on P-gp and BCRP also
the potential to inhibit effectively transporters of the OATP family (Griffin et al., 2011;
Gutmann et al., 1999). Ritonavir, saquinavir, lopinavir, and indinavir have been shown
to effectively inhibit OATP1B1 and OATP1B3 with IC50s in the range of 0.5-12.3 µM
(Annaert et al., 2010). Pham et al. reported clinical data showing an increase in ator-
vastatin and rosuvastatin AUCs by co-administration of ritonavir and tipranivir which
they attributed to inhibition of OATP1B1 (Pham et al., 2009). Additionally, some HIV
protease inhibitors such as saquiniavir, indinavir, and nelifinavir have been found to inhibit
transporters of the organic cation transporter family (Jung et al., 2008). Taken together,
these data indicate that telaprevir exhibits a similar pattern for drug transporter inhibition
as other protease inhibitors used in HIV therapy.
In conclusion, we demonstrated that telaprevir exhibited a potent inhibitory effect on drug
transporters of the SLC family. In order to characterize these interactions it would be
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of value to examine if telaprevir is also a substrate of these transporters. Up to date, no
data about the intracellular uptake of telaprevir by drug transporters are available. Our
data indicated that combinations of telaprevir with substrates of drug transporters such as
OCT2, OATP1B1, and OATP1B3 should be carefully monitored. Further studies will be
needed to extrapolate from our in vitro experiments to the in vivo situation in humans and
to confirm potential drug interactions.
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Chapter 8
Conclusion and Outlook
Within the scope of this work, in vitro based permeation studies were used to determine
drug clearances and drug-drug interaction potentials in human. In chapter 4 we introduced
a novel IVIVE method that allows the prediction of the human renal clearance based
on filtration, secretion and reabsorption. We showed that our method can be applied to
investigate the mechanism driving the human renal clearance and to assess the contribution
of each process to the net renal excretion. In chapter 5 we predicted the quantitative
OATP1B1,- and OATP1B3-mediated uptake of statins in hepatocytes, based on relative
transporter expression (REF) and relative transporter activity (RAF) data. Our results
demonstrated a direct relationship between transporter expression and activity. By that we
showed that REF-scaling can be applied to extrapolate transporter activities determined
in transporter-transfected cell lines into hepatocyte values. In chapter 6 we applied the
mechanistic extended clearance concept to predict the drug-drug interaction potential of
statins based on in vitro studies. On one hand, we confirmed the applicability of the
mechanistic clearance concept to predict the human hepatic clearance based on IVIVE
and on the other hand we showed that the ECCCS provides a powerful tool to anticipate
the DDI potential of statins. Finally, in chapter 7, we assessed the inhibitory potential
of telaprevir, a new marketed antiviral agent, on major drug transporters of the SLC
family. We showed that telaprevir significantly inhibited the uptake of transporter-specific
reference compounds of major renal and hepatic drug transporters. In the following the
significance of each study is illustrated in the context of drug development.
Renal clearance prediction
Renal clearance is recognized as major elimination pathway of drugs from the body.
Therefore, the assessment of the contribution of the net renal clearance to the total body
clearance is of interest in preclinical drug development. However, to date in vitro-based
methods that would allow the early assessment of human renal drug clearances are lacking.
Reported methods either require a multitude of in vitro input parameters, or are restricted
to compounds that do not undergo reabsorption. In contrast, our novel method allows
the prediction of the renal clearance of basic and neutral NMEs simply by measuring
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the bidirectional drug transport in LLC-PK1 cells. Furthermore, the use of a cell line as
underlying in vitro system accounts for a broad application of our model since it is not
restricted to the availability of primary cells. However, the ideal in vitro system would be a
human cell line that is feasible for drug transmembrane transport studies and that contains
a functional organic anion and cation transport system. Currently lacking, in the future
such a cell line might become available and thus our model could be improved to predict
the net renal clearance for any NME, including anionic compounds.
Besides the prediction of the net human renal clearance our model was shown to allow
insights into the mechanisms driving renal drug excretion. By that, we demonstrated
that the contribution of filtration, secretion, and reabsorption to the net renal clearance
correlated with the compounds assignments to the BDDCS. Consequently, estimates about
the involvement of these processes to the net renal elimination of drugs can be made if
their BDDCS assignments are known.
Furthermore, since our novel IVIVE method allows a mechanistic assessment of the
underlying renal clearance pathways, the impact of pathway inhibition on the net renal
clearance can be investigated. Thus, our model can provide a valuable in vitro tool to
assess the renal DDI potential of NMEs in preclinical drug development.
Transporter expression- activity relationship
First investigations on the quantitative relationship between transporter expression and
activity were performed with the help of western blot analysis. However, this approach is
limited to the availability of transporter-specific antibodies. More recently, QTAP methods
have been demonstrated to be a valuable tool to determine absolute transporter abundances
in tissue and cell samples. First attempts have been made to use transporter protein expres-
sion levels determined by QTAP to predict the transporter activities. However, to date the
validation of QTAP-based REF-scaling with an independent method such as RAF-scaling
was still lacking. Our study is therefore expected to provide a proof of concept for the
application of REF-based scaling. Thus, we anticipate that REF-scaling is likely applicable
to extrapolate transporter activities from recombinant cell systems to any tissue, given the
respective protein abundance data were known. REF-based scaling would therefore enable
the characterization of active drug transport even in tissues for which currently no in vitro
systems are available.
We further demonstrated that REF-scaling can be used to assess the absolute contribution
of the OATP1B1 and OATP1B3 mediated uptake of statins into human cryopreserved
hepatocytes. To complete the characterization of the active hepatic uptake of cerivastatin,
fluvastatin, pitavastatin, and lovastatin, REF-scaling could be further applied to assess
the involvement of other hepatic transporters including OATP2B1 and NTCP. Once the
uptake profiles are assessed, the transporter contributions could be used to assess the
impact of specific transporter inhibition on drug exposure using physiological-based or
static pharmacokinetic modeling. This would help to further improve predictions of the
DDI potential of statins or any compound where this method was applied to.
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QTAP analysis demonstrated to be a powerful tool to determine the transporter protein
abundances in cryopreserved hepatocytes and cell lines. In the frame of this study only
OATP1B1 and OATP1B3 abundances were investigated. However, QTAP enables the
absolute quantification of any transporter in any in vitro system of interest. Given the
demonstrated direct translation of transporter expression into activity, knowledge about
transporter expression levels would be very valuable to characterize in vitro systems regard-
ing their transporter abundances. For example, HEK293, LLC-PK1, and MDCK cells are
widely used host cell lines to generate transporter-transfected in vitro systems. However,
they also express endogenous drug transporters which could impact the transporter uptake
or efflux. Absolute quantification of endogenous drug transporter could therefore help to
asses their impact on drug permeation studies.
Prediction of the drug-drug interaction potential: the victim perspective
Commonly, clinical DDI studies are performed in the late drug development phase. Yet,
the assessment of the impact of co-medication on the exposure of a NMEs is of interest in
early drug development. The application of the extended clearance concept to anticipate
DDI can be used in preclinical drug development since the hepatic clearance mechanism
can be assessed by IVIVE. We therefore expect this bottom-up approach to provide a
powerful tool for a first risk assessment of NMEs.
Our study demonstrated that the application of the extended clearance concept provides a
valuable tool to anticipate the DDI potential of statins. By that, the assignments of statins
to the ECCCS well projected their major DDI potential. Since statins are widely prescribed,
the likelihood for statin patients to receive co-medication is high. Our DDI assessment
could therefore be valuable in order to select a statin that is not affected by the patients
co-medication. In future, ECCCS assignments of any compound could therefore be used
to contribute to personalized medical treatment.
Prediction of the drug-transporter interaction potential: the perpetrator
perspective
Above we discussed the impact of co-medication on NMEs as potential victim drugs.
Yet, it is crucial to characterize NMEs with respect to their perpetrator potential. Since
drug transporters play a pivotal role in disposition and drug clearance the assessment of
the inhibitory potential of NMEs on transporters is of importance in drug development.
We demonstrated in our study that telaprevir is anticipated to exhibit clinically relevant
inhibition of OATP1B1, OATP1B3, and OCT2 mediated transport. In order to anticipate
the interaction potential of telaprevir with any victim drug, our generated IC50 values can
be applied to perform static DDI assessments.
Furthermore, in clinics, co-medication with telaprevir and atorvastatin increased systemic
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exposure of atorvastatin by over seven-fold. Our study demonstrated that the inhibition
of OATP1B1 and OATP1B3 likely contributes to the observed effects. Thus our study
contributed to the mechanistic understanding of clinically observed DDIs with telaprevir.
Summary
With the help of this work the safety profiles of NMEs can now be assessed in preclinical
drug development based on in vitro methods. Thus, in a first step the renal and hepatic
clearances can be determined based on the IVIVE methods. Subsequently, the mechanistic
extended clearance concept can be applied to assess the DDI potential of NMEs. Assuming,
that hepatic drug uptake is a major DDI risk of the NME, the contribution of specific drug
transporters to the DDI potential could be further investigated using REF-scaling. Finally,
NMEs can be characterized in terms of their inhibitory potential on renal and hepatic drug
transporters to assess their risk as clinical perpetrators.
It is therefore expected, that the establishment, validation, and application of novel in vitro
based methods, described in this work, will add significant value in the early assessment of
the PK profile of NMEs.
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